

Assay for bipolar affective disorderField of the Invention

The present invention relates to a method of diagnosing bipolar affective disorder  
5 (BAD) and for determining a predisposition of a subject to bipolar affective disorder.  
Furthermore, the present invention relates to methods of identifying and producing  
candidate compounds for the treatment of bipolar affective disorder.

Background of the Invention10 *I. General*

This specification contains nucleotide and amino acid sequence information prepared  
using PatentIn Version 3.1, presented herein after the claims. Each nucleotide  
sequence is identified in the sequence listing by the numeric indicator <210> followed  
by the sequence identifier (e.g. <210>1, <210>2, <210>3, etc). The length and type of  
15 sequence (DNA, protein (PRT), etc), and source organism for each nucleotide  
sequence, are indicated by information provided in the numeric indicator fields <211>,  
<212> and <213>, respectively. Nucleotide sequences referred to in the specification  
are defined by the term "SEQ ID NO:", followed by the sequence identifier (eg. SEQ  
ID NO: 1 refers to the sequence in the sequence listing designated as <400>1).

20

The designation of nucleotide residues referred to herein are those recommended by the  
IUPAC-IUB Biochemical Nomenclature Commission, wherein A represents Adenine,  
C represents Cytosine, G represents Guanine, T represents thymine, Y represents a  
pyrimidine residue, R represents a purine residue, M represents Adenine or Cytosine, K  
25 represents Guanine or Thymine, S represents Guanine or Cytosine, W represents  
Adenine or Thymine, H represents a nucleotide other than Guanine, B represents a  
nucleotide other than Adenine, V represents a nucleotide other than Thymine, D  
represents a nucleotide other than Cytosine and N represents any nucleotide residue.

30 As used herein the term "derived from" shall be taken to indicate that a specified  
integer may be obtained from a particular source albeit not necessarily directly from  
that source.

Throughout this specification, unless the context requires otherwise, the word  
35 "comprise", or variations such as "comprises" or "comprising", will be understood to  
imply the inclusion of a stated step or element or integer or group of steps or elements

or integers but not the exclusion of any other step or element or integer or group of elements or integers.

Throughout this specification, unless specifically stated otherwise or the context  
5 requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.

10 Each embodiment described herein is to be applied *mutatis mutandis* to each and every other embodiment unless specifically stated otherwise.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be  
15 understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

20 The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

25 The present invention is performed without undue experimentation using, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA technology, peptide synthesis in solution, solid phase peptide synthesis, histology and immunology. Such procedures are described, for example, in the following texts that are incorporated by reference:

- 30 (i) Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, New York, Second Edition (1989), whole of Vols I, II, and III;
- (ii) DNA Cloning: A Practical Approach, Vols. I and II (D. N. Glover, ed., 1985), IRL Press, Oxford, whole of text;
- 35 (iii) Oligonucleotide Synthesis: A Practical Approach (M. J. Gait, ed., 1984) IRL Press, Oxford, whole of text, and particularly the papers therein by Gait, pp1-

- 22; Atkinson *et al.*, pp35-81; Sproat *et al.*, pp 83-115; and Wu *et al.*, pp 135-151;
- (iv) Nucleic Acid Hybridisation: A Practical Approach (B. D. Hames & S. J. Higgins, eds., 1985) IRL Press, Oxford, whole of text;
  - 5 (v) Immobilized Cells and Enzymes: A Practical Approach (1986) IRL Press, Oxford, whole of text;
  - (vi) Perbal, B., A Practical Guide to Molecular Cloning (1984);
  - (vii) Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.), whole of series;
  - 10 (viii) J.F. Ramalho Ortigão, "The Chemistry of Peptide Synthesis" *In*: Knowledge database of Access to Virtual Laboratory website (Interactiva, Germany);
  - (ix) Sakakibara, D., Teichman, J., Lien, E. Land Fenichel, R.L. (1976). *Biochem. Biophys. Res. Commun.* **73** 336-342
  - (x) Bodanszky, M. (1984) *Principles of Peptide Synthesis*, Springer-Verlag, Heidelberg.
  - 15

## 2. Description of the related art

Bipolar affective disorder, also known as manic-depressive illness, is one of the most common mental disorders with a population lifetime prevalence of approximately 1%.

20 Currently, there are approximately 2-3 million adults in the US that are diagnosed with bipolar affective disorder. This disease usually commences in late adolescence or early adulthood and is characterised by periods of elevated mood (mania) and/or periods of depression (Goodwin, *et al.*, 1990, Manic Depressive Illness, Oxford University Press, New York).

25

The most severe and clinically distinct forms of bipolar affective disorder are bipolar I disorder (severe bipolar affective (mood) disorder) and schizoaffective disorder (manic type). These disorders are characterized by at least one full episode of mania, with or without episodes of major depression (defined by lowered mood, or depression, with

30 associated disturbances in rhythmic behaviours such as sleeping, eating, and sexual activity). Other forms of bipolar affective disorder include bipolar II disorder (characterised by at least one major depressive episode and at least one hypomanic episode), and unipolar disorder (characterised by recurrent major depressive episodes).

35 Symptoms of a manic episode include, for example, increased energy, activity and restlessness, extreme irritability and provocative, aggressive or intrusive behaviour. A

manic episode is deemed to have occurred if several of these symptoms are present all day, nearly every day, for a week. Symptoms of a depressive episode include, for example, anxiety, pessimism, decreased energy, fatigue, loss of appetite or unexplained weight loss or gain. A depressive episode is diagnosed if several of these symptoms  
5 last all day, nearly every day for a period of two weeks or longer. Severe episodes of mania or depression may also be accompanied by periods of psychosis or psychotic symptoms.

Currently, bipolar affective disorder is only diagnosed by clinical assessment.  
10 Diagnosis is based upon two main schemes, the International Classification of Diseases of the World Health Organisation (10th Edition) and the Diagnostic and Statistic Manual (4th Edition). However, these schemes only detect bipolar affective disorder following onset of the disease. Furthermore, delays in accurate diagnosis using these schemes may extend many years and be associated with instability of presentation. For  
15 example, in an adult cohort diagnosed with their first psychotic episode, only 75% of patients were diagnosed with bipolar affective disorder after six months (Fennig *et al.*, *Am. J. Psychiatry* 1994).

Additionally, the subjective classification systems currently in use for the diagnosis of  
20 bipolar affective disorder often lead to incorrect diagnoses as schizophrenia, shizoffective disorder or psychotic depression.

As a consequence of the current inadequacies in diagnostics for bipolar affective disorder, several groups have attempted to identify a marker useful in the early  
25 diagnosis, and determination of a predisposition to the disorder.

Segregation analyses and twin studies have suggested that there is a genetic component to bipolar affective disorder (Bertelson, *et al.*, *Br. J. Psychiat.* 130:, 330-351, 1977; Freimer and Reus, in *The Molecular and Genetic Basis of Neurological Disease*,  
30 Rosenberg *et al.*, eds., Butterworths, New York, 1992 pp. 951-965; Pauls *et al.*, *Arch. Gen. Psychiat.* 49: 703-708, 1992). However, efforts to identify the chromosomal location of genes that might be linked to bipolar affective disorder have been disappointing. For example, reports of linkage between bipolar affective disorder and markers on the X chromosome and chromosome 11 could not be independently  
35 replicated nor confirmed in the re-analyses of the original pedigrees (Baron *et al.*,

*Nature* 326: 289-292, 1987; Egeland *et al.* *Nature* 325: 783-787, 1987; Kelsoe, *et al.*, *Nature* 342: 238-243, 1989; Baron *et al.*, 1993, *Nature Genet.* 3: 49-55, 1993).

Recent investigations have suggested possible localization of gene that are linked to  
5 bipolar affective disorder on chromosomes 18p and 21q (Berrettini, *et al.* *Proc. Natl. Acad. Sci. USA* 91, 5918-5921, 1991; Murray *et al.*, *Science* 265: 2049-2054, 1994; Pauls *et al.*, *Am. J. Hum. Genet.* 57: 636-643, 1995; Maier *et al.*, *Psych. Res.* 59: 7-15, 1995; Straub *et al.*, *Nature Genet.* 8: 291-296, 1994). However, such linkage studies have failed to sufficiently define or validate a locus that is closely linked to the disorder  
10 or a predisposition thereto.

A further recent study has suggested that map position 4q35 of the human genome comprises a bipolar affective disorder susceptibility locus (US 6,274,352). This study used linkage analysis with a limited number of microsatellite markers to map a bipolar  
15 affective disorder locus to map position 4q35 of the genome. However, the study provides no fine mapping results or association studies to suggest a candidate gene or a candidate allele of a gene that is associated with a bipolar affective disorder.

Efforts to identify candidate bipolar susceptibility genes based upon function alone  
20 have also met with limited success. This is partly because our understanding of bipolar disorder aetiology is poor.

Furthermore, there are currently no diagnostic approaches available for determining severity of a bipolar affective disorder. Such methods are useful from the perspective of  
25 improving treatment regimes. In particular, the availability of such methods permits more appropriate and targeted treatment to be commenced at an early stage of the disorder. This is in marked contrast to current empirical treatment regimes, which generally commence when severe symptoms have already developed.

30 Accordingly, there is a clear need to develop improved diagnostic methods for determining a predisposition towards bipolar affective disorder in a subject, and for the early diagnosis of the disorder. Diagnostic assays that rapidly and reliably diagnose bipolar affective disorder prior to onset of the disease are particularly desirable as are indicators of whether or not a subject will respond to a particular treatment.

35

Summary of invention

In work leading up to the present invention the inventors sought to identify markers that are sufficiently tightly linked or associated with a bipolar affective disorder or a predisposition thereto in a human subject, to permit their application in improved diagnostics and prognostics.

5

As exemplified herein, the present inventors have identified a bipolar affective disease susceptibility locus 4q35.2, by conducting linkage analysis of a large bipolar pedigree. Further analysis, using markers for single nucleotide polymorphisms (SNPs) in the 4q35.2 region confirms the significant association between this region of the human  
10 genome and a bipolar affective disorder. The inventors have also shown that several SNPs that are significantly associated with a bipolar affective disorder phenotype are within the human FAT gene, suggesting that the human FAT gene is a susceptibility gene for bipolar affective disorder in humans. Accordingly, polymorphisms within the human FAT gene appear to be statistically correlated with the development of a bipolar  
15 affective disorder. This conclusion is further supported by a highly significant association between SNPs located at the 3' end of the FAT gene and the development of a bipolar affective disorder.

Accordingly, one aspect of the present invention provides a method for determining a  
20 bipolar affective disorder or a predisposition to a bipolar affective disorder, said method comprising detecting a marker within a FAT gene or an expression product thereof that is associated with a bipolar affective disorder in a sample derived from a subject, wherein the presence of said marker is indicative of a bipolar affective disorder or a predisposition to a bipolar affective disorder in the subject.

25

For the purposes of nomenclature, the nucleotide sequence of a human FAT gene is exemplified herein as SEQ ID NO: 1. Preferably, a FAT gene is at least about 80% identical to the sequence set forth in SEQ ID NO: 1.

30 As used herein, the term "marker" shall be taken to mean a nucleic acid that comprises a nucleotide sequence associated with and/or linked to an allele of a gene that is associated with a bipolar affective disorder and/or is associated with a polymorphism in a genome wherein said polymorphism is associated with a bipolar affective disorder. In those embodiments related to detection of a marker that is in a region of the genome  
35 that is transcribed the term "marker" shall also be taken to mean an expression product of a gene or an allele of a gene that is associated with a bipolar affective disorder, such

as, for example, a pre-mRNA molecule, a 5'capped mRNA, a polyadenylated mRNA and/or a mature or processed mRNA. In those embodiments related to antigen-based or antibody-based assays, those skilled in the art will appreciate that the term "marker" also means a peptide, polypeptide or protein that comprises an amino acid sequence  
5 encoded by an allele of a gene that is associated with a bipolar affective disorder and/or is associated with a polymorphism in a genome wherein said polymorphism is associated with a bipolar affective disorder. A "marker" will generally comprise a sequence that comprises the allele or polymorphism and/or is linked thereto.

10 As used herein, the term "associated with a bipolar affective disorder" shall be taken to mean that the detection of a marker is significantly correlated with the development of a bipolar affective disorder in a subject. More preferably, the detection of the marker is significantly correlated with the development of a bipolar affective disorder in a plurality of subjects. Even more preferably, the detection of the marker is significantly  
15 correlated with the development of a bipolar affective disorder in a plurality of unrelated subjects.

In one embodiment, the marker that is associated with a bipolar affective disorder is within a nucleic acid that comprises a nucleotide sequence at least about 80% identical  
20 to a FAT cDNA or FAT mRNA. For example, the nucleotide sequences of splice variants of FAT mRNA are set forth in SEQ ID NO: 2 and SEQ ID NO: 4.

In another embodiment, a marker that is associated with a bipolar affective disorder is within a nucleic acid that is capable of encoding a FAT polypeptide. For example, the  
25 amino acid sequences of isoforms of a FAT polypeptide are set forth in SEQ ID NO: 3 and SEQ ID NO: 5.

In a preferred embodiment, a marker that is associated with a bipolar affective disorder is a polymorphism of a FAT gene. As used herein, the term "polymorphism" shall be  
30 taken to mean a difference in the nucleotide sequence of the genome that occurs in a normal population of individuals. Such a polymorphism may induce changes in a mRNA and/or polypeptide encoded by the genomic DNA in which it occurs, eg. by changing an encoded amino acid or by altering the splicing or the frequency of splicing of an mRNA. Accordingly, a "polymorphism that is associated with a bipolar affective  
35 disorder" means that a particular form of the polymorphism is correlated with the development of a bipolar affective disorder in a subject, ie. in a population of subjects,

those that suffer from a bipolar affective disorder are more likely to comprise the specific polymorphism than those subjects that do not suffer from a bipolar affective disorder.

- 5 As will be apparent to the skilled artisan a polymorphism that is associated with a bipolar affective disorder that occurs in a region of a FAT gene that is transcribed into mRNA or controls the transcription of mRNA (eg. controls splicing of mRNA) is detectable in an expression product of a FAT gene. Clearly, the present invention encompasses a method of determining a bipolar affective disorder or a predisposition to
- 10 a bipolar affective disorder comprising detecting a marker associated with a bipolar affective disorder in a FAT expression product, such as, for example, a pre-mRNA molecule, a 5' capped mRNA, a polyadenylated mRNA, and/or a mature mRNA or cDNA derived therefrom.
- 15 Furthermore, a polymorphism that is associated with a bipolar affective disorder that occurs within a protein-coding region of a FAT gene may also cause a change in a polypeptide encoded by the FAT gene. Accordingly, the present invention also encompasses a method of determining a bipolar affective disorder or a predisposition to a bipolar affective disorder comprising detecting a marker associated with a bipolar
- 20 affective disorder in a FAT polypeptide.

In a further particularly preferred embodiment, the marker comprises, consists of or is located within the 3' region of a FAT genomic gene, or the corresponding region of an expression product thereof. Preferably, the polymorphism occurs within the 3' region

25 of the FAT genomic gene that encodes one or more intracellular EVH1 domains of the FAT protein (i.e., comprising the sequence F/L PPPP). Preferably, the 3' region of the FAT genomic gene comprises or consists of the region spanning from nucleotide position 139,260 to nucleotide position 170,001 of SEQ ID NO: 1 (ie a nucleic acid that comprises or consists of the sequence set forth in SEQ ID NO: 6).

30

In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 146,012 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

35



In a further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,108 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

5

In a still further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,199 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

10

In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,333 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

15

In a preferred embodiment, a marker that is associated with a bipolar affective disorder comprises or consists of a single nucleotide polymorphism (SNP). Methods of determining a SNP that is associated with a specific disorder are known in the art and/or described herein.

20

In a particularly preferred embodiment, a marker that is associated with a bipolar affective disorder comprises or consists of a SNP selected from the group consisting of a cytosine at position 80,217 of SEQ ID NO: 1 (designated rs172903), a thymine at position 130,625 of SEQ ID NO: 1 (designated rs2249916), a thymine at position 130,613 of SEQ ID NO: 1 (designated rs2249917), a guanine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position 142,199 of SEQ ID NO: 1 (designated rs767168), an adenine at position 142,460 of SEQ ID NO: 1 (designated rs2289550), a guanine at position 145,782 of SEQ ID NO: 1 (designated rs1280097), a guanine at position 146,008 of SEQ ID NO: 1 (designated rs1280096), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), an adenine at position 148,199 of SEQ ID NO: 1 (designated rs2306988), an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987), a cytosine at position 151,403 of SEQ ID NO: 1 (designated rs3775309) and a thymine at position 153,127 of SEQ ID NO: 1 (designated rs1973352).

35

In an even more particularly preferred embodiment, a marker associated with a bipolar affective disorder comprises or consists of a SNP selected from the group consisting of a guanine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), a cytosine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987) and a thymidine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

- 10 In one embodiment, a marker associated with a bipolar affective disorder in a subject without a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a guanine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865) and an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

In another embodiment, a marker associated with a bipolar affective disorder in a subject with a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a thymidine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), an adenine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a cytosine at position 148,108 of SEQ ID NO: 1 (designated rs1298865) and a cytosine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

In one embodiment, the marker is in its homozygous form. As used herein, the term "homozygous form" shall be taken to mean that the same form of the marker associated with a bipolar affective disorder occurs at the same locus on homologous chromosomes. For example, the same nucleotide is found at the site of a SNP located FAT gene on both copies of chromosome 4.

- 30 As will be apparent to the skilled artisan, a marker that is associated with a bipolar affective disorder is preferably detectable by standard procedures, for example by nucleic acid hybridisation or antibody binding. Accordingly, a nucleic acid marker is preferably at least about 8 nucleotides in length (for example, for detection using a locked nucleic acid (LNA) probe). To provide more specific hybridisation, a marker is preferably at least about 15 nucleotides in length or more preferably at least 20 to 30 nucleotides in length. Such markers are particularly amenable to detection by nucleic

acid hybridisation-based detection means assays, such as, for example any known format of PCR or ligase chain reaction.

- Preferably, a protein marker encoded by nucleic acid that is associated with a bipolar affective disorder is suitable for antigen-based detection. As will be apparent to the skilled artisan, even a single amino acid change in a polypeptide is detectable in an antigen-based assay. However, for an antibody or ligand to detect such a change, a marker is preferably at least about 6 amino acids in length, more preferably at least about 8 to 10 amino acids in length, even more preferably at least about 14 amino acids in length. A protein marker may also be an entire protein, e.g. wherein the protein that is associated with a bipolar affective disorder is, for example, a conformation different to the protein in a normal or healthy individual or is truncated relative to the the protein in a normal or healthy individual.
- Means for detecting a marker will be known to the skilled artisan and, in general, any nucleic acid-based or antigen-based detection means can be employed.

In one embodiment, the marker is detected by hybridising a nucleic acid probe comprising the sequence of the marker to a marker linked to nucleic acid in a biological sample derived from a subject under at least moderate, or preferably high stringency hybridisation conditions and detecting the hybridisation using a detection means, wherein hybridisation of the probe to the sample nucleic acid indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder. Preferably, the detection means is a nucleic acid hybridisation or amplification reaction.

In another embodiment, the marker is detected by hybridising a nucleic acid probe comprising the sequence of the marker to a nucleic acid that is linked to the marker in nucleic acid in a biological sample derived from a subject and detecting the hybridisation by a detection means, wherein hybridisation of the probe to the sample nucleic acid indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder. Preferably, the detection means is an amplification reaction, or a nucleic acid extension reaction.

Methods of designing and producing or synthesizing probes will be known to the skilled artisan and/or described herein.

The present invention also provides a method for determining a bipolar affective disorder or a predisposition to a bipolar affective disorder in a subject, said method comprising:

- 5 (i) amplifying nucleic acid from the subject using an amplification reaction, wherein the amplification reaction is performed using a pair of primers selected from the group consisting of:
- (a) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 32 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 33;
- 10 (b) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 34 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 35;
- (c) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 36 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 37;
- 15 (d) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 38 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 39;
- (e) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 40 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 41;
- 20 (f) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 42 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 43;
- 25 (g) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 44 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 45;
- (h) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 46 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 47;
- 30 (i) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 48 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 49;
- (j) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 50 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 51;
- 35

- (k) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 53 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 54; and
- 5 (l) a primer comprising the nucleotide sequence set forth in SEQ ID NO: 56 and a primer comprising the nucleotide sequence set forth in SEQ ID NO: 57;
- (ii) detecting a polymorphism in the amplified nucleic acid from (i), wherein said polymorphism is indicative of a bipolar affective disorder or a predisposition to a bipolar affective disorder in the subject.

10

Preferably, the polymorphism is detected by determining the nucleotide sequence of the amplified nucleic acid.

15 In another embodiment, the marker is detected by contacting a biological sample derived from a subject with an antibody or ligand capable of specifically binding to said marker for a time and under conditions sufficient for an antibody/ligand complex to form and then detecting the complex wherein detection of the complex indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder.

20 Clearly the present invention encompasses the use of a multiplex assay to determine the predisposition of a subject to a bipolar affective disorder or to diagnose a bipolar affective disorder. In this regard, such a multiplexed assay may detect two or more nucleic acid markers that are associated with bipolar affective disorder. Alternatively, or in addition, a multiplexed assay may detect two or more peptide, polypeptide or

25 protein markers that are associated with bipolar affective disorder. Clearly, the combination of nucleic acid- based and antigen-based detection methods is contemplated by the invention.

The biological sample used in an assay to determine the presence of a bipolar affective disorder or a predisposition to a bipolar affective disorder will comprise a nucleated

30 cell. Preferably, the biological sample is selected from the group consisting of whole blood, serum, plasma, peripheral blood mononuclear cells (PBMC), a buffy coat fraction, saliva, urine, a buccal cell and a skin cell.

35 Alternatively, the biological sample is a cell isolated using a method selected from the group consisting of aminocentesis, chorionic villus sampling, fetal blood sampling (e.g.

cordocentesis or percutaneous umbilical blood sampling and other fetal tissue sampling (e.g. fetal skin biopsy).

- As the FAT polypeptide is expressed in a variety of tissues in developing embryo, an antigen based assay is particularly useful in prenatal testing to determine predisposition to a bipolar affective disorder in a suitable biological sample for prenatal testing comprises a cell derived from a tissue selected from the group consisting of brain (a neural crest cell), spinal cord, skin, lung, kidney, pancreas.
- 10 As will be apparent to the skilled artisan, the size of a biological sample will depend upon the detection means used. For example, an assay, such as, for example, PCR or single nucleotide primer extension may be performed on a sample comprising a single cell, although greater numbers of cells are preferred. Alternative forms of nucleic acid detection may require significantly more cells than a single cell. Furthermore, protein-
- 15 based assays require sufficient cells to provide sufficient protein for an antigen based assay.

Preferably, the biological sample has been derived previously from the subject.

- 20 In one embodiment, the method is performed using genomic DNA derived from a biological sample. In another embodiment, the method is performed using mRNA or cDNA derived from the biological sample. In a still further embodiment, the method of the present invention is performed using protein derived from the biological sample.
- 25 Another aspect of the present invention provides a method for determining a bipolar affective disorder or a predisposition to a bipolar affective disorder, said method comprising detecting a marker that is linked to map position 4q35.2 of the human genome in a sample derived from a subject, wherein the detection is indicative of a bipolar affective disorder or a predisposition to a bipolar affective disorder in the
- 30 subject.

As used herein, the terms "linked" and "map to" shall be taken to refer to a sufficient proximity between a marker and nucleic acid comprising all or part of map position 4q35.2 of the human genome or an expression product thereof to permit said linked

35 nucleic acid to be useful for diagnosing bipolar affective disorder in a subject. Those

skilled in the art will be aware that for linked nucleic acid to be used in this manner, it must be sufficiently close to map position 4q35.2 so as to be in linkage disequilibrium or for there to be a low recombination frequency between the linked nucleic acid and map position 4q35.2. Preferably, the linked nucleic acid and the locus are less than  
5 about 25cM apart, more preferably less than about 10cM apart, even more preferably less than about 5cM apart, still even more preferably less than about 3cM apart and still even more preferably less than about 1cM apart.

10 In one embodiment the method of determining the predisposition of a subject to bipolar affective disorder or diagnosing bipolar affective disorder comprises determining the presence or absence of the a marker linked to chromosome 4q35.2 in a test sample derived from a subject, wherein a presence or absence of the marker linked to chromosome 4q35.2 indicates that the subject being tested is predisposed to or suffers from bipolar affective disorder.

15

In another embodiment of the invention, the marker is a peptide, polypeptide or protein that is encoded by nucleic acid that is linked with map position 4q35.2 of the human genome.

20 In one embodiment, a marker that is linked to map position 4q35.2 of the human genome occurs in a region of the genome that does not encode a protein, such as, for example, an intron, a 5' untranslated region, a 3' untranslated region or a promoter region of a genomic gene. In another embodiment, a marker that is linked to map position 4q35.2 of the human genome occurs in a region of the genome that encodes a  
25 protein. Accordingly, the term "a marker that is linked to map position 4q35.2" clearly extends to a marker that comprises and/or is detected in an mRNA encoded by a gene that is linked to map position 4q35.2 of the human genome.

In one embodiment, the marker linked to map position 4q35.2 is located between or  
30 comprises the microsatellite markers designated D4S1164 (SEQ ID NO: 21) and D4S1192 (SEQ ID NO: 27). Preferably, the marker linked to map position 4q35.2 is located between or comprises the microsatellite markers designated D4S910 (SEQ ID NO: 22) and D4S1374 (SEQ ID NO: 28). More preferably, the marker linked to map

position 4q35.2 is located between the microsatellite markers designated D4S3173 (SEQ ID NO: 23) and D4S1375 (SEQ ID NO: 29). Even more preferably, the marker linked to map position 4q35.2 is located between or comprises the microsatellite markers D4S3236 (SEQ ID NO: 24) and designated D4S3051 (SEQ ID NO: 30). Still  
5 more preferably, the marker linked to map position 4q35.2 is located between or comprises the microsatellite markers designated D4S2827 (SEQ ID NO: 25) and D4S2643 (SEQ ID NO: 31).).

In a preferred embodiment, the marker linked to map position 4q35.2 is located  
10 between or comprises the microsatellite markers designated D4S2827 (SEQ ID NO: 25) and D4S2643 (SEQ ID NO: 31).

In a preferred embodiment, the marker linked to map position 4q35.2 comprises or consists of a nucleic acid that comprises a nucleotide sequence at least about 80%  
15 identical to the genomic region that comprises a human FAT gene (i.e. the sequence set forth in SEQ ID NO: 1). More preferably, the marker comprises or consists of a genomic gene capable of encoding a nucleic acid (i.e. mRNA) that comprises a nucleotide sequence at least about 80% identical to any FAT cDNA or mRNA encoded by a FAT genomic gene. For example, the nucleotide sequence of two alternative  
20 splice forms of FAT are set forth in SEQ ID NO: 2 or SEQ ID NO: 4. In an alternative embodiment, the marker comprises or consists of a genomic gene that encodes an isoform of a FAT protein. For example, the amino acid sequence of two forms of a FAT protein encoded by different splice forms of a FAT gene are set forth in SEQ ID NO: 3 or SEQ ID NO: 5.

25

In a further particularly preferred embodiment, the marker comprises, consists of or is located within the 3' region of a FAT genomic gene, or the corresponding region of an expression product thereof. Preferably, the polymorphism occurs within the 3' region of the FAT genomic gene that encodes one or more intracellular EVH1 domains of the  
30 FAT protein (i.e., comprising the sequence F/L PPPP). Preferably, the 3' region of the FAT genomic gene comprises or consists of the region spanning from nucleotide position 139,260 to nucleotide position 170,001 of SEQ ID NO: 1 (ie a nucleic acid that comprises of consists of the sequence set forth in SEQ ID NO: 6).



In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 146,012 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

5

In a further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,108 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

10

In a still further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,199 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

15

In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,333 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

20

Preferably, a marker comprises or is contained within a FAT gene or a transcription product thereof, such as, for example, a pre-mRNA molecule, a 5'capped mRNA, a polyadenylated mRNA and/or a mature or processed mRNA. More preferably, a marker comprises is contained within or consists of a nucleotide sequence at least about 80% identical to a sequence selected from the group consisting of:

- 25 (i) a sequence at least about 80% homologous to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;  
(ii) a sequence capable of encoding an amino acid sequence at least 80% homologous to the sequence set forth in SEQ ID NO: 3 and SEQ ID NO: 5; and  
30 (iii) a sequence complementary to a sequence set forth in (i) or (ii).

In one embodiment, the marker linked to map position 4q35.2 comprises or consists of a microsatellite marker selected from the group consisting of D4S1164 (SEQ ID NO: 21), D4S1192 (SEQ ID NO: 27), D4S910 (SEQ ID NO: 22), D4S1374 (SEQ ID NO: 28), D4S3173 (SEQ ID NO: 23), D4S1375 (SEQ ID NO: 29), D4S3236 (SEQ ID NO: 35

24), D4S3051 (SEQ ID NO: 30), D4S2827 (SEQ ID NO: 25) and D4S2643 (SEQ ID NO: 31).

In another embodiment, the marker linked to map position 4q35.2 comprises or consists  
5 of a single nucleotide polymorphism (SNP). Preferably, the SNP is selected from the  
group consisting of a cytosine at position 80,217 of SEQ ID NO: 1 (designated  
rs172903), a thymine at position 130,625 of SEQ ID NO: 1 (designated rs2249916), a  
thymine at position 130,613 of SEQ ID NO: 1 (designated rs2249917), a guanine at  
position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position  
10 142,199 of SEQ ID NO: 1 (designated rs767168), an adenine at position 142,460 of  
SEQ ID NO: 1 (designated rs2289550), a guanine at position 145,782 of SEQ ID NO: 1  
(designated rs1280097), a guanine at position 146,008 of SEQ ID NO: 1 (designated  
rs1280096), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a  
thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), an adenine at  
15 position 148,199 of SEQ ID NO: 1 (designated rs2306988), an adenine at position  
148,333 of SEQ ID NO: 1 (designated rs2306987), a cytosine at position 151,403 of  
SEQ ID NO: 1 (designated rs3775309) and a thymine at position 153,127 of SEQ ID  
NO: 1 (designated rs1973352).

20 In a particularly preferred embodiment, a marker linked to map position 4q35.2 is a  
SNP selected from the group consisting of a guanine at position 139,968 of SEQ ID  
NO: 1 (designated rs2637777), a guanine at position 146,012 of SEQ ID NO: 1  
(designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated  
rs1298865) and an adenine at position 148,333 of SEQ ID NO: 1 (designated  
25 rs2306987).

In one embodiment, a marker associated with a bipolar affective disorder in a subject  
without a family history of psychiatric illness comprises or consists of a SNP selected  
from the group consisting of a guanine at position 139,968 of SEQ ID NO: 1  
30 (designated rs2637777), a guanine at position 146,012 of SEQ ID NO: 1 (designated  
rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865  
and an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

In another embodiment, a marker associated with a bipolar affective disorder in a subject with a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a thymidine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), an adenine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a cytosine at position 148,108 of SEQ ID NO: 1 (designated rs1298865 and a cytosine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

Methods of detecting a marker associated with a bipolar affective disorder as described *supra* shall be taken to apply *mutatis mutandis* to the methods of detecting a marker linked to map position 4q35.2 of the human genome.

The present invention also encompasses methods of genetic screening to determine a subject that carries a gene or allele of a gene or a polymorphism that confers susceptibility to a bipolar affective disorder or is associated with a bipolar affective disorder or carries a marker for a bipolar affective disorder that is linked to map position 4q35.2 of the human genome, ie. determining a subject that is homozygous or heterozygous for a susceptibility gene or allele. Accordingly, a further aspect of the present invention provides a method for determining a subject that carries a gene or allele of a gene or a polymorphism that is associated with a bipolar affective disorder comprising detecting a marker within a FAT gene that is associated with a bipolar affective disorder in a sample derived from the subject, wherein detection of said marker indicates that the subject is a carrier of a gene or allele of a gene or a polymorphism is associated with a bipolar affective disorder.

In one embodiment, the subject is heterozygous for one gene or allele of a gene or one polymorphism that confers susceptibility to a bipolar affective disorder or is associated with a bipolar affective disorder. Accordingly, an assay to detect a marker associated with a bipolar affective disorder and/or linked to map position 4q35.2 of the human genome may indicate that the subject comprises a marker associated with a bipolar affective disorder and a marker that is not associated with a bipolar affective disorder (eg., two different nucleotides at a SNP position, one of which is associated with a bipolar affective disorder). Alternatively, or in addition, the subject may comprise a marker that is associated with a bipolar affective disorder in a subject with a family history of psychiatric illness and a marker that is associated with a bipolar affective disorder in a subject that does not have a family history of psychiatric illness.

Clearly, this aspect of the present invention is useful for determining the likelihood, or susceptibility of a child to develop a bipolar affective disorder based upon screening of the parents of the child (eg., genetic counselling). Such an assay may be performed  
5 prior to pregnancy, during pregnancy or even after birth. Methods of determining the risk of a child developing a disorder or the predisposition of a child to the development of a bipolar affective disorder based upon the genotype of the parents of the child are known in the art and described, for example, in Young (*In: Introduction to Risk Calculation in Genetic Counselling* (Oxford Medical Publications), Oxford University  
10 Press; 1991.

As the methods of the present invention are particularly useful for determining whether or not a subject is likely to suffer from a bipolar affective disorder or is susceptible to a bipolar affective disorder, these methods are particularly useful in methods of treatment  
15 or prophylaxis of a bipolar affective disorder.

Accordingly, the present invention additionally provides a method of treatment or prophylaxis of a bipolar affective disorder comprising:

- (i) performing a method described herein for determining a bipolar affective  
20 disorder or a predisposition to a bipolar affective disorder; and
- (ii) administering or recommending a therapeutic for the treatment of bipolar affective disorder.

In one embodiment, the administration or recommendation of a therapeutic for the  
25 treatment of a bipolar affective disorder is based upon the diagnosis of a bipolar affective disorder or the diagnosis of a predisposition to a bipolar affective disorder.

This embodiment of the invention applies *mutatis mutandis* to a method of monitoring the efficacy of treatment. In such a monitoring procedure, it is possible to modify the  
30 therapeutic regimen based upon altered expression of the marker that is detected.

As will be apparent to the skilled artisan, this aspect of the present invention also encompasses methods for the prophylaxis or prophylactic therapy of a bipolar affective disorder. Accordingly, a preferred embodiment of the invention provides a method for  
35 the prophylaxis of a bipolar affective disorder comprising determining a subject at risk of developing a bipolar affective disorder using a method described herein; and

administering or recommending a compound that delays or prevents onset of a bipolar affective disorder, such as, for example, lithium or valproate. Preferably, the administration or recommendation of the compound is based upon the determination of a subject at risk of developing (ie. predisposed to developing) a bipolar affective disorder.

A marker useful for determining a subject at risk of developing a bipolar affective disorder and means for detecting said marker are described herein.

Given the tight association of the human FAT gene to a bipolar affective disorder, and the provision of numerous markers, the present invention further provides methods for identifying new markers of a bipolar affective disorder.

Accordingly, the present invention additionally provides a method for identifying a marker that is associated with a bipolar affective disorder, said method comprising:

- (i) identifying a polymorphism or allele within a FAT gene or an expression product thereof;
- (ii) analyzing a panel of subjects to determine those that suffer from a bipolar affective disorder, wherein not all members of the panel comprise the polymorphism or allele; and
- (iii) determining the variation in the development of a bipolar affective disorder wherein said variation indicates that the polymorphism or allele is associated with a subject's predisposition to a bipolar affective disorder.

Another aspect of the present invention provides a method of identifying a marker for bipolar affective disorder comprising identifying a marker that is linked to chromosome position 4q35.2 of the human genome, wherein said marker is present in an individual suffering from a bipolar affective disorder and said marker is not present in a suitable control subject .

In another embodiment, the present invention provides a method of identifying a marker that determines a subject's predisposition to a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder comprising:

- (i) identifying a locus that is associated with the genetic variation in a bipolar affective disorder;

- (ii) identifying a marker that is linked to the locus (i), wherein said marker is associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder;
- (iii) analyzing a panel of subjects to determine those that suffer from a bipolar affective disorder, wherein not all members of the panel comprise or express the marker; and
- (iv) determining the variation in the presence or absence of the marker between the members of the panel wherein said variation indicates that the marker is involved in determining or is associated with a subjects predisposition for bipolar affective disorder and/or is diagnostic of bipolar affective disorder.

In a related embodiment, the present invention provides a method of identifying a marker that determines a subject's predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder comprising:

- (i) identifying a locus that is associated with genetic variation in a bipolar affective disorder in a subject;
- (ii) identifying an allele of a gene that is linked to the locus at (i), wherein said allele is a candidate allele that determines or is associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder;
- (iii) analyzing a panel of subjects to determine those that suffer from bipolar affective disorder, wherein not all members of the panel comprise or express the allele; and
- (iv) determining the variation in expression at (iii) wherein said variation in the presence or absence of the allele between the members of the panel indicates that the allele is a marker involved in determining or is associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder.

In a further embodiment, the present invention provides a method of identifying a marker that determines a subject's predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder comprising:

- (i) identifying a locus that is associated with genetic variation in a bipolar affective disorder in a subject;
- (ii) identifying several alleles of a gene that are linked to the locus (i), wherein said gene is a candidate gene that determines or is associated with a subjects

- predisposition for bipolar affective disorder and/or is diagnostic of a bipolar affective disorder;
- (iii) analyzing a panel of subjects to determine those that suffer from bipolar affective disorder, wherein each of the members of the panel comprise or  
5 express at least one of the alleles; and
- (iv) determining the variation at (iii) wherein said variation in the presence or absence of the alleles between the members of the panel indicates that the gene is a marker involved in determining or is associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar  
10 affective disorder.

In a preferred embodiment, a marker, allele and/or locus is linked to map position 4q35.2 of the human genome and is associated with a bipolar affective disorder.

- 15 In a preferred embodiment, the identified marker consists of a FAT gene, comprises a FAT gene or is contained within a FAT gene.

In another preferred embodiment, the identified marker is an allele of a FAT gene and/or an expression product thereof and/or a polymorphism that occurs within a FAT  
20 gene and/or an expression product thereof.

Clearly, the present invention extends to the use of a marker that is associated with a bipolar affective disorder and is within a FAT gene or an expression product thereof and/or is linked to map position 4q35.2 of the human genome in the manufacture of a  
25 diagnostic reagent for determining the predisposition of a subject to a bipolar affective disorder or diagnosing a bipolar affective disorder.

The present invention also provides a marker that is associated with a bipolar affective disorder and is within a FAT gene or an expression product thereof and/or is linked to  
30 map position 4q35.2 of the human genome when used to determine the predisposition of a subject to a bipolar affective disorder or diagnose a bipolar affective disorder.

The present invention additionally provides a probe or primer comprises at least about  
35 20 nucleotides and is capable of hybridizing to the sequence set forth in SEQ ID NO: 1

and detect a marker in a FAT gene that is associated with a bipolar affective disorder or a predisposition to a bipolar affective disorder.

Preferably, the probe or primer comprises a nucleotide sequence selected from the  
5 group consisting of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO:  
35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO:  
40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO:  
45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO:  
50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO:  
10 55, SEQ ID NO: 56, SEQ ID NO: 57 and SEQ ID NO: 58.

Furthermore, the invention provides for the use of a probe or primer comprising at least  
about 20 nucleotides that is capable of hybridizing to the sequence set forth in SEQ ID  
NO: 1 and detecting a marker in a FAT gene that is associated with a bipolar affective  
disorder or a predisposition to a bipolar affective disorder in the manufacture of a  
15 diagnostic reagent for determining the predisposition of a subject to a bipolar affective  
disorder or diagnosing a bipolar affective disorder. Preferably, the probe or primer  
comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 32,  
SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37,  
SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42,  
20 SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47,  
SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52,  
SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57  
and SEQ ID NO: 58.

25 As exemplified herein, the level of FAT gene expression is modulated by known  
therapeutics of a bipolar affective disorder, and, in particular, lithium and valproate.  
Accordingly, another aspect of the present invention provides a method of determining  
a candidate compound for the treatment of a bipolar affective disorder comprising:

- 30 (i) administering a candidate compound to an animal or cell comprising or  
expressing a marker that is associated with a bipolar affective disorder and/or is  
linked to map position 4q35.2 of the human genome and determining the level  
of FAT expression in said cell or animal;
- (ii) administering a candidate compound to an animal or cell that does not comprise  
or express a marker that is associated with a bipolar affective disorder and/or is  
35 linked to map position 4q35.2 of the human genome and determining the level  
of FAT expression in said cell or animal; and



- (iii) comparing the level of FAT expression at (i) and (ii), wherein a decreased level of FAT expression at (i) relative to (ii) indicates that the compound is a candidate compound for the treatment of a bipolar affective disorder.

5

Preferably, the level of FAT expression is determined by determining the level of a FAT polypeptide in a cell or animal.

In a particularly preferred embodiment, the level of FAT expression is determined by  
10 determining the level of a FAT mRNA in a cell.

#### Brief description of the drawings

Figure 1 is a graphical representation showing selected microsatellite markers on human chromosome 4 that show a significant association with bipolar affective  
15 disorder. The markers that showed a significant association with bipolar affective disorder are located at map position 4q35.2 and span approximately 5 megabases (Mb).

Figure 2 is a graphical representation showing a transcript map of known and predicted transcripts that map to chromosome 4q35.2. Expressed tag sequences that map to this  
20 region of the genome are also indicated at the base of the figure.

Figure 3 is a schematic representation of the human FAT genomic gene showing the location of the single nucleotide polymorphisms (SNPs) that show an association with bipolar affective disorder. The SNPs that show a significant association with bipolar  
25 affective disorder are located in exon 26 and intron 26 of the FAT gene.

Figure 4 is a tabular representation showing linkage disequilibrium in the SNPs detected in control subjects (ie., subjects that do not suffer from bipolar affective disorder). Note that the SNPs located between exon 19 and intron 26 are in linkage  
30 disequilibrium, representing a haplotype block in this region.

Figure 5 is a tabular representation showing linkage disequilibrium in the SNPs detected in subjects that suffer from a bipolar affective disorder. Note that specific SNPs located between exon 19 and intron 26 are in linkage disequilibrium in bipolar  
35 affective disorder subjects, indicating that there is a haplotype block in this region of the FAT gene.

Figure 6 is a tabular representation showing the linkage disequilibrium (LD) 26 SNPs (indicated by their RefSNP ID) analysed in the Australian case-control cohort. SNPs showing significant evidence of association with bipolar disorder are boxed. The output of LD analysis using Haploview is shown. Haplotype blocks, determined using the default confidence interval algorithm, are indicated on the LD output. The associated SNPs all fall within an 8.7 kb haplotype block (Block 3).

Figure 7 is a graphical representation showing the effect of lithium and valproate on the level of FAT mRNA. Mice were administered with lithium or valproate and the level of FAT mRNA expression relative to GAPDH mRNA expression was determined using real time PCR. High doses of lithium were observed to significantly reduce the levels of FAT expression, while high doses of valproate also appear to reduce FAT mRNA expression. \*,  $p=0.027$

Figure 8 is a graphical representation showing the region of the exon trap vectors used in the analysis of alternative splicing of the human FAT gene. Clones 1 to 3 all comprised exon 26 of the FAT gene in addition to regions of introns 25 and 26. Clone 1 comprises thymine at a position corresponding to nucleotide position 148,129 of SEQ ID NO: 1 (rs1298865) and an adenine at a position corresponding to nucleotide position 148,333 of SEQ ID NO: 1 (rs2306987); clone 2 comprises a cytosine at a position corresponding to nucleotide position 148,129 (rs1298865) of SEQ ID NO: 1 and a thymine at a position corresponding to nucleotide position 148,333 of SEQ ID NO: 1 (rs2306987); and clone 3 comprises a thymine at a position corresponding to nucleotide position 148,129 of SEQ ID NO: 1 (rs1298865).

Figure 9 is a graphical representation of a photograph showing analysis by RT-PCR of spliced mRNA derived from exon-trap clones following transfection in HEK293 cells. Lane M, 100bp DNA size marker. Lane C1, exon-trap assay positive control. Lane C2, exon-trap assay negative control. Lane 1, cDNA derived from clone 1. Lane 2, cDNA derived from clone 2. Lane 3, cDNA derived from clone 3. The identity of the arrowed bands was determined by DNA sequencing. The band labelled "ex26" represents correctly spliced *FAT* exon 26 mRNA. The band labelled "cryptic" represents *FAT* exon 26 mRNA that has been spliced to the final 55bp of the cloned *FAT* genomic sequence (and additional flanking vector sequence) via activation of a cryptic splice acceptor site that lies 93bp downstream of the SNP designated rs2306987.

Detailed description of the preferred embodiments*Methods of detecting a marker within a FAT gene that is associated with a bipolar affective disorder*

- 5 One aspect of the present invention provides a method for determining a bipolar affective disorder or a predisposition to a bipolar affective disorder, said method comprising detecting a marker within a FAT gene or an expression product thereof that is associated with a bipolar affective disorder in a sample derived from a subject, wherein the presence of said marker is indicative of a bipolar affective disorder or a  
10 predisposition to a bipolar affective disorder in the subject.

- As used herein, the term "predisposition to a bipolar affective disorder" shall be taken to mean that a subject is susceptible to a form of bipolar affective disorder or is more likely to develop a bipolar affective disorder than a normal individual or a normal  
15 population of individuals. In this regard, a marker that is indicative of a predisposition to a bipolar affective disorder may itself cause a bipolar affective disorder or, alternatively, be correlated with the development of a bipolar affective disorder.

- The term "a bipolar affective disorder" shall be taken to include all forms of bipolar  
20 affective disorder, including bipolar I disorder (severe bipolar affective (mood) disorder), schizoaffective disorder, bipolar II disorder or unipolar disorder.

In one embodiment, a bipolar affective disorder is a type I bipolar affective disorder.

- 25 In another embodiment, a bipolar affective disorder is a type II bipolar affective disorder.

In a further embodiment, a bipolar affective disorder is a schizoaffective disorder.

- 30 In a still further embodiment, a bipolar affective disorder is unipolar disorder.

- In one embodiment, the marker that is associated with a bipolar affective disorder comprises, consists of or is within a nucleic acid that comprises a nucleotide sequence at least about 80% identical to a FAT cDNA or FAT mRNA. For example, the  
35 nucleotide sequences of splice variants of FAT mRNA are set forth in SEQ ID NO: 2 and SEQ ID NO: 4.

As used herein, the term "FAT gene" shall be taken to include a genomic FAT gene, i.e. a gene that comprises a nucleotide sequence at least about 80% identical to the sequence set forth in SEQ ID NO: 1. Preferably, the degree of sequence identity is at least about 85% to 90% identity, more preferably, 90% to 95% identity and even more preferably 98% to 99% identity.

Preferably, the FAT gene is a human FAT gene.

10 In another embodiment, a FAT gene is a gene that encodes a nucleic acid (i.e. a FAT mRNA or FAT cDNA) at least about 80% identical to the sequence set forth in SEQ ID NO: 2 or 4. Preferably, the degree of sequence identity is at least about 85% to 90% identity, more preferably, 90% to 95% identity and even more preferably 98% to 99% identity.

15

In yet another embodiment, a FAT gene is capable of encoding a FAT polypeptide, e.g. a polypeptide comprising an amino acid sequence at least about 80% identical to the sequence set forth in SEQ ID NO: 3 or 5. Preferably, the degree of sequence identity is at least about 85% to 90% identity, more preferably, 90% to 95% identity and even more preferably 98% to 99% identity.

20 In determining whether or not two amino acid sequences fall within the defined percentage identity limits supra, those skilled in the art will be aware that it is possible to conduct a side-by-side comparison of the amino acid sequences. In such comparisons or alignments, differences will arise in the positioning of non-identical residues depending upon the algorithm used to perform the alignment. In the present context, references to percentage identities and similarities between two or more amino acid sequences shall be taken to refer to the number of identical and similar residues respectively, between said sequences as determined using any standard algorithm known to those skilled in the art. In particular, amino acid identities and similarities are calculated using software of the Computer Genetics Group, Inc., University Research Park, Maddison, Wisconsin, United States of America, e.g., using the GAP program of Devereaux *et al.*, *Nucl. Acids Res.* 12, 387-395, 1984, which utilizes the algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48, 443-453, 1970. Alternatively, the CLUSTAL W algorithm of Thompson *et al.*, *Nucl. Acids Res.* 22, 4673-4680, 1994, is used to obtain an alignment of multiple sequences, wherein it is necessary or desirable

to maximise the number of identical/similar residues and to minimise the number and/or length of sequence gaps in the alignment. Amino acid sequence alignments can also be performed using a variety of other commercially available sequence analysis programs, such as, for example, the BLAST program available at NCBI.

5

As used herein the term "NCBI" shall be taken to mean the database of the National Center for Biotechnology Information at the National Library of Medicine at the National Institutes of Health of the Government of the United States of America, Bethesda, MD, 20894.

10

In determining whether or not two nucleotide sequences fall within a particular percentage identity limitation recited herein, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison or multiple alignment of sequences. In such comparisons or alignments, differences may arise in the positioning of non-identical residues, depending upon the algorithm used to perform the alignment. In the present context, reference to a percentage identity between two or more nucleotide sequences shall be taken to refer to the number of identical residues between said sequences as determined using any standard algorithm known to those skilled in the art. For example, nucleotide sequences may be aligned and their identity calculated using the BESTFIT program or other appropriate program of the Computer Genetics Group, Inc., University Research Park, Madison, Wisconsin, United States of America (Devereaux et al, Nucl. Acids Res. 12, 387-395, 1984).

In a preferred embodiment, a marker associated with a bipolar affective disorder comprises, consists of or is located within a nucleic acid that comprises a nucleotide sequence at least about 80% identical to a sequence selected from the group consisting of:

- (i) a sequence at least about 80% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;
- 30 (ii) a sequence capable of encoding a polypeptide comprising an amino acid sequence at least 80% homologous to the sequence set forth in SEQ ID NO: 3 and SEQ ID NO: 5; and
- (iii) a sequence complementary to a sequence set forth in (i) or (ii).

Preferably a marker associated with a bipolar affective disorder comprises a nucleic acid comprising a nucleotide sequence at least about 80% identical to at least about 20 contiguous nucleotides in a sequence selected from the group consisting of:

- (i) a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2  
5 and SEQ ID NO: 4;
- (ii) a sequence capable of encoding a polypeptide comprising an amino acid sequence at least 80% homologous to the sequence set forth in SEQ ID NO: 3 and SEQ ID NO: 5; and
- (iii) a sequence complementary to a sequence set forth in (i) or (ii).

10

In a preferred embodiment, a marker that is associated with a bipolar affective disorder is a polymorphism of a FAT gene. As used herein, the term "polymorphism" shall be taken to mean a difference in the nucleotide sequence of the genome that occurs in a normal population of individuals. Such a polymorphism may induce changes in a  
15 mRNA and/or polypeptide encoded by the genomic DNA in which it occurs, eg. by changing an encoded amino acid or by altering the splicing or the frequency of splicing of an mRNA. Accordingly, a "polymorphism that is associated with a bipolar affective disorder" means that a particular form of the polymorphism is correlated with the development of a bipolar affective disorder in a subject, ie. in a population of subjects,  
20 those that suffer from a bipolar affective disorder are more likely to comprise the specific polymorphism that those subjects that do not suffer from a bipolar affective disorder.

As will be apparent to the skilled artisan a polymorphism that is associated with a  
25 bipolar affective disorder that occurs in a region of a FAT gene that is transcribed into mRNA or controls the transcription of mRNA (eg. controls splicing of mRNA) is detectable in an expression product of a FAT gene. Clearly the present invention encompasses a method of determining a bipolar affective disorder or a predisposition to a bipolar affective disorder comprising detecting a marker associated with a bipolar  
30 affective disorder in a FAT expression product, such as, for example, a pre-mRNA molecule, a 5' capped mRNA, a polyadenylated mRNA, and/or a mature mRNA or cDNA derived therefrom. For example, the present inventors have demonstrated that a polymorphism in the FAT gene that is associated with a bipolar affective disorder is capable of inducing production of an altered splice form of the FAT gene.  
35 Accordingly, detection of the altered splice form in a sample from a subject is

indicative of a bipolar affective disorder or a predisposition to a bipolar affective disorder.

Furthermore, a polymorphism that is associated with a bipolar affective disorder that  
5 occurs within a protein-coding region of a FAT gene may also cause a change in a polypeptide encoded by the FAT gene. Accordingly, the present invention also encompasses a method of determining a bipolar affective disorder or a predisposition to a bipolar affective disorder comprising detecting a marker associated with a bipolar affective disorder in a FAT polypeptide.

10

In a further particularly preferred embodiment, the marker comprises, consists of or is located within the 3' region of a FAT genomic gene, or the corresponding region of an expression product thereof. Preferably, the 3' region of the FAT genomic gene comprises or consists of the region spanning from nucleotide position 139,260 to  
15 nucleotide position 170,001 of SEQ ID NO: 1 (ie a nucleic acid that comprises of consists of the sequence set forth in SEQ ID NO: 6).

In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from  
20 nucleotide position 146,012 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

In a further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from  
25 nucleotide position 148,108 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

In a still further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from  
30 nucleotide position 148,199 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from  
35 nucleotide position 148,333 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

In a preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene or an expression product thereof that encodes one or more EVH1 domains of FAT. As used herein, the term EVH1 domain shall be taken to refer to the region of the FAT gene that comprises the amino acid sequence F/L PPPP. Accordingly, it is preferred that the marker comprises, consists of or is located within the region of the FAT genomic gene or an expression product thereof that encodes a polypeptide comprising an amino acid sequence from amino acid number 476 to amino acid number 608 of SEQ ID NO: 3.

10

In one embodiment, a marker associated with a bipolar affective disorder is a simple nucleotide polymorphism. As used herein, the term "simple nucleotide polymorphism" shall be taken to mean a polymorphism that comprises or consists of one or more small changes (i.e., an insertion, a deletion, a transition or a transversion) to the genome of a subject or an expression product thereof. For example, a simple nucleotide polymorphism comprises or consists of, a single nucleotide insertion or deletion, insertion or deletion of two, three or four or more nucleotides, transition of one or more nucleotides, or transversion of one or more nucleotides.

20 In a preferred embodiment, a marker that is associated with a bipolar affective disorder comprises or consists of a single nucleotide polymorphism (SNP). Methods of determining a SNP that is associated with a specific disorder are known in the art and/or described herein.

25 In a particularly preferred embodiment, a marker that is associated with a bipolar affective disorder comprises or consists of a SNP selected from the group consisting of a cytosine at a position corresponding to nucleotide 80,217 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 130,625 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 130,613 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 139,968 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 139,968 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 142,199 of SEQ ID NO: 1, an adenine at a position corresponding to nucleotide 142,460 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 145,782 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 146,008 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 146,012 of SEQ ID NO: 1, an adenine at a position

30

35



corresponding to nucleotide 146,012 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, a cytosine at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, an adenine at a position  
5 corresponding to nucleotide 148,199 of SEQ ID NO: 1, an adenine at a position corresponding to nucleotide 148,333 of SEQ ID NO: 1, a thymine at position 148,333 of SEQ ID NO: 1, a cytosine at a position corresponding to 148,333 of SEQ ID NO: 1, a cytosine at a position corresponding to nucleotide 151,403 of SEQ ID NO: 1 and a thymine at a position corresponding to nucleotide 153,127 of SEQ ID NO: 1.

10

In an even more particularly preferred embodiment, a marker associated with a bipolar affective disorder comprises or consists of a SNP selected from the group consisting of a guanine at a position corresponding to nucleotide 139,968 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 146,012 of SEQ ID NO: 1, a thymine  
15 at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, a cytosine at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, an adenine at a position corresponding to nucleotide 148,333 of SEQ ID NO: 1 and a thymine at position 148,333 of SEQ ID NO: 1.

20 In an even more particularly preferred embodiment, a marker associated with a bipolar affective disorder comprises or consists of a SNP selected from the group consisting of a guanine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), a cytosine at position 148,108 of  
25 SEQ ID NO: 1 (designated rs2306990), an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987) and a thymidine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

In one embodiment, a marker associated with a bipolar affective disorder in a subject  
30 without a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a guanine at a position corresponding to 139,968 of SEQ ID NO: 1, a guanine at a position corresponding to 146,012 of SEQ ID NO: 1, a thymine at a position corresponding to 148,108 of SEQ ID NO: 1 and a thymine at a position corresponding to 148,333 of SEQ ID NO: 1.

35

In another embodiment, a marker associated with a bipolar affective disorder in a subject with a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a thymine at a position corresponding to 139,968 of SEQ ID NO: 1, an adenine at a position corresponding to 146,012 of SEQ ID NO: 1, a cytosine at a position corresponding to 148,108 of SEQ ID NO: 1 and a cytosine at a position corresponding to 148,333 of SEQ ID NO: 1.

In one embodiment, the marker is in its homozygous form.

- 10 A subject is considered to have a family history of psychiatric illness if a first, second, third or fourth, preferably a first or second degree relative suffers from a psychiatric illness. Preferably, the psychiatric illness is a bipolar affective disorder.

In one embodiment the method of determining the predisposition of a subject to bipolar affective disorder or diagnosing bipolar affective disorder comprises determining the presence or absence of the a marker within a FAT gene that is associated with a bipolar affective disorder in a test sample derived from a subject, wherein a presence or absence of the marker linked to chromosome 4q35.2 indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder.

20

Preferably, the marker that is present and indicates that the subject being tested is predisposed to or suffers from bipolar affective disorder comprises or consists of a nucleotide selected from the group consisting of a cytosine at position 80,217 of SEQ ID NO: 1 (designated rs172903), a cytosine at position 130,625 of SEQ ID NO: 1 (designated rs2249916), a cytosine at position 130,613 of SEQ ID NO: 1 (designated rs2249917), a guanine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position 142,199 of SEQ ID NO: 1 (designated rs767168), an adenine at position 142,460 of SEQ ID NO: 1 (designated rs2289550), a guanine at position 145,782 of SEQ ID NO: 1 (designated rs1280097), a guanine at position 146,008 of SEQ ID NO: 1 (designated rs1280096), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), an adenine at position 148,199 of SEQ ID NO: 1 (designated rs2306988), an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987), a cytosine at position 151,403 of SEQ ID NO: 1 (designated rs3775309) and a thymine at position 153,127 of SEQ ID NO: 1 (designated rs1973352).

In one embodiment, a marker associated with a bipolar affective disorder in a subject without a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a guanine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), a guanine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a thymine at position 148,108 of SEQ ID NO: 1 (designated rs1298865) and an adenine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

In another embodiment, a marker associated with a bipolar affective disorder in a subject with a family history of psychiatric illness comprises or consists of a SNP selected from the group consisting of a thymidine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), an adenine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a cytosine at position 148,108 of SEQ ID NO: 1 (designated rs1298865) and a cytosine at position 148,333 of SEQ ID NO: 1 (designated rs2306987).

In another embodiment, the marker that is absent and indicates that the subject being tested is predisposed to or suffers from bipolar affective disorder comprises or consists of a nucleotide selected from the group consisting of a guanine at position 80,217 of SEQ ID NO: 1, a thymine at position 130,625 of SEQ ID NO: 1 (designated rs2249916), a thymine at position 130,613 of SEQ ID NO: 1 (designated rs2249917), a thymine at position 139,968 of SEQ ID NO: 1 (designated rs2637777), an adenine at position 142,199 of SEQ ID NO: 1 (designated rs767168), a guanine at position 142,460 of SEQ ID NO: 1 (designated rs2289550), a cytosine at position 145,782 of SEQ ID NO: 1 (designated rs1280097), an adenine at position 146,008 of SEQ ID NO: 1 (designated rs1280096), an adenine at position 146,012 of SEQ ID NO: 1 (designated rs2306990), a cytosine at position 148,108 of SEQ ID NO: 1 (designated rs1298865), a thymine at position 148,199 of SEQ ID NO: 1 (designated rs2306988), a thymine at position 148,333 of SEQ ID NO: 1 (designated rs2306987), an adenine at position 151,403 of SEQ ID NO: 1 (designated rs3775309) and an adenine at position 153,127 of SEQ ID NO: 1 (designated rs1973352).

Furthermore, the present invention is useful for determining a subject that will respond to treatment for a bipolar affective disorder. Such a method is useful as a subject that suffers from a psychiatric illness other than bipolar affective disorder that is mistakenly diagnosed with a bipolar affective disorder using the classification system currently in use may not respond to treatments designed for subjects that suffer from a bipolar affective disorder.

The present invention also encompasses a method of determining a subject that will respond to a particular treatment for bipolar affective disorder (i.e. pharmacogenomics). As will be apparent to the skilled artisan, a marker that is associated with a bipolar affective disorder is preferably detectable by standard procedures, for example by nucleic acid hybridisation or antibody binding. Accordingly, a nucleic acid marker is preferably at least about 8 nucleotides in length (for example, for detection using a locked nucleic acid (LNA) probe). To provide more specific hybridisation, a marker is preferably at least about 15 nucleotides in length or more preferably at least about 20 to 30 nucleotides in length. Such markers are particularly amenable to detection by nucleic acid hybridisation-based detection means assays, such as, for example any known format of PCR or ligase chain reaction.

Preferably, a protein marker encoded by nucleic acid that is associated with a bipolar affective disorder is suitable for antigen-based detection. As will be apparent to the skilled artisan, even a single amino acid change in a polypeptide is detectable in an antigen-based assay. However, for an antibody or ligand to detect such a change, a marker is preferably at least about 6 amino acids in length, more preferably at least about 8 to 10 amino acids in length, even more preferably at least about 14 amino acids in length. A protein marker may also be an entire protein, e.g. wherein the protein that is associated with a bipolar affective disorder is, for example, a conformation different to the protein in a normal or healthy individual.

Means for detecting the marker will be known to the skilled artisan and, in general, any nucleic acid-based or antigen-based detection means can be employed.

In one embodiment, the marker is detected by hybridising a nucleic acid probe or primer comprising the sequence of the marker to a marker linked to nucleic acid in a biological sample derived from a subject under at least moderate, or preferably high, stringency hybridisation conditions and detecting the hybridisation using a detection means, wherein hybridisation of the probe to the sample nucleic acid indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder. Preferably, the detection means is a nucleic acid hybridisation or amplification reaction.

In another embodiment, the marker is detected by hybridising a nucleic acid probe comprising the sequence of the marker to a nucleic acid that is linked to the marker in

nucleic acid in a biological sample derived from a subject and detecting the hybridisation by a detection means, wherein hybridisation of the probe to the sample nucleic acid indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder. Preferably, the detection means is an amplification reaction,  
5 or a nucleic acid extension reaction.

For the purposes of defining the level of stringency to be used in these diagnostic assays, a low stringency is defined herein as being a hybridisation and/or a wash carried out in 6 x SSC buffer, 0.1% (w/v) SDS at 28°C, or equivalent conditions. A moderate  
10 stringency is defined herein as being a hybridisation and/or washing carried out in 2 x SSC buffer, 0.1% (w/v) SDS at a temperature in the range 45°C to 65°C, or equivalent conditions. A high stringency is defined herein as being a hybridisation and/or wash carried out in 0.1 x SSC buffer, 0.1% (w/v) SDS, or lower salt concentration, and at a temperature of at least 65°C, or equivalent conditions. Reference herein to a particular  
15 level of stringency encompasses equivalent conditions using wash/hybridisation solutions other than SSC known to those skilled in the art.

Generally, the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the  
20 hybridisation and/or wash. Those skilled in the art will be aware that the conditions for hybridisation and/or wash may vary depending upon the nature of the hybridisation matrix used to support the sample DNA, or the type of hybridisation probe used.

As will be apparent to the skilled artisan a probe or primer capable of specifically  
25 detecting a marker that is associated with a bipolar affective disorder is any probe or primer that is capable of specifically hybridising to the region of the genome that comprises said marker, or an expression product thereof. As used herein "specifically hybridises" means that the polynucleotide used as a probe is used under conditions where a target polynucleotide is found to hybridize to the probe at a level significantly above  
30 background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity  
35 of interaction are measured, for example, by radiolabelling the probe, e.g. with <sup>32</sup>P.

In one embodiment, a preferred probe or primer comprises, consists of or is within a nucleic acid comprising nucleotide sequence at least about 80% identical to a sequence selected from the group consisting of:

- (i) a sequence at least about 80% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;
  - (ii) a sequence capable of encoding an amino acid sequence at least 80% identical to the sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5; and
  - (iii) a sequence complementary to a sequence set forth in (i) or (ii).
- 10 Preferably, a probe or primer comprises a nucleic acid comprising a nucleotide sequence at least about 80% identical to a sequence of 20 contiguous nucleotides from a nucleotide sequence selected from the group consisting of:
- (i) a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;
  - (ii) a sequence capable of encoding an amino acid sequence at least 80% identical to the sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 5; and
  - (iii) a sequence complementary to a sequence set forth in (i) or (ii).

#### Probe/Primer Design

- 20 As will be apparent to the skilled artisan, the specific probe or primer used in an assay of the present invention will depend upon the assay format used. Clearly, a probe or primer that is capable of specifically hybridising to or detecting the marker of interest is preferred. Methods of designing probes and/or primers for, for example, PCR or hybridisation are known in the art and described, for example, in Dieffenbach and Dveksler (Eds) (In: PCR Primer: A Laboratory Manual, Cold Spring Harbour Laboratories, NY, 1995). Furthermore, several software packages are publicly available that design optimal probes and/or primers for a variety of assays, e.g. Primer 3 available from the Center for Genome Research, Cambridge, MA, USA. Probes and/or primers useful for detection of a marker associated with bipolar affective disorder are assessed to determine those that do not form hairpins, self-prime or form primer dimers (e.g. with another probe or primer used in a detection assay). Furthermore, a probe or primer (or the sequence thereof) is assessed to determine the temperature at which it denatures from a target nucleic acid (i.e. the melting temperature of the probe or primer, or  $T_m$ ). Methods of determining  $T_m$  are known in the art and described, for example, in Santa Lucia, *Proc. Natl. Acad. Sci. USA*, 95: 1460-1465, 1995 or Bresslauer *et al.*, *Proc. Natl. Acad. Sci. USA*, 83: 3746-3750, 1986.

For example, a primer or probe useful for detecting a SNP in an allele specific PCR assay or a ligase chain reaction assay is designed such that the 3' terminal nucleotide hybridises to the site of the SNP. The 3' terminal nucleotide may be complementary to  
5 any of the nucleotides known to be present at the site of the SNP. When complementary nucleotides occur in both the probe or primer and at the site of the polymorphism the 3' end of the probe or primer hybridises completely to the marker of interest and facilitates, for example, PCR amplification or ligation to another nucleic acid. Accordingly, a probe or primer that completely hybridises to the target nucleic  
10 acid produces a positive result in an assay.

A primer useful for a primer extension reaction is designed such that it specifically hybridises to a region adjacent to a specific nucleotide of interest, eg a SNP. While the specific hybridisation of a probe or primer may be estimated by determining the degree  
15 of homology of the probe or primer to any nucleic acid using software, such as, for example, BLAST, the specificity of a probe or primer can only be determined empirically using methods known in the art.

A locked nucleic acid (LNA) or protein-nucleic acid (PNA) probe or a molecular  
20 beacon useful for, for example, detection of a SNP or microsatellite by hybridisation is at least about 8 to 12 nucleotides in length. Preferably, the nucleic acid, or derivative thereof, that hybridises to the site of the SNP or microsatellite is positioned at approximately the centre of the probe, thereby facilitating selective hybridisation and accurate detection.

25 Methods of producing/synthesising probes and/or primers useful in the present invention are known in the art. For example, oligonucleotide synthesis is described, in Gait (Ed) (In: *Oligonucleotide Synthesis: A Practical Approach*, IRL Press, Oxford, 1984); LNA synthesis is described, for example, in Nielsen *et al*, *J. Chem. Soc. Perkin Trans., 1*: 3423, 1997; Singh and Wengel, *Chem. Commun.* 1247, 1998; and PNA synthesis is described, for example, in Egholm *et al.*, *Am. Chem. Soc.*, 114: 1895, 1992; Egholm *et al.*, *Nature*, 365: 566, 1993; and Orum *et al.*, *Nucl. Acids Res.*, 21: 5332, 1993.

Methods of detecting a marker genetically linked to a region of the genome, such as, for example a microsatellite marker or a SNP are known in the art and/or described herein.

5 Nucleic acid detection methods

- Methods for detecting nucleic acids are known in the art and include for example, hybridisation based assays, amplification based assays and restriction endonuclease based assays. For example, a change in the sequence of a region of the genome or an expression product thereof, such as, for example, an insertion, a deletion, a transversion, a transition, alternative splicing or a change in the preference of or occurrence of a splice form of a gene is detected using a method, such as, polymerase chain reaction (PCR) strand displacement amplification, ligase chain reaction, cycling probe technology or a DNA microarray chip amongst others.
- 10
- 15 Methods of PCR are known in the art and described, for example, in Dieffenbach (ed) and Dveksler (ed) (*In: PCR Primer: A Laboratory Manual*, Cold Spring Harbour Laboratories, NY, 1995). Generally, for PCR two non-complementary nucleic acid primer molecules comprising at least about 20 nucleotides in length, and more preferably at least 30 nucleotides in length are hybridised to different strands of a nucleic acid template molecule, and specific nucleic acid molecule copies of the template are amplified enzymatically. PCR products may be detected using electrophoresis and detection with a detectable marker that binds nucleic acids. Alternatively, one or more of the oligonucleotides are labelled with a detectable marker (e.g. a fluorophore) and the amplification product detected using, for example, a lightcycler (Perkin Elmer, Wellesley, MA, USA). Clearly, the present invention also encompasses quantitative forms of PCR, such as, for example, Taqman assays.
- 20
- 25

- Strand displacement amplification (SDA) utilises oligonucleotides, a DNA polymerase and a restriction endonuclease to amplify a target sequence. The oligonucleotides are hybridised to a target nucleic acid and the polymerase used to produce a copy of this region. The duplexes of copied nucleic acid and target nucleic acid are then nicked with an endonuclease that specifically recognises a sequence at the beginning of the copied nucleic acid. The DNA polymerase recognises the nicked DNA and produces another copy of the target region at the same time displacing the previously generated nucleic acid. The advantage of SDA is that it occurs in an isothermal format, thereby facilitating high-throughput automated analysis.
- 30
- 35



Ligase chain reaction (described in EU 320,308 and US 4,883,750) uses at least two oligonucleotides that bind to a target nucleic acid in such a way that they are adjacent. A ligase enzyme is then used to link the oligonucleotides. Using thermocycling the  
5 ligated oligonucleotides then become a target for further oligonucleotides. The ligated fragments are then detected, for example, using electrophoresis, or MALDI-TOF. Alternatively, or in addition, one or more of the probes is labelled with a detectable marker, thereby facilitating rapid detection.

10 Cycling Probe Technology uses chimeric synthetic probe that comprises DNA-RNA-DNA that is capable of hybridising to a target sequence. Upon hybridisation to a target sequence the RNA-DNA duplex formed is a target for RNase H thereby cleaving the probe. The cleaved probe is then detected using, for example, electrophoresis or MALDI-TOF.

15

In one embodiment, a marker that is associated with a bipolar affective disorder occurs within a protein coding region of a genomic gene (e.g. a FAT gene) and is detectable in mRNA encoded by that gene. For example, such a marker may be an alternate splice-form of a mRNA encoded by a genomic gene (eg. a splice form not observed in a  
20 subject that does not carry the polymorphism, or, alternatively, an increase or decrease in the level of a splice form in a subject that carries a polymorphism). Such a marker may be detected using, for example, reverse-transcriptase PCR (RT-PCR), transcription mediated amplification (TMA) or nucleic acid sequence based amplification (NASBA), although any mRNA or cDNA based hybridisation and/or amplification protocol is  
25 clearly amenable to the instant invention

Methods of RT-PCR are known in the art and described, for example, in Dieffenbach (ed) and Dveksler (ed) (*In: PCR Primer: A Laboratory Manual*, Cold Spring Harbour Laboratories, NY, 1995).

30

Methods of TMA or self-sustained sequence replication (3SR) use two or more oligonucleotides that flank a target sequence, a RNA polymerase, RNase H and a reverse transcriptase. One oligonucleotide (that also comprises a RNA polymerase binding site) hybridises to an RNA molecule that comprises the target sequence and the  
35 reverse transcriptase produces cDNA copy of this region. RNase H is used to digest the RNA in the RNA-DNA complex, and the second oligonucleotide used to produce a

copy of the cDNA. The RNA polymerase is then used to produce a RNA copy of the cDNA, and the process repeated.

NASBA systems relies on the simultaneous activity of three enzymes (a reverse transcriptase, RNase H and RNA polymerase) to selectively amplify target mRNA sequences. The mRNA template is transcribed to cDNA by reverse transcription using an oligonucleotide that hybridises to the target sequence and comprises a RNA polymerase binding site at its 5' end. The template RNA is digested with RNase H and double stranded DNA is synthesised. The RNA polymerase then produces multiple RNA copies of the cDNA and the process is repeated.

Clearly, the hybridisation to and/or amplification of a marker associated with a bipolar affective disorder using any of these methods is detectable using, for example, electrophoresis and/or mass spectrometry. In this regard, one or more of the probes/primers and/or one or more of the nucleotides used in an amplification reactions may be labelled with a detectable marker to facilitate rapid detection of a marker, for example, a fluorescent label (e.g. Cy5 or Cy3) or a radioisotope (e.g.  $^{32}\text{P}$ ).

Alternatively, amplification of a nucleic acid may be continuously monitored using a melting curve analysis method, such as that described in, for example, US 6,174,670.

In a particularly preferred embodiment, a marker associated with a bipolar affective disorder comprises a single nucleotide polymorphism. As used herein, the term "single nucleotide polymorphism" shall be taken to mean that a specific nucleic acid in the genome of a subject or an expression product thereof (the SNP may also be transcribed) may be any of two possible nucleic acid bases, or any of three nucleic acid bases, or any of four nucleic acid bases. Within a population all (or both) forms of the polymorphism will be represented, however, it is preferable that individuals with a specific form of a polymorphism also develop and/or suffer from a bipolar effective disorder. In this regard, the individual may be homozygous or heterozygous for the specific polymorphism. Preferably, the subject is homozygous for one form of the SNP.

Additional methods for detecting SNPs are known in the art, and reviewed, for example, in Landegren *et al*, *Genome Research* 8: 769-776, 1998).

For example, a SNP that introduces or alters a sequence that is a recognition sequence for a restriction endonuclease is detected by digesting DNA with the endonuclease and detecting the fragment of interest using, for example, Southern blotting (described in Ausubel *et al* (In: Current Protocols in Molecular Biology. Wiley Interscience, ISBN 5 047 150338, 1987) and Sambrook *et al* (In: Molecular Cloning: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, New York, Third Edition 2001)). Alternatively, a nucleic acid amplification method described *supra*, is used to amplify the region surrounding the SNP. The amplification product is then incubated with the endonuclease and any resulting fragments detected, for example, by 10 electrophoresis, MALDI-TOF or PCR.

The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam-Gilbert method (see Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (2nd Ed., 15 CSHP, New York 1989); Zyskind *et al.*, Recombinant DNA Laboratory Manual, (Acad. Press, 1988)). For example, a region of the genomic FAT gene of a subject suspected of suffering from a bipolar affective disorder or at risk of suffering from a bipolar affective disorder is amplified using an amplification reaction, e.g., PCR. Following purification of the amplification of the amplification product, this is used in 20 a sequencing reaction to determine the sequence of one or both alleles at the site of a SNP of interest.

Alternatively, a SNP is detected using single stranded conformational polymorphism (SSCP) analysis. SSCP analysis relies upon the formation of secondary structures in 25 nucleic acids and the sequence dependent nature of these secondary structures. In one form of this analysis an amplification method, such as, for example, a method described *supra*, is used to amplify a nucleic acid that comprises a SNP. The amplified nucleic acids are then denatured, cooled and analysed using, for example, non-denaturing polyacrylamide gel electrophoresis, mass spectrometry, or liquid 30 chromatography (eg. HPLC or dHPLC). Regions that comprise different sequences form different secondary structures, and as a consequence migrate at different rates through, for example, a gel and/or a charged field. Clearly, a detectable marker may be incorporated into a probe/primer useful in SSCP analysis to facilitate rapid marker detection.

Alternatively, any nucleotide changes may be detected using, for example, mass spectrometry or capillary electrophoresis. For example, amplified products of a region of DNA comprising a SNP from a test sample are mixed with amplified products from a normal/healthy individual. The products are denatured and allowed to reanneal. Those  
5 samples that comprise a different nucleotide at the position of the SNP will not completely anneal to a nucleic acid molecule from a normal/healthy individual thereby changing the charge and/or conformation of the nucleic acid, when compared to a completely annealed nucleic acid. Such incorrect base pairing is detectable using, for example, mass spectrometry.

10

As exemplified herein, mass spectrometry is also useful for detecting the molecular weight of a short amplified product, wherein a nucleotide change causes a change in molecular weight of the nucleic acid molecule (such a method is also described, for example, in US 6,574,700).

15

Allele specific PCR (as described, for example, In Liu *et al*, *Genome Research*, 7: 389-398, 1997) is also useful for determining the presence of one or other allele of a SNP. An oligonucleotide is designed, in which the most 3' base of the oligonucleotide hybridizes to a specific form of the the SNP of interest (i.e., allele). During a PCR  
20 reaction, if the 3' end of the oligonucleotide does not hybridise to a target sequence, little or no PCR product is produced, indicating that a base other than that present in the oligonucleotide is present at the site of SNP in the sample. PCR products are then detected using, for example, gel or capillary electrophoresis or mass spectrometry.

25 Primer extension methods (described, for example, in Dieffenbach (ed) and Dveksler (ed) (*In*: PCR Primer: A Laboratory Manual, Cold Spring Harbour Laboratories, NY, 1995)) are also useful for the detection of a SNP. An oligonucleotide that hybridises to the region of a nucleic acid adjacent to the SNP. This oligonucleotide is then used in a primer extension protocol with a polymerase and a free nucleotide diphosphate that  
30 corresponds to either or any of the possible bases that occur at the SNP. Preferably the nucleotide-diphosphate is labelled with a detectable marker (e.g. a flurophore). Following primer extension, unbound labelled nucleotide diphosphates are removed, e.g. using size exclusion chromatography or electrophoresis, or hydrolized, using for example, alkaline phosphatase, and the incorporation of the labelled nucleotide into the  
35 oligonucleotide is detected, indicating the base that is present at the site of the SNP.

Alternatively, or in addition, as exemplified herein primer extension products are detected using mass spectrometry (eg. MALDI-TOF).

Clearly, the present invention extends to high-throughput forms of primer extension  
5 analysis, such as, for example, minisequencing (Sy Vämen *et al.*, *Genomics* 9: 341-342, 1995). In such a method, a probe or primer (or multiple probes or primers) are immobilized on a solid support (e.g. a glass slide). A biological sample comprising nucleic acid is then brought into direct contact with the probe/s or primer/s, and a primer extension protocol performed with each of the free nucleotide bases labelled  
10 with a different detectable marker. The nucleotide present at a SNP or a number of SNPs is then determined by determining the detectable marker bound to each probe and/or primer.

Fluorescently labelled locked nucleic acid (LNA) molecules or fluorescently labelled  
15 protein-nucleic acid (PNA) molecules are useful for the detection of SNPs (as described in Simeonov and Nikiforov, *Nucleic Acids Research*, 30(17): 1-5, 2002). LNA and PNA molecules bind, with high affinity, to nucleic acid, in particular, DNA. Fluorophores (in particular, rhodamine or hexachlorofluorescein) conjugated to the LNA or PNA probe fluoresce at a significantly greater level upon hybridisation of the probe  
20 to target nucleic acid compared to a probe that has not hybridized to a target nucleic acid. However, the level of increase of fluorescence is not enhanced to the same level when even a single nucleotide mismatch occurs. Accordingly, the degree of fluorescence detected in a sample is indicative of the presence of a mismatch between the LNA or PNA probe and the target nucleic acid, such as, in the presence of a SNP.  
25 Preferably, fluorescently labelled LNA or PNA technology is used to detect a single base change in a nucleic acid that has been previously amplified using, for example, an amplification method described *supra*.

As will be apparent to the skilled artisan, LNA or PNA detection technology is  
30 amenable to a high-throughput detection of one or more markers immobilising an LNA or PNA probe to a solid support, as described in Orum *et al.*, *Clin. Chem.* 45: 1898-1905, 1999.

Similarly, Molecular Beacons are useful for detecting SNPs directly in a sample or in  
35 an amplified product (see, for example, Mhlang and Malmberg, *Methods* 25: 463-471, 2001). Molecular beacons are single stranded nucleic acid molecules with a stem-and-

loop structure. The loop structure is complementary to the region surrounding the SNP of interest. The stem structure is formed by annealing two "arms" complementary to each other, that are on either side of the probe (loop). A fluorescent moiety is bound to one arm and a quenching moiety that suppresses any detectable fluorescence when the molecular beacon is not bound to a target sequence bound to the other arm. Upon binding of the loop region to its target nucleic acid the arms are separated and fluorescence is detectable. However, even a single base mismatch significantly alters the level of fluorescence detected in a sample. Accordingly, the presence or absence of a particular base at the site of a SNP is determined by the level of fluorescence detected.

A single nucleotide polymorphism can also be identified by hybridisation to nucleic acid arrays, an example of which are described in WO 95/11995. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

Clearly, the present invention encompasses other methods of detecting a SNP that is within a FAT gene and associated with a bipolar affective disorder, such as, for example, SNP microarrays (available from Affymetrix, or described, for example, in US 6,468,743 or Hacia *et al*, *Nature Genetics*, 14: 441, 1996), Taqman assays (as described in Livak *et al*, *Nature Genetics*, 9: 341-342, 1995), solid phase minisequencing (as described in Syvämen *et al*, *Genomics*, 13: 1008-1017, 1992), minisequencing with FRET (as described in Chen and Kwok, *Nucleic Acids Res.* 25: 347-353, 1997) or pyrominisequencing (as reviewed in Landegren *et al*, *Genome Res.*, 8(8): 769-776, 1998).

#### Protein detection methods

In another embodiment of the invention, the marker is a peptide, polypeptide or protein encoded by a nucleic acid that is within a FAT gene and associated with a bipolar

affective disorder. In accordance with this embodiment, the marker is detected by contacting a biological sample derived from a subject with an antibody or ligand that specifically binds to said marker for a time and under conditions sufficient for an antibody/ligand-antigen complex to form and then detecting the complex wherein  
5 detection of the complex indicates that the subject being tested is predisposed to or suffers from a bipolar affective disorder.

As used herein the term "ligand" shall be taken in its broadest context to include any chemical compound, polynucleotide, peptide, protein, lipid, carbohydrate, small  
10 molecule, natural product, polymer, etc. that is capable of selectively binding, whether covalently or not, to one or more specific sites on a FAT polypeptide. The ligand may bind to its target via any means including hydrophobic interactions, hydrogen bonding, electrostatic interactions, van der Waals interactions, pi stacking, covalent bonding, or magnetic interactions amongst others. It is particularly preferred that a ligand is able to  
15 specifically bind to a specific form of a FAT polypeptide (e.g. a FAT polypeptide that comprises a marker that is linked with bipolar affective disorder).

As used herein, the term "antibody" refers to intact monoclonal or polyclonal antibodies, immunoglobulin (IgA, IgD, IgG, IgM, IgE) fractions, humanized  
20 antibodies, or recombinant single chain antibodies, as well as fragments thereof, such as, for example Fab, F(ab)2, and Fv fragments.

Clearly an antibody or ligand that is specifically capable of differentiating between a polypeptide or protein marker that is associated with a bipolar affective disorder and a  
25 peptide, polypeptide or protein that is not associated with a bipolar affective disorder is preferable. For example, the antibody or ligand may detect a single amino acid change in a peptide, polypeptide or protein (i.e. compared to a normal and/or healthy individual), or alternatively an insertion or deletion of two or more amino acids (compared to a normal and/or healthy individual). Antibodies and ligands that  
30 specifically bind to such alternate forms of a FAT polypeptide are clearly encompassed by the present invention.

Antibodies capable of specifically binding a FAT polypeptide, particularly a FAT peptide, polypeptide or protein that is a marker associated with a bipolar affective  
35 disorder are produced using methods known in the art. For example, a monoclonal antibody may be prepared using a hybridoma method (essentially as described by

Kohler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976); Kohler *et al.*, *Eur. J. Immunol.* 6:292 (1976); Hammerling *et al.*, in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., (1981) pp. 563-681 ). In general, such procedures involve immunizing an animal (preferably a mouse) with a FAT polypeptide antigen or a FAT polypeptide-expressing cell. Splenocytes of such immunized mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention, e.g. the SP2O cell line. Following fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones that secrete antibodies capable of binding a form of a FAT polypeptide of interest and/or a fragment thereof.

Alternatively, a monoclonal antibody capable of binding to a form of a FAT polypeptide of interest or a fragment thereof is produced using a method such as, for example, a human B-cell hybridoma technique (Kozbar *et al.*, *Immunol. Today* 4:72, 1983), a EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.* *Monoclonal Antibodies in Cancer Therapy*, 1985 Allen R. Bliss, Inc., pages 77-96), or screening of combinatorial antibody libraries (Huse *et al.*, *Science* 246:1275, 1989).

A polyclonal or monoclonal antibody may be produced using a method essentially as described by Harlow and Lane (*In: Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In one such technique, an immunogen comprising a FAT polypeptide or a fragment thereof is injected into any one of a variety of animals (e.g. a mouse, a rat, a rabbit, a sheep, a pig, a chicken or a goat). The immunogen is derived from a natural source, produced by recombinant expression means, or artificially generated, such as by chemical synthesis (e.g., BOC chemistry or FMOC chemistry). In this regard, a FAT polypeptide or a fragment thereof may serve as the immunogen without modification. Alternatively, a FAT polypeptide or a fragment thereof is joined to a carrier protein, such as, for example bovine serum albumin. The immunogen and optionally a carrier for the protein is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and blood collected from said the animals periodically. Optionally, the immunogen is injected in the presence of an adjuvant, such as, for example Freund's complete or incomplete adjuvant to enhance the immune response to the immunogen. Monoclonal or polyclonal antibodies specific for the polypeptide may then be purified from the



blood isolated from an animal by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Methods for detecting a protein in a biological sample are known in the art and/or  
5 described herein.

For example, a standard solid-phase ELISA or FLISA format is particularly useful in determining the presence of a protein in a variety of samples.

10 In one form such an assay involves immobilising a biological sample onto a solid matrix, such as, for example a polystyrene or polycarbonate microwell or dipstick, a membrane, or a glass support (e.g. a glass slide). An antibody that specifically binds to a marker associated with a bipolar affective disorder is brought into direct contact with the immobilised biological sample, and forms a direct bond with any of its target  
15 protein present in said sample. This antibody is generally labelled with a detectable reporter molecule, such as, for example, a fluorescent label (e.g. FITC or Texas Red), a fluorescent semiconductor nanocrystal (as described in US 6,306,610) in the case of a FLISA or an enzyme (e.g. horseradish peroxidase (HRP), alkaline phosphatase (AP) or  $\beta$ -galactosidase) in the case of an ELISA, or alternatively a second labelled antibody  
20 can be used that binds to the first antibody. Following washing to remove any unbound antibody the label is detected either directly, in the case of a fluorescent label, or through the addition of a substrate, such as for example hydrogen peroxide, TMB, or toluidine, or 5-bromo-4-chloro-3-indol-beta-D-galactopyranoside (x-gal) in the case of an enzymatic label.

25 In another form, an ELISA or FLISA consists of immobilizing an antibody or ligand that specifically binds to a marker associated with a bipolar affective disorder on a solid matrix, such as, for example, a membrane, a polystyrene or polycarbonate microwell, a polystyrene or polycarbonate dipstick or a glass support. A sample is then brought into  
30 physical relation with said antibody, and said the marker associated with a bipolar affective disorder is bound or 'captured'. The bound protein is then detected using a labelled secondary antibody, for example, an anti-human FAT antibody for the detection of human FAT. Alternatively, a third labelled antibody can be used that binds the second (detecting) antibody.

35

It will be apparent to the skilled person that the assay formats described herein are amenable to high throughput formats, such as, for example automation of screening processes, or a microarray format as described in Mendoza *et al.*, *Biotechniques* 27(4): 778-788, 1999. Furthermore, variations of the above-described assay will be apparent  
5 to those skilled in the art, such as, for example, a competitive ELISA.

In another embodiment, Western blotting is used to determine the presence of a marker associated with a bipolar affective disorder in a sample. In such an assay, protein from a sample is separated using sodium dodecyl sulphate polyacrylamide gel  
10 electrophoresis (SDS-PAGE) using techniques well known in the art and described in, for example, Scopes (*In: Protein Purification: Principles and Practice*, Third Edition, Springer Verlag, 1994). Separated proteins are then transferred to a solid support, such as, for example, a membrane (e.g., a PVDF membrane), using methods known in the art, for example, electrotransfer. This membrane is then blocked and probed with a  
15 labeled antibody or ligand that specifically binds to the marker associated with a bipolar affective disorder. Alternatively, a labeled secondary, or even tertiary, antibody or ligand is used to detect the binding of a specific primary antibody. The presence of the label is then determined using an assay appropriate for the label used. An appropriate assay to detect the label will be apparent to the skilled artisan.

20

In another embodiment, a marker associated with a bipolar affective disorder is detected using immunohistochemistry or immunofluorescence. For example, a cell or tissue section that is to be analysed to determine the presence of a marker associated with a bipolar affective disorder is fixed to stabilize and protect both the cell and the  
25 proteins contained within the cell. Preferably, the method of fixation does not disrupt or destroy the antigenicity of the marker of bipolar affective disorder, thus rendering it undetectable. Methods of fixing a cell are known in the art and include for example, treatment with paraformaldehyde, treatment with alcohol, treatment with acetone, treatment with methanol, treatment with Bouin's fixative and treatment with  
30 glutaraldehyde. Following fixation a cell is incubated with a ligand or antibody capable of binding the marker associated with a bipolar affective disorder. The ligand or antibody may be labeled with a detectable marker, such as, for example, a fluorescent label (e.g. FITC or Texas Red), a fluorescent semiconductor nanocrystal (as described in US 6,306,610) or an enzyme (e.g. horseradish peroxidase (HRP)), alkaline  
35 phosphatase (AP) or  $\beta$ -galactosidase. Alternatively, a second labeled antibody that binds to the first antibody can be used to detect the first antibody. Following washing

to remove any unbound antibody, the marker of bipolar affective disorder bound to said labeled antibody is detected using the relevant detection means. Means of detecting a detectable marker will vary depending upon the type of label used and will be apparent to the skilled artisan.

5

Optionally, a method of detecting a a marker associated with a bipolar affective disorder using immunofluorescence or immunohistochemistry will comprise additional steps such as, for example, cell permeabilization (using, for example, n-octyl- $\beta$ D-glucopyranoside, deoxycholate, a non-ionic detergent such as Triton X-100 NP-40, low  
10 concentrations of ionic detergents, such as, for example SDS or saponin) and/or antigen retrieval (using, for example, heat).

Alternatively, a marker associated with a bipolar affective disorder is detected using a method such as, for example, mass spectrometry, matrix-assisted laser  
15 desorption/ionization time of flight (MALDI-TOF), electrospray ionisation (ESI), protein chip, biosensor technology, or fluorescence resonance energy transfer, is clearly contemplated in the present invention.

For example, biosensor devices generally employ an electrode surface in combination  
20 with current or impedance measuring elements to be integrated into a device in combination with the assay substrate (such as that described in U.S. Patent No. 5,567,301). An antibody that specifically binds to a marker associated with a bipolar affective disorder is preferably incorporated onto the surface of a biosensor device and a biological sample contacted to said device. A change in the detected current or  
25 impedance by the biosensor device indicates protein binding to said antibody. Some forms of biosensors known in the art also rely on surface plasmon resonance to detect protein interactions, whereby a change in the surface plasmon resonance surface of reflection is indicative of a protein binding to a ligand or antibody (U.S. Patent No. 5,485,277 and 5,492,840).

30

Biosensors are of particular use in high throughput analysis due to the ease of adapting such systems to micro- or nano-scales. Furthermore, such systems are conveniently adapted to incorporate several detection reagents, allowing for multiplexing of diagnostic reagents in a single biosensor unit. This permits the simultaneous detection  
35 of several proteins or peptides in a small amount of body fluids, such as, for example, biological samples obtained for prenatal testing.

Clearly other forms of biosensor are encompassed by the present invention, such as, for example, evanescent biosensors, microcantilever biosensors (as described in for example USSN 20030010097) or membrane biosensors as described in, for example,  
5 US 5,234,566.

#### Biological samples

In one embodiment, the biological sample is any sample that comprises a nucleated cell. More preferably, the biological sample comprises a cell that comprises a marker  
10 within a FAT gene or an expression product thereof that is associated with a bipolar affective disorder. Accordingly, preferred biological samples are samples derived from a human. Preferably, the biological sample is easily isolated, e.g. a sample selected from the group consisting of whole blood, serum, plasma, peripheral blood mononuclear cells (PBMC), a buffy coat fraction, saliva, semen, tears, sweat, hair,  
15 urine, a buccal cell and a skin cell.

Such samples are particularly preferred for use in assays that detect a marker within a FAT gene that is associated with a bipolar affective disorder that is detectable in genomic DNA.

20

In another embodiment, a biological sample comprises a cell or cell extract or mixture thereof derived from a tissue selected from the group consisting of a brain, a spinal cord, skin, a lung, a kidney and a pancreas.

25 Such samples are known to express the FAT gene at various stages of development i.e. while an embryo is developing. In particular tissue selected from the group consisting of a brain, a spinal cord, skin, a lung, a kidney and a pancreas express FAT during embryo development. Accordingly, a cell isolated from such a tissue are particularly useful in detecting a marker associated with a bipolar affective disorder in the  
30 developing embryo, ie *in utero* or prenatal testing.

Methods of isolating such a sample are known in the art and include, for example amniocentesis, chorionic villus sampling, fetal blood sampling (e.g. cordocentesis or percutaneous umbilical blood sampling) and other fetal tissue sampling (e.g., fetal skin  
35 biopsy).

As will be apparent from the preceding description, a method of detecting a marker associated with a bipolar affective disorder in an expression product of a FAT gene are particularly amenable to prenatal testing for a predisposition to a bipolar affective disorder.

5

In contrast, a method of detecting a marker associated with a bipolar affective disorder in genomic DNA is amenable to an assay for determining a bipolar affective disorder or a predisposition to bipolar affective disorder at any stage (i.e. pre-natal, post-natal and/or post-mortem).

10

Preferably, a biological sample has been isolated or derived previously from a subject by, for example, surgery, or using a syringe or swab.

Cell preparations or nucleic acid preparation derived from such tissues or cells are not to be excluded. The sample can be prepared on a solid matrix for histological analyses, or alternatively, in a suitable solution such as, for example, an extraction buffer or suspension buffer, and the present invention clearly extends to the testing of biological solutions thus prepared.

20 In one embodiment, a biological sample is derived or isolated from a subject suspected of suffering from a bipolar affective disorder. Such a subject may have been assessed by another method, such as, for example, by clinical assessment.

In another embodiment, a biological sample is derived or isolated from a subject at risk of developing a bipolar affective disorder, such as, for example, a subject with a family history of a bipolar affective disorder.

As will be apparent to the skilled artisan, detecting a marker that is associated with a bipolar affective disorder may also involve the step of detecting said marker (or another form of said marker) in a suitable control sample, eg. a normal individual or a typical population.

As used herein, the term "normal individual" shall be taken to mean that the subject is selected on the basis that they do not comprise or express a marker that is linked to bipolar affective disorder, nor do they suffer from a bipolar affective disorder. In

particular said normal individual does not comprise or express a marker within a FAT gene that is associated with a bipolar affective disorder.

Furthermore, the normal subject has not been diagnosed with any form of bipolar affective disorder using the International Classification of Diseases of the World Health Organisation (10th Edition) and the Diagnostic and Statistic Manual (4th Edition). Preferably, said individual has not suffered from a major depressive or manic episode as defined in the International Classification of Diseases of the World Health Organisation (10th Edition) and the Diagnostic and Statistic Manual (4th Edition).

Alternatively, or in addition, a suitable control sample is a control data set comprising measurements of the marker being assayed for a typical population of subjects known not to suffer from a bipolar affective disorder.

In the present context, the term "typical population" with respect to subjects known not to suffer from a bipolar affective disorder and/or comprise or express a marker of a bipolar affective disorder shall be taken to refer to a population or sample of subjects tested using, for example, the International Classification of Diseases of the World Health Organisation (10th Edition) and the Diagnostic and Statistic Manual (4th Edition) and determined not to suffer from a bipolar affective disorder and/or tested to determine the presence or absence of a marker of bipolar affective disorder, wherein said subjects are representative of the spectrum of healthy subjects or subjects known not to suffer from bipolar affective disorder.

Given that bipolar affective disorder is a quantitative trait, a subject may suffer from bipolar affective disorder and not comprise or express a marker of bipolar affective disorder described herein. Alternatively, a subject may not suffer from a bipolar affective disorder, yet comprise or express a marker of bipolar affective disorder as described herein. However, a suitable control sample for the instant invention is a sample derived from a subject that does not suffer from a bipolar affective disorder and does not comprise or express a marker of a bipolar affective disorder.

In one embodiment, the method is performed using genomic DNA derived from a biological sample. In another embodiment, the method is performed using mRNA or cDNA derived from the biological sample.

*Methods of detecting a marker linked to map position 4q35.2 of the human genome*

While determining a marker associated with a bipolar affective disorder, the present inventors found that the region of the genome linked to map position 4q35.2 of the human genome comprises a susceptibility locus for a bipolar affective disorder.

- 5 Accordingly, another aspect of the present invention provides a method for determining a bipolar affective disorder or a predisposition to a bipolar affective disorder, said method comprising detecting a marker for a bipolar affective disorder which marker is linked to map position 4q35.2 of the human genome in a sample derived from a subject, wherein the detection is indicative of a bipolar affective disorder of a predisposition to
- 10 a bipolar affective disorder in the subject.

- In one embodiment, the marker linked to map position 4q35.2 is located between or comprises the microsatellite markers designated D4S1164 (SEQ ID NO: 21) and D4S1192 (SEQ ID NO: 27). Preferably, the marker linked to map position 4q35.2 is
- 15 located between or comprises the microsatellite markers designated D4S910 (SEQ ID NO: 22) and D4S1374 (SEQ ID NO: 28). More preferably, the marker linked to map position 4q35.2 is located between or comprises the microsatellite markers designated D4S3173 (SEQ ID NO: 23) and D4S1375 (SEQ ID NO: 29). Even more preferably, the marker linked to map position 4q35.2 is located between or comprises the
- 20 microsatellite markers designated D4S3236 (SEQ ID NO: 24) and D4S3051 (SEQ ID NO: 30). Still more preferably, the marker linked to map position 4q35.2 is located between or comprises the microsatellite markers designated D4S2827 (SEQ ID NO: 25) and D4S2643 (SEQ ID NO: 31)

- 25 As used herein, the term “map position 4q35.2 of the human genome” shall be taken to refer to the region of the human genome that comprises a genomic gene encoding a FAT gene. As will be apparent to those skilled in the art a “genomic gene” includes both protein-encoding regions (i.e. exons) and non-coding regions (i.e. 5'-upstream regulatory regions such as the promoter and 5'-untranslated region, intervening
- 30 sequences or introns, and 3'-untranslated region). Accordingly, a genomic gene encoding FAT protein includes all such features and not merely the protein-encoding portion thereof.

- In one embodiment, the marker linked to map position 4q35.2 comprises or consists of
- 35 a microsatellite marker. Preferably, the microsatellite marker is selected from the group consisting of D4S1164 (SEQ ID NO: 21), D4S1192 (SEQ ID NO: 27), D4S910

(SEQ ID NO: 22), D4S1374 (SEQ ID NO: 28), D4S3173 (SEQ ID NO: 23), D4S1375 (SEQ ID NO: 29), D4S3236 (SEQ ID NO: 24), D4S3051 (SEQ ID NO: 30), D4S2827 (SEQ ID NO: 25) and D4S2643 (SEQ ID NO: 31).

- 5 In a preferred embodiment, the marker linked to map position 4q35.2 comprises, consists of or is within a nucleotide sequence at least about 80% identical to a sequence selected from the group consisting of:
- (i) a sequence at least about 80% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4;
  - 10 (ii) a sequence capable of encoding a polypeptide comprising an amino acid sequence at least 80% identical to the sequence set forth in SEQ ID NO: 3 and SEQ ID NO: 5; and
  - (iii) a sequence complementary to a sequence set forth in (i) or (ii).
- 15 In another preferred embodiment, the marker comprises, consists of or is located within the 3' region of a FAT genomic gene, or the corresponding region of an expression product thereof. Preferably, the 3' region of the FAT genomic gene comprises or consists of the region spanning from nucleotide position 139,260 to nucleotide position 170,001 of SEQ ID NO: 1 (ie a nucleic acid that comprises or consists of the sequence
- 20 set forth in SEQ ID NO: 6).

In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 146,012 to nucleotide position 170,001 of SEQ ID NO: 1, or the

25 corresponding region of an expression product thereof.

In a further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,108 to nucleotide position 170,001 of SEQ ID NO: 1, or the

30 corresponding region of an expression product thereof.

In a still further preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,199 to nucleotide position 170,001 of SEQ ID NO: 1, or the

35 corresponding region of an expression product thereof.



In another preferred embodiment, the marker comprises, consists of or is located within the region of the FAT genomic gene corresponding to the region spanning from nucleotide position 148,333 to nucleotide position 170,001 of SEQ ID NO: 1, or the corresponding region of an expression product thereof.

5

In a preferred embodiment, a marker that is associated with a bipolar affective disorder comprises or consists of a single nucleotide polymorphism (SNP). Methods of determining a SNP that is associated with a specific disorder are known in the art and/or described herein.

10

In a particularly preferred embodiment, a marker for a bipolar affective disorder which marker is linked to map position 4q35.2 of the human genome comprises or consists of a SNP. Preferably, the SNP is selected from the group consisting of a cytosine at a position corresponding to nucleotide 80,217 of SEQ ID NO: 1, a thymine at a position  
15 corresponding to nucleotide 130,625 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 130,613 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 139,968 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 139,968 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 142,199 of SEQ ID NO: 1, an adenine at a position  
20 corresponding to nucleotide 142,460 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 145,782 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 146,008 of SEQ ID NO: 1, a guanine at a position corresponding to nucleotide 146,012 of SEQ ID NO: 1, an adenine at a position corresponding to nucleotide 146,012 of SEQ ID NO: 1, a thymine at a position  
25 corresponding to nucleotide 148,108 of SEQ ID NO: 1, a cytosine at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, a thymine at a position corresponding to nucleotide 148,108 of SEQ ID NO: 1, an adenine at a position corresponding to nucleotide 148,199 of SEQ ID NO: 1, an adenine at a position corresponding to nucleotide 148,333 of SEQ ID NO: 1, a thymine at position 148,333  
30 of SEQ ID NO: 1, a cytosine at a position corresponding to 148,333 of SEQ ID NO: 1, a cytosine at a position corresponding to nucleotide 151,403 of SEQ ID NO: 1 and a thymine at a position corresponding to nucleotide 153,127 of SEQ ID NO: 1.

As will be apparent to the skilled artisan, a marker that is linked to map position 4q35.2  
35 of the human genome should be detectable using standard procedures, for example by nucleic acid hybridisation or antibody binding. Accordingly, a nucleic acid marker is

preferably at least about 8 nucleotides in length (for example, for detection using a LNA probe). To provide more specific hybridisation a marker is preferably at least about 15 nucleotides in length or more preferably at least 20 to 30 nucleotides in length. Such markers are particularly amenable to detection by nucleic acid  
5 hybridisation-based assays, such as, for example, any known format of PCR or ligase chain reaction. A marker that is a microsatellite is at least about 60 nucleotides in length, preferably at least about 80 nucleotides in length, more preferably at least about 100 nucleotides in length. However, it will be apparent to the skilled artisan that such a marker is detectable with one or more probes of shorter length (e.g. at least about 8 to  
10 about 20 nucleotides in length, more preferably, about 12 to about 20 nucleotides in length, and, even more preferably, about 15 to about 20 nucleotides in length).

Preferably a protein marker is encoded by nucleic acid that is linked to map position 4q35.2 is suitable for antigen-based detection. As will be apparent to the skilled artisan,  
15 even a single amino acid change in a polypeptide is detectable in an antigen-based assay. However, for an antibody or ligand to detect such a change, a marker is preferably at least about 6 amino acids in length, more preferably at least about 8 to 10 amino acids in length, even more preferably at least about 14 amino acids in length. A protein marker may also be an entire protein, e.g. wherein the protein that is associated  
20 with a bipolar affective disorder is, for example, a conformation different to the protein in a normal or healthy individual.

Methods of detecting nucleic acid and proteinaceous markers associated with a bipolar affective disorder described supra shall be taken to apply mutatis mutandis to methods  
25 of detecting a marker linked to map position 4q35.2 of the human genome.

Clearly the present invention encompasses the use of a multiplex assay to determine the predisposition of a subject to a bipolar affective disorder or to diagnose a bipolar affective disorder. In this regard, such a multiplexed assay may detect two or more  
30 nucleic acid markers that are associated with bipolar affective disorder and/or linked to map position 4q35.2 of the human genome. Alternatively, or in addition, a multiplexed assay may detect two or more peptide, polypeptide or protein markers that are associated with bipolar affective disorder and or encoded by nucleic acid linked to map position 4q35.2 of the human genome. The combination of nucleic acid- based and  
35 antigen-based detection methods is also contemplated by the invention.

As a further alternative, a method for the present invention for determining a bipolar affective disorder or a predisposition to a bipolar affective disorder is multiplexed with an assay that detects an allele or polymorphism of another gene or expression product thereof associated with a bipolar affective disorder. For example, a method of the present invention is multiplexed with an assay that detects an allele, polymorphism or mutation of a gene (or an expression product thereof) selected from the group consisting of a tyrosine hydroxylase as described in Leboyer *et al.*, *Lancet*, 335: 932, 1990), a serotonin transporter (5-HTT; hSERT) (as reported in Collier *et al.*, *Neuroreport*, 7: 1675-1679, 1996 and Kirov *et al.*, *Psychol. Med.*, 29: 1249-1254, 1999), a catechol-o-methyl transferase (COMT) (as described, for example, in Lachman *et al.*, *Psych. Genet.* 7: 13-17, 1997), a dopamine DRD3 receptor, a serotonin 5HT2A receptor (as described, for example, in Massat *et al.*, *Am. J. Hum. Genet.* 96: 136-140, 2000) and a monoamine oxidase A (MAOA) (Furlong *et al.*, *Am. J. Med. Genet* 88: 398-406, 1999).

*Methods of determining a marker associated with a bipolar affective disorder*

Given the tight association of the human FAT gene to a bipolar affective disorder, and the provision of numerous markers, the present invention further provides methods for identifying new markers for a bipolar affective disorder.

Another aspect of the present invention provides a method for identifying a marker that is associated with a bipolar affective disorder, said method comprising:

- (i) identifying a polymorphism or allele within a FAT gene or an expression product thereof;
- (ii) analyzing a panel of subjects to determine those that suffer from a bipolar affective disorder, wherein not all members of the panel comprise the polymorphism or allele; and
- (iii) determining the variation in the development of a bipolar affective disorder wherein said variation indicates that the polymorphism or allele is associated with a subject's predisposition to a bipolar affective disorder.

Methods for determining the association between a marker and a disease, disorder and/or a phenotype are known in the art and reviewed, for example, in King (Ed) Rotter (Ed) and Motulski (Ed), *The Genetic Basis of Common Disease*, Oxford University Press, 2nd Edition, ISBN 0195125827, and Miller and Cronin (Eds), *Genetic*

Polymorphisms and Susceptibility to Disease, Taylor and Francis, 1st Edition, ISBN 0748408223.

Generally, determining an association between a marker (eg a polymorphism and/or allele) and a disease, disorder or phenotype involves comparing the frequency of a polymorphism or allele at a specific locus between a sample of unrelated affected individuals (ie they comprise the phenotype of interest and/or suffer from the disease/disorder of interest) and an appropriate control that is representative of the allelic distribution in the normal population. Accordingly, association studies are performed at the population level rather than within families, as is the case for linkage studies.

Several methods are useful for determining an association between a marker and a disease, disorder and/or phenotype of interest. However, any such study should consider several parameters to avoid difficulties, such as, for example, population stratification, that may produce false positive results.

Population stratification occurs when there are multiple subgroups with different allele frequencies present within a population. The different underlying allele frequencies in the sampled subgroups may be independent of the disease, disorder and/or phenotype within each group, and, as a consequence, may produce erroneous conclusions of linkage disequilibrium or association.

Generally, problems of population stratification are avoided by using appropriate control samples. For example, case-comparison based design may be used in which a comparison between a group of unrelated probands with the disease, disorder and/or phenotype and a group of control (comparison) individuals who are unrelated to each other or to the probands, but who have been matched to the proband group on relevant variable (other than affection status) that may influence genotype (eg. sex, ethnicity and/or age).

Alternatively, controls are screened to exclude those subjects that have a personal history of the disease, disorder and/or phenotype of interest (and/or a family history of the disease, disorder and/or phenotype of interest). Such a "supernormal" control group is representative of the allele distribution of individuals unaffected by a disease, disorder and/or phenotype of interest.

Alternatively, a family-based association method may be used, in which non-transmitted alleles of the parents of a singly, ascertained proband are used as a random sample of alleles from which the proband was sampled. Such non-transmitted alleles  
5 are used to construct a matched control sample.

One extension of a family-based association method (the transmission disequilibrium test, TDT) uses a McNemar statistic to test for excess transmission of a marker allele to affected individuals above that expected by chance (Spielman *et al.*, *Am. J. Hum. Genet.*, 52: 506-516, 1993). Essentially, TDT considers parents who are heterozygous  
10 for an allele and/or polymorphism associated with a disease, disorder or phenotype and evaluates the frequency with which the allele and/or polymorphism or its alternate is transmitted to affected offspring. By only studying heterozygous parental genotypes TDT provides a test of association between linked loci and, as a consequence, avoids  
15 false associations between unlinked loci in the presence of population stratification.

The TDT method has been further refined to account for, for example multiallelic markers (Sham and Curtis *Ann. Hum. Genet.*, 59: 323-326, 1995), multiple siblings in a family (Spielman and Ewens *Am. J. Hum. Genet.*, 62:450-458, 1998), missing parental  
20 data (Curtis, *Ann. Hum. Genet.*, 61: 319-333, 1997) and quantitative traits (Allison, *Am. J. Hum. Genet.*, 60: 676-690, 1997 and Martin *et al.*, *Am. J. Hum. Genet.*, 67: 146-154, 2000).

In general, analysis of association is a test to detect non-random distribution of one or  
25 more alleles and/or polymorphisms within subjects affected by a disease/disorder and/or phenotype of interest. The comparison between the test population and a suitable control population is made under the null hypothesis assumption that the locus to which the alleles and/or polymorphisms are linked has no influence on phenotype, and from this a nominal p-value is produced. For analysis of a biallelic polymorphism  
30 (eg a SNP) using a case control study, a chi-square analysis (or equivalent test) of a 2 x 2 contingency table (for analysis of alleles ) or a 3 x 2 contingency table (for analysis of genotypes) is used.

For analysis using a family-based association study, marker data from members of the  
35 family of each proband are used to estimate the expected null distributions and an

appropriate statistical test performed that compares observed data with that expected under the null hypothesis.

- Another method useful in the analysis of association of a marker with a disease,  
5 disorder and/or phenotype is the genomic control method (Devlin and Roeder,  
*Biometrics*, 55: 997-1004, 1999). For a case-control analysis of candidate  
allele/polymorphism the genetic control method computes chi-square test statistics for  
both null and candidate loci. The variability and/or magnitude of the test statistics  
10 observed for the null loci are increased if population stratification and/or unmeasured  
genetic relationships among the subjects exists. This data is then used to derive a  
multiplier that is used to adjust the critical value for significance test for candidate loci.  
In this manner, genetic control permits analysis of stratified case-control data without  
an increased rate of false positives.
- 15 A structured association approach (Pritchard *et al.*, *Am. J. Hum. Genet.*, 67: 170-181,  
2000) uses marker loci unlinked to a candidate marker to infer subpopulation  
membership. Latent class analysis is used to control for the effect of population  
substructure. Essentially, null loci are used to estimate the number of subpopulations  
and the probability of a subject's membership to each subpopulation. This method is  
20 then capable of accounting for a change in allele/polymorphism frequency as a result of  
population substructure.

- Alternatively, or in addition, should a particular gene or gene product be likely to be  
involved in a disease, disorder or phenotype of interest a Bayesian statistical approach  
25 may be used to determine the significance of an association between an allele and/or  
polymorphism of that gene and the disease, disorder or phenotype of interest. Such an  
approach takes account of the prior probability that the locus under examination is  
involved in the disease, disorder or phenotype of interest (eg, Morris *et al.*, *Am. J. Hum.  
Genet.*, 67: 155-169, 2001).

- 30 Publicly available software are used to determine an association between an allele  
and/or polymorphism and a bipolar affective disorder or a predisposition to a bipolar  
affective disorder. Such software include, for example, the following:
- (i) Analysis of Complex Traits (ACT), which includes methods for multivariate  
35 analysis of complex traits. ACT is based on the research reported in Amos, et

- al., Ann. Hum. Genet. 60:143-160, 1996 and Amos, Am.J.Hum.Genet., 54:535-543, 1994;
- (ii) ADMIXMAP, a general-purpose program for modelling admixture using marker genotypes and trait data of individuals from an admixed population; useful for estimate individual and population level admixture, test for a relationship between disease risk and individual admixture in case-control, cross-sectional or cohort studies, localize genes underlying ethnic differences in disease risk by admixture mapping and control for population structure (variation in individual admixture) in genetic association studies so as to eliminate associations with unlinked genes;
- (iii) ANALYZE, an accessory program for the LINKAGE program that facilitates both parametric and non-parametric tests for association;
- (iii) BAMA (Bayesian analysis of multilocus association), useful for selecting a trait-associated subset of markers among many candidates; and
- (iv) CLUMP, a Monte Carlo method for assessing significance of a case-control association study with multi-allelic marker;
- (v) ET-TDT (evolutionary tree - transmission disequilibrium test) and ETTDT (extended transmission disequilibrium test), extensions of the TDT test; and
- (vi) FBAT (family based association test), useful for testing for association/linkage between disease phenotypes and haplotypes by utilizing family-based controls

Preferably, a marker that is determined using any of the methods described *supra* is within a FAT gene and is associated with a bipolar affective disorder.

*25 Methods of determining a marker for a bipolar affective disorder linked to map position 4q35.2 of the human genome*

Another aspect of the present invention provides a method for identifying a marker for bipolar affective disorder comprising identifying a marker that is linked to chromosome position 4q35.2 of the human genome, wherein said marker is present in an individual suffering from bipolar affective disorder and said marker is not present in a suitable control sample, eg. a normal or healthy individual or a typical population of subjects that do not suffer from a bipolar affective disorder or the distribution of the marker is significantly associated with a bipolar affective disorder.

Preferably, the identified marker is present in a plurality of individuals suffering from bipolar affective disorder, and/or not present in a plurality of normal and/or healthy individuals.

- 5 In another embodiment, the present invention provides a method of identifying a marker that determines a subject's predisposition to a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder comprising:
- (i) identifying a locus that is associated with the genetic variation in a bipolar affective disorder;
  - 10 (ii) identifying a marker that is linked to the locus at (i), wherein said marker associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder ;
  - (iii) analyzing a panel of subjects to determine those that suffer from bipolar affective disorder, wherein not all members of the panel comprise or express the
  - 15 marker; and
  - (iv) determining the variation in the presence or absence of the marker between the members of the panel wherein said variation indicates that the marker is involved in determining or is associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder.

20

In a related embodiment, the present invention provides a method of identifying a marker that determines a subject's predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder comprising:

- (i) identifying a locus that is associated with genetic variation in a bipolar affective
- 25 disorder in a subject;
- (ii) identifying an allele of a gene that is linked to the locus at (i), wherein said allele is a candidate allele that determines or is associated with a subjects predisposition for bipolar affective disorder and/or is diagnostic of a bipolar affective disorder ;
- 30 (iii) analyzing a panel of subjects to determine those that suffer from bipolar affective disorder, wherein not all members of the panel comprise or express the allele and;
- (iv) determining the variation in expression at (iii), wherein said variation in the presence or absence of the allele between the members of the panel indicates
- 35 that the allele is a marker involved in determining or associated with a subjects



predisposition for bipolar affective disorder and/or is diagnostic of a bipolar affective disorder.

In a further embodiment, the present invention provides a method of identifying a marker that determines a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder comprising:

- (i) identifying a locus that is associated with genetic variation in a bipolar affective disorder in a subject;
- (ii) identifying several alleles of a gene that are linked to the locus (i), wherein said gene is a candidate gene that determines a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder;
- (iii) analyzing a panel of subjects to determine those that suffer from a bipolar affective disorder, wherein each of the members of the panel comprise or express at least one of the alleles; and
- (iv) determining the variation at (iii) wherein said variation in the presence or expression of the alleles between the members of the panel indicates that the gene is a marker involved in determining or is associated with a subjects predisposition for a bipolar affective disorder and/or is diagnostic of a bipolar affective disorder.

In a preferred embodiment, the marker, allele or gene is linked to map position 4q35.2 of the human genome and is associated with a bipolar affective disorder.

In a preferred embodiment, the identified marker consists of a FAT gene, comprises a FAT gene or is contained within a FAT gene. In another preferred embodiment, the identified marker is an allele of a FAT gene.

A number of mapping methods for determining useful loci and estimating their effects have been described (e.g. as reviewed in, Broeckel and Schork, *J Physiol*, 2003, Zheng *et al.*, *World J Gastroenterol.* 9(8):1646-56, 2003, Tomer, *Autoimmun Rev. Aug;1(4):198-204*, 2002, Haines and Pericack (Eds) *In: Approaches to gene mapping in complex human diseases*, John Wiley & Sons; 1 edition, 1998). In the present context, these methods are applied to identify the major component(s) of the total genetic variance that contribute(s) to the variation in the development of a bipolar affective disorder in a subject, such as, for example, determined by clinical assessment

(e.g. using the International Classification of Diseases of the World Health Organisation (10th Edition) and the Diagnostic and Statistic Manual (4th Edition). More particularly, the segregation of known markers is used to map and/or characterize an underlying locus associated with a bipolar affective disorder. The locus method  
5 involves searching for associations between the segregating molecular markers and a bipolar affective disorder in a segregating population of subjects (i.e. by using pedigree studies), to identify the linkage of the marker to the locus.

As for statistical methods, Single Marker Analysis (Point Analysis) is used to detect a  
10 locus in the vicinity of a single marker. The number of subjects that develop a bipolar affective disorder in a population of subjects (e.g. humans) segregating for a particular marker, are compared according to the marker class. The difference in the number of subjects that develop a bipolar affective disorder provides an estimate of the phenotypic effect of substituting one allele for another allele at the locus. To determine whether or  
15 not the inferred phenotypic effect is significantly different from zero, a simple statistical test, such as t-test or F-test, is used. A significant value indicates that a locus is located in the vicinity of the marker. Single point analysis does not require a complete molecular linkage map. The further the locus is from the marker, the less likely it is to be detected statistically, as a consequence of recombination between the  
20 marker and the gene.

In the Anova, t-test or GLM approach, the association between marker genotype and development of a bipolar affective disorder comprises:

- (i) classifying a number of subjects in a particular pedigree/s by marker genotype,  
25 such as for example, using microsatellite analyses or SNP analyses (using methods known in the art and/or described herein), thereby establishing classes of subjects;
- (ii) determining the number of subjects that develop a bipolar affective disorder in each class of subjects in the pedigree, using a t-test, GLM or ANOVA; and

- (iii) determining the significance of the differences in the mean at (ii), wherein a significant difference indicates that the marker is linked to the locus that determines a predisposition to or causes a bipolar affective disorder.

5 As will be known to those skilled in the art, the difference between the means of the classes provides an estimate of the effect of the locus in determining the predisposition of a subject to a bipolar affective disorder.

In the regression approach, the association between marker genotype and phenotype is  
10 determined by a process comprising:

- (i) assigning numeric codes to marker genotypes; and
- (ii) determining the regression value  $r$  for development of a bipolar affective disorder against the codes, wherein a significant value for  $r$  indicates that the marker is linked to the locus for a bipolar affective disorder, and wherein the  
15 regression slope gives an estimate of the effect of a particular locus on the development of a bipolar affective disorder.

For QTL interval mapping, the Mapmaker algorithm developed by Lincoln *et al.*, Constructing genetic linkage maps with MAPMAKER/EXP version 3.0: A tutorial and  
20 reference manual. Whitehead Institute for Biomedical Research, Cambridge, MA, USA, 1993, can be used. The principle behind interval mapping is to test a model for the presence of a QTL at many positions between two mapped marker loci. This model is a fit of a presumptive QTL to development of a bipolar affective disorder wherein the suitability of the fit is tested by determining the maximum likelihood that a QTL for a  
25 bipolar affective disorder lies between two segregating markers. For example, in the case of a QTL located between two segregating markers, the 2-loci marker genotypes of segregating subjects will each contain mixtures of QTL genotypes. Accordingly, it is possible to search for loci parameters that best approximate the distribution in the development of a bipolar affective disorder for each marker class. Models are  
30 evaluated by computing the likelihood of the observed distributions with and without fitting a QTL effect. The map position of a QTL is determined as the maximum

likelihood from the distribution of likelihood values (LOD scores: ratio of likelihood that the effect occurs by linkage: likelihood that the effect occurs by chance), calculated for each locus.

- 5 Interval mapping by regression (Haley and Knott., *Heredity* 69, 315-324, 1992) is a simplification of the maximum likelihood method *supra* wherein basic QTL analysis or regression on coded marker genotypes is performed, except that phenotypes are regressed on the probability of a QTL genotype as determined from the linkage between development of a bipolar affective disorder and the nearest flanking markers.
- 10 In most cases, regression mapping gives estimates of QTL position and effect that are almost identical to those given by the maximum likelihood method. The approximation deviates only at places where there are large gaps, or many missing genotypes.

- In the composite interval mapping (CIM) method (Jansen and Stam, *Genetics* 136, 1447-1455, 1994; Utz and Melchinger, 1994, *supra*; Zeng, *Genetics* 136, 1457-1468, 1994), the analysis is performed in the usual way, except that the variance from other QTLs is accounted for by including partial regression giving more power and precision than simple interval mapping, because the effects of other QTLs are not present as residual variance. CIM can remove the bias that can be caused by the QTLs that are
- 15 20 linked to the position being tested.

Publicly available software are used to map a locus for a bipolar affective disorder. Such software include, for example, the following:

- (i) QTL Cartographer (<http://statgen.mcsu.edu/qtlcart/cartographer.html>) for single-  
25 marker regression, interval mapping, or composite interval mapping;
- (ii) MapQTL (<http://www.cpro.dlo.nl/cbw/>); Qgene for performing either single-  
marker regression or interval regression to map loci; and
- (iii) SAS for detecting a locus by identifying associations between marker genotype  
and a bipolar affective disorder by a single marker analysis approach such as  
30 ANOVA, t-test, GLM or REG.

Preferably, a marker that is determined using any of the methods described *supra* is in linkage disequilibrium with a locus associated with bipolar affective disorder. "Linkage disequilibrium" refers to co-inheritance of two alleles at frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given control population. The expected frequency of occurrence of two alleles that are inherited independently is the frequency of the first allele multiplied by the frequency of the second allele. Alleles that co-occur at expected frequencies are said to be in "linkage disequilibrium". The cause of linkage disequilibrium is often unclear. It can be due to selection for certain allele combinations or to recent admixture of genetically heterogeneous populations. In addition, in the case of markers that are very tightly linked to a disease gene, an association of an allele (or group of linked alleles) with the disease gene is expected if the disease mutation occurred in the recent past, so that sufficient time has not elapsed for equilibrium to be achieved through recombination events in the specific chromosomal region. When referring to allelic patterns that comprise more than one allele, a first allelic pattern is in linkage disequilibrium with a second allelic pattern if all the alleles that comprise the first allelic pattern are in linkage disequilibrium with at least one of the alleles of the second allelic pattern

Clearly, the present invention extends to the use of a marker that is linked to map position 4q35.2 of the human genome and/or associated with a bipolar affective disorder in the manufacture of a diagnostic reagent for determining the predisposition of a subject to bipolar affective disorder or diagnosing bipolar affective disorder.

The present invention also provides a marker that is linked to map position 4q35.2 of the human genome and/or associated with a bipolar affective disorder when used to determine the predisposition of a subject to bipolar affective disorder or diagnose bipolar affective disorder.

*Methods of determining a candidate compound for treatment of bipolar affective disorder.*

Currently, there are few known therapeutics for the treatment of bipolar affective disorder. Furthermore, the mode of action of those therapeutics that are currently in use is unknown. The identification of the involvement of the FAT gene in bipolar

affective disorder provides an assay for use in determining candidate compounds for the treatment of a bipolar affective disorder.

The present inventors have shown that the level of FAT mRNA is reduced in mice that are treated with lithium, a compound that is a known therapeutic of a bipolar affective disorder and appears to be reduced in mice treated with the therapeutic compound valproate. Accordingly, another aspect of the present invention provides a method of determining a candidate compound for the treatment of a bipolar affective disorder comprising:

- 10 (i) administering a candidate compound to an animal or cell comprising or expressing a marker within a FAT gene that is associated with a bipolar affective disorder and determining the level of FAT expression in said cell or animal;
- (ii) administering a candidate compound to an animal or cell that does not comprise or express a marker within a FAT gene that is associated with a bipolar affective disorder and determining the level of FAT expression in said cell or animal; and
- 15 (iii) comparing the level of FAT expression at (i) and (ii) wherein a decreased level of FAT expression at (i) relative to (ii) indicates that the compound is a candidate compound for the treatment of a bipolar affective disorder.

The inventors have shown that the level of mouse FAT is modulated by administration of lithium or valproate. Accordingly, the present invention additionally provides a method of determining a candidate compound for the treatment of a bipolar affective disorder comprising:

- 25 (i) administering a candidate compound to an animal or cell capable of expressing a FAT gene and determining the level of FAT expression in said cell or animal;
- (ii) determining the level of FAT expression in an animal or cell capable of expressing a FAT gene in the absence of the candidate compound; and
- 30 (iii) comparing the level of FAT expression at (i) and (ii), wherein a decreased level of FAT expression at (i) relative to (ii) indicates that the compound is a candidate compound for the treatment of a bipolar affective disorder.

- 35 Preferably, the level of FAT expression is determined by determining the level of a FAT polypeptide in a cell or animal.

In a particularly preferred embodiment, the level of FAT expression is determined by determining the level of a FAT mRNA in a cell.

- 5 Methods of determining the level of a nucleic acid or polypeptide are known in the art and/or described herein.

For example, standard solid-phase ELISA assay formats are particularly useful for identifying the level of expression of a FAT polypeptide. In accordance with this  
10 embodiment, an antibody that specifically binds to a FAT polypeptide is immobilized on a solid matrix, such as, for example an array of polymeric pins or a glass support. Lysate from a cell that has been incubated in the presence of a candidate compound or a cell that has not been incubated in the presence of a candidate compound is brought into physical relation with the immobilized antibody. The cell may also have been  
15 incubated in the presence of a compound that is a known therapeutic of a bipolar affective disorder, eg valproate or lithium, as a positive control. The level of captured FAT polypeptide is then detected with a suitable antibody, eg another anti-FAT antibody that binds to an epitope different to that of the capture antibody, or an anti-human antibody. The antibody is generally labeled with fluorescent molecules or  
20 conjugated to an enzyme (e.g. horseradish peroxidase), or alternatively, a second labeled antibody can be used that binds to the first antibody. The amount of FAT polypeptide is then determined using, for example, a standard curve determined using known amounts of, for example, recombinant FAT polypeptide. Alternatively, the level of a FAT polypeptide detected in the sample comprising a candidate compound  
25 may be directly compared to the level of FAT detected in a sample comprising no compound. Clearly, such an assay will require some degree of normalisation, eg., for total protein concentration.

In a particularly preferred embodiment, an amplification technique, such as, for  
30 example, real-time PCR is used to determine the level of FAT mRNA expression in a cell treated with a candidate compound. Methods of real-time PCR are known in the art and described, for example in Gibson *et al.*, *Genome Research* 6: 995-1001, 1996; Heid *et al.*, *Genome Research* 6:986-994, 1996). Real-time PCR is a technique that evaluates the level of PCR product accumulation during amplification. This technique  
35 permits quantitative evaluation of mRNA levels in multiple samples. Briefly, mRNA is extracted from a cell, tissue or organism and cDNA is prepared using standard

techniques. Oligonucleotides and fluorescent probes are designed for specific detection of expression products of genes of interest using methods known in the art and/or described herein. To quantitate the amount of specific RNA in a sample, a standard curve is generated along using a known concentration of the nucleic acid of interest, e.g., a recombinant nucleic acid cloned into a plasmid or phagemid. Standard curves may be generated using the Ct values determined in the real-time PCR, which are related to the initial cDNA concentration used in the assay. In addition, a standard curve is generated for a positive control nucleic acid (eg.  $\beta$ -actin or HPRT). Such standard curves permit standardization of initial RNA content of a tissue sample to the amount of control for comparison purposes.

It will be apparent to the skilled person that the assay formats described herein are amenable to high throughput screening of samples.

As will be apparent to the skilled artisan, the method of the present aspect of the invention is preferably though not necessarily performed in an animal or cell expressing a human FAT gene. Preferably, the human FAT gene comprises one or more markers that are associated with bipolar affective disorder. More preferably, the human FAT gene comprises a cytosine at position 80,217 of SEQ ID NO: 1, a thymine at position 130,625 of SEQ ID NO: 1, a thymine at position 130,613 of SEQ ID NO: 1, a guanine at position 139,968 of SEQ ID NO: 1, a guanine at position 142,199 of SEQ ID NO: 1, an adenine at position 142,460 of SEQ ID NO: 1, a guanine at position 145,782 of SEQ ID NO: 1, a guanine at position 146,008 of SEQ ID NO: 1, a guanine at position 146,012 of SEQ ID NO: 1, a thymine at position 148,108 of SEQ ID NO: 1, an adenine at position 148,199 of SEQ ID NO: 1, an adenine at position 148,333 of SEQ ID NO: 1, a cytosine at position 151,403 of SEQ ID NO: 1 or a thymine at position 153,127 of SEQ ID NO: 1. More preferable, the human FAT gene comprises a guanine at position 139,968 of SEQ ID NO: 1, a guanine at position 146,012 of SEQ ID NO: 1, a thymine at position 148,108 of SEQ ID NO: 1 and an adenine at position 148,333 of SEQ ID NO: 1.

Preferably, the human FAT gene is a genomic gene, such as, for example, the sequence set forth in SEQ ID NO: 1. However, a human FAT cDNA is clearly encompassed by the present invention. As will be apparent to the skilled artisan, only those markers associated with bipolar affective disorder that are in a protein coding region or control



the production of a protein coding region (eg a splice-donor or splice-acceptor site) of a human FAT gene are found in a human FAT cDNA.

In one embodiment, the human FAT gene is placed or is located in operable connection  
5 with the endogenous FAT promoter, thereby driving expression in those cells in which FAT is expressed in nature. In another embodiment, the human FAT gene is placed in operable connection with a heterologous promoter, for example to drive expression in a variety of tissues, or to produce inducible expression.

10 Placing a nucleic acid molecule under the regulatory control of, i.e., "in operable connection with", a promoter sequence means positioning said molecule such that expression is controlled by the promoter sequence. Promoters are generally positioned 5' (upstream) to the coding sequence that they control. To construct heterologous promoter/structural gene combinations, it is generally preferred to position the  
15 promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function. Similarly, the preferred positioning of a regulatory sequence element with respect to a  
20 heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the gene from which it is derived. Again, as is known in the art, some variation in this distance can also occur.

Typical promoters suitable for expression in a or in a mammalian cell, mammalian  
25 tissue or intact mammal include, for example a promoter selected from the group consisting of, retroviral LTR elements, the SV40 early promoter, the SV40 late promoter, the cytomegalovirus (CMV) promoter, the CMV IE (cytomegalovirus immediate early) promoter, the EF<sub>1 $\alpha$</sub>  promoter (from human elongation factor 1 $\alpha$ ), the EM7 promoter, the UbC promoter (from human ubiquitin C), a neuron specific enolase  
30 (NSE) promoter, the human aromatic L-amino acid decarboxylase (Chatelin *et al.*, *Brain Res Mol Brain Res.* 97(2):149-60, 2001).

Preferred mammalian cells for expression of the nucleic acid fragments include neuronal cell lines, such as, for example, a hNT2 cell, a GT1 cell, a LN18 cell, a Daoy  
35 cell, a NCIH250 cell, a DU145 cell, a SK-N-DZ cell or a PFSK cell.

Alternatively, a FAT encoding nucleic acid placed in operable connection with, for example, a constitutive promoter may be used to express FAT in any cell. For example a cell selected from the group consisting of a COS cell, a CHO cell, a murine 10T cell, a MEF cell, a NIH3T3 cell, a MDA-MB-231 cell, a MDCK cell, a HeLa cell, a K562  
5 cell, a HEK 293 cell and a 293T cell.

Methods of producing expression constructs are known in the art and are described, for example, in Ausubel *et al* (*In: Current Protocols in Molecular Biology*. Wiley Interscience, ISBN 047 150338, 1987) or Sambrook *et al* (*In: Molecular Cloning: Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, New York, Third Edition 2001).  
10

Following production of a suitable gene construct, said construct is introduced into the relevant cell. Methods of introducing the gene constructs into a cell or organism for  
15 expression are well known to those skilled in the art and are described for example, in Ausubel *et al* (*In: Current Protocols in Molecular Biology*. Wiley Interscience, ISBN 047 150338, 1987) and (Sambrook *et al* (*In: Molecular Cloning: Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, New York, Third Edition 2001). The method chosen to introduce the gene construct in depends upon the cell type in  
20 which the gene construct is to be expressed. Means for introducing recombinant DNA into a mammalian cell include, but are not limited to electroporation, PEG mediated transfection, microinjection, transfection mediated by DEAE-dextran, transfection mediated by calcium phosphate, transfection mediated by liposomes, such as, for example, Lipofectamine (Invitrogen) and/or cellfectin (Invitrogen), transduction by  
25 adenoviruses, herpesviruses, togaviruses or retroviruses and microparticle bombardment such as by using DNA-coated tungsten or gold particles (Agacetus Inc., WI,USA).

Alternatively, the gene construct is used to produce a transgenic animal, for example a transgenic mouse. Means of producing transgenic animals are known in the art and  
30 described, for example, in Hogan *et al* (*In: Manipulating the Mouse Embryo. A Laboratory Manual*, 2<sup>nd</sup> Edition. Cold Spring Harbour Laboratory. ISBN: 0879693843, 1994). For example, a gene construct comprising a human FAT cDNA or genomic gene is microinjected into the pronucleus of a fertilised mammalian oocyte. The oocyte is then microinjected into a uterus of a pseudopregnant recipient female mammal. Any  
35 offspring that are born are screened for presence of the transgene using in their genome, for example, PCR screening or Southern hybridisation using methods known in the art.

Those mice that comprise the transgene are bred, and their offspring assayed for transgene expression, using, for example, Northern blotting, RT-PCR or Western blotting. Such mice are then useful for the screening assay of the present invention.

- 5 Transgenic animals are also produced by nuclear transfer technology as described in Schnieke, A.E. *et al.*, 1997, Science, 278: 2130 and Cibelli, J.B. *et al.*, 1998, Science, 280: 1256. Using this method, cells, e.g. fibroblasts, from donor animals are stably transfected with a plasmid incorporating the coding sequences for a form of a FAT polypeptide. Stable transfectants are then fused to enucleated oocytes, cultured and  
10 transferred into female recipients.

- As will be apparent to the skilled artisan, it is preferable that a cell or animal only expresses the form of the FAT gene that comprises a marker associated with bipolar affective disorder. Accordingly, the endogenous form of a FAT gene may be disrupted  
15 using, for example, homologous recombination.

- Methods of producing a non-human animal, preferably, a non-human mammal deficient in a gene (i.e. a knockout animal) are known in the art and described, for example in Hogan *et al* (*In: Manipulating the Mouse Embryo. A Laboratory Manual*,  
20 2<sup>nd</sup> Edition. Cold Spring Harbour Laboratory. ISBN: 0879693843, 1994). For example, to produce a mutant mammal by homologous recombination an embryonic stem (ES) cell line capable of contributing to the germ line is transfected using an method known in the art and/or described herein with a targeting construct. A targeting construct typically comprises at least 2 regions that are almost identical to the  
25 region of the genome to be targeted that flank a detectable reporter molecule (such as, for example, a neomycin resistance gene or a  $\beta$ -galactosidase gene). Following transfection of ES cells, those that have successfully integrated the targeting construct into their genome (by homologous recombination) (as determined, for example, by PCR, Southern blotting, or negative selection) are microinjected into a wild-type  
30 blastocyst in order to produce a chimeric animal. As many ES cell lines retain the ability to differentiate into all cell types present in an animal, the chimera can have tissues, including the germ line, with contribution from both the normal blastocyst and the mutant ES cells. Germ-line chimeras are bred to yield animals that are heterozygous for the mutation introduced into the ES cell, and can be interbred to produce  
35 homozygous mutant mice.

Homologous recombination can also be used to produce homozygous mutant cell lines, for example as described by te Riele *et al.*, 1990, Cruz *et al.*, 1991; and Mortensen *et al.*, 1991). Clearly, cell based assays are preferred for rapid determination of candidate compounds for the treatment of a bipolar affective disorder.

5

As will be apparent to the skilled artisan, a candidate compound for the treatment of a bipolar affective disorder that is determined using a cell based assay may be validated in an animal model. Such validation ensures that the compound only influences the onset or progression of a bipolar affective disorder, and is not, for example toxic to the animal.

10

A preferred model in which to validate a compound for the treatment of bipolar affective disorder is a FAT deficient animal produced using a method described *supra* that is transgenic for human FAT that comprises a marker that is associated with a bipolar disease. Methods of determining a bipolar affective disorder in an animal are described, for example, in Gogos *et al.*, 95(17): 9991-9996. For example, an animal is studied to determine anxiety behaviour and prepulse inhibition. Preferably, a candidate compound for the treatment of bipolar affective disorder reduces anxiety behaviour and/or prepulse inhibition in a genetically modified animal subject to levels similar to that observed in a wild-type animal. As will be apparent to the skilled artisan, a candidate compound that is validated in an animal model is then further validated in clinical trials.

15

20

In one embodiment of the present invention, a modulator is a small molecule (e.g. a chemical compound, agonist, antagonist, allosteric modulator, competitive inhibitor, or non-competitive inhibitor of FAT activity).

25

In one embodiment, the compound administered comprises nucleic acid, For example, the nucleic acid is an antagonist of FAT expression, such as, for example, an antisense nucleic acid, peptide nucleic acid (PNA), ribozyme, or interfering RNA, which is complementary, in whole or in part, to a target molecule comprising a sense strand, and can hybridise with the target molecule. When introduced into a cell using suitable methods, such a nucleic acid inhibits the expression of the FAT gene encoded by the sense strand. Antisense nucleic acid, ribozymes (e.g. Cech *et al.*, USSN 4,987,071; Cech *et al.*, USSN 5,116,742; Bartel and Szostak, *Science* 261, 1411-1418, 1993), nucleic acid capable of forming a triple helix (e.g. Helene, *Anticancer Drug Res.* 6,

30

35

569-584, 1991), PNAs (Hyrup *et al.*, *Bioorganic & Med. Chem.* 4, 5-23, 1996; O'Keefe *et al.*, *Proc. Natl Acad. Sci. USA* 93, 14670-14675, 1996), interfering RNAs (Elbashir *et al.*, *Nature* 411, 494-498, 2001; Sharp, *Genes Devel.* 15, 485-490, 2001; Lipardi *et al.*, *Cell* 107, 297-307, 2001; Nishikura, *Cell* 107, 415-418, 2001) or small interfering  
5 RNAs (siRNA) may be produced by standard techniques known to the skilled artisan, based upon the sequences disclosed herein.

Accordingly, the antisense nucleic acid comprises a nucleic acid that is complementary to at least about 15-20 contiguous nucleotides of a sequence having at least about 80%  
10 identity to SEQ ID NOs: 1, 2 or 4. Ribozyme, PNA, interfering RNA or siRNA comprises a sequence that is complementary to at least about 15-20 contiguous nucleotides of a sequence having at least about 80% identity to SEQ ID NOs: 2 or 4 or a sequence transcribed from the sequence set forth in SEQ ID NO: 1 and can hybridise thereto. Preferably, an antisense ribozyme, PNA, interfering RNA or siRNA is capable  
15 of specifically hybridising to a FAT gene that comprises a marker that is associated with bipolar affective disorder

Longer molecules, comprising a sequence that is complementary to at least about 25, or 30, or 35, or 40, or 45, or 50 contiguous nucleotides of mRNA encoding a human FAT  
20 polypeptide are also encompassed by the present invention.

In one embodiment, a construct comprising an antisense nucleic acid, ribozyme, PNA, interfering RNA or siRNA, can be introduced into a suitable cell to inhibit expression of FAT. In another embodiment, such a construct can be introduced into some or all of  
25 the cells of a mammal. The antisense nucleic acid, ribozyme, PNA, or interfering RNA, inhibits expression of the target gene.

An antisense oligonucleotide is also useful for altering the splicing of a mRNA, eg. a FAT mRNA. Accordingly, alternate splicing of a FAT mRNA to include an additional  
30 sequence and/or an additional sequence, is be suppressed using an antisense oligonucleotide that hybridises to the splice junction of the region of FAT that is to be excluded. Such an approach has been shown to be successful for the suppression of the inclusion of exon 10 into the tau protein (Kalbfuss *et al.*, *J. Biol. Chem.* 276: 42986-42993, 2001.

The use of antibodies that can inhibit one or more functions characteristic of a FAT protein, such as a binding activity, is also encompassed by the present invention. .

Furthermore, the use of ligands, such as, for example, peptides that modulate activity of a FAT polypeptide is also encompassed by the present invention. Preferably, such a peptide is expressed within the cell, although the peptide may also be introduced into the cell using methods known in the art.

As will be apparent to the skilled artisan the present invention encompasses peptides that modulate the interaction of a FAT polypeptide with another peptide, polypeptide or protein, wherein that interaction inhibits the development of bipolar affective disorder.

The modulators identified using the methods described herein are useful for the therapeutic or prophylactic treatment of a bipolar affective disorder.

15

The present invention clearly encompasses the use of any *in silico* analytical method and/or industrial process for carrying the screening methods described herein into a pilot scale production or industrial scale production of an inhibitory compound identified in such screens. This invention also provides for the provision of information for any such production. Accordingly, a further aspect of the present invention provides a process for identifying or determining a compound or modulator *supra*, said method comprising:

- (i) performing a method as described herein to thereby identify or determine a compound for the treatment of a bipolar affective disorder;
- 25 (ii) optionally, determining the structure of the compound; and
- (iii) providing the compound or the name or structure of the compound such as, for example, in a paper form, machine-readable form, or computer-readable form.

Naturally, for compounds that are known albeit not previously tested for their function using a screen provided by the present invention, determination of the structure of the compound is implicit in step (i) *supra*. This is because the skilled artisan will be aware of the name and/or structure of the compound at the time of performing the screen.

As used herein, the term "providing the compound" shall be taken to include any chemical or recombinant synthetic means for producing said compound or

35

alternatively, the provision of a compound that has been previously synthesized by any person or means.

In a preferred embodiment, the compound or the name or structure of the compound is provided with an indication as to its use e.g., as determined by a screen described herein.

A further aspect of the present invention provides a process for producing a compound *supra*, said method comprising:

10 a process for identifying or determining a compound or modulator *supra*, said method comprising:

- (i) performing a method as described herein to thereby identify or determine a compound for the treatment of a bipolar affective disorder;
- (ii) optionally, determining the structure of the compound;
- 15 (iii) optionally, providing the name or structure of the compound such as, for example, in a paper form, machine-readable form, or computer-readable form; and
- (iv) providing the compound.

20 In a preferred embodiment, the synthesized compound or the name or structure of the compound is provided with an indication as to its use e.g., as determined by a screen described herein.

A further aspect of the present invention provides a method of manufacturing a compound for the treatment of a bipolar affective disorder comprising:

- (i) determining a candidate compound for the treatment of bipolar affective disorder; and
- (ii) using the compound in the manufacture of a therapeutic or prophylactic for the treatment of bipolar affective disorder.

30

In one embodiment, the method comprises the additional step of isolating the candidate compound. Alternatively, a compound is identified and is produced for use in the manufacture of a compound for the treatment of a bipolar affective disorder.

35 Formulation of a compound to be administered will depend upon the route of administration selected (e.g. solution, emulsion, capsule). An appropriate composition

or medicament comprising the compound can be prepared in a physiological carrier or vehicle (see, generally Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Co., Pa., 1985).

- 5 Alternatively, or in addition the nucleic acid encoding the protein/peptide can be introduced into a host cell capable of expressing said protein/peptide for delivery. In accordance with this embodiment, the cells can be implanted (either alone or in a barrier device), injected or introduced by any other method known in the art.
- 10 Preferably, the compound is a pharmaceutical compound.

Formulation of a pharmaceutical compound will vary according to the route of administration selected (e.g., solution, emulsion, capsule). An appropriate composition comprising the identified modulator to be administered can be prepared in a

15 physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils, for instance. Intravenous vehicles can include various additives,

20 preservatives, or fluid, nutrient or electrolyte replenishers and the like (See, generally, Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Co., Pa., 1985). For inhalation, the agent can be solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).

25 Furthermore, where the agent is a protein or peptide, the agent can be administered via *in vivo* expression of the recombinant protein. *In vivo* expression can be accomplished via somatic cell expression according to suitable methods (see, e.g. U.S. Pat. No. 5,399,346). In this embodiment, nucleic acid encoding the protein can be incorporated into a retroviral, adenoviral or other suitable vector (preferably, a replication deficient

30 infectious vector) for delivery, or can be introduced into a transfected or transformed host cell capable of expressing the protein for delivery. In the latter embodiment, the cells can be implanted (alone or in a barrier device), injected or otherwise introduced in an amount effective to express the protein in a therapeutically effective amount.

35 As will be apparent to a skilled artisan, a compound that is active *in vivo* is particular preferred. A compound that is active in a human subject is even more preferred.



Accordingly, when manufacturing a compound that is for the treatment of a bipolar affective disorder it is preferable to ensure that any components added to the compound do not inhibit or modify the activity of said compound.

- 5 The present invention is described further in the following non-limiting examples.

## EXAMPLE 1

Mapping a bipolar affective disorder locus to map position 4q35.2 of the human genome

## 5 1.1 Samples

The families used in the present study were ascertained as part of an ongoing bipolar genetics study via the Mood Disorders Unit, Prince of Wales Hospital/School of Psychiatry, University of New South Wales, Sydney, Australia. Medium to large multigenerational pedigrees with illness over at least two generations and containing a minimum of three affected individuals, at least two of whom were diagnosed with bipolar I (BPI), were recruited. Families were almost entirely of British or Irish descent. The families were assessed using the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger *et al. Arch. Gen. Psychiatry*, 51: 849-859, 1994), with interviews being undertaken by experienced psychologists and psychiatric nurses trained in this instrument. Best-estimate Research Diagnostic Criteria diagnoses were made by senior psychiatrists after independent evaluation of DIGS interviews, family informant data (using the FIGS instrument), and medical records. All marrying-in-individuals were routinely question about any family history of psychiatric illness to ensure unilateral descent of bipolar disorder in the pedigrees. All individuals who participated in the study provided appropriate informed written consent. The study was approved by the Ethics Committee of the University of New South Wales and complies with the guidelines of the National Health and Medical Research Council and the Helsinki Declaration.

The pedigree cohort in the present study comprises 55 pedigrees. The cohort is made up of 36 extended pedigrees, eight nuclear pedigrees with multiple affected offspring, and 11 affected sib pairs with parents. The 55 pedigrees contain 983 individuals with 674 individuals available for analysis including 214 affected individuals. In total, there are 108 individuals with BPI, 13 with bipolar II (BPII), 30 with schizoaffective disorder-manic type (SZ/MA), and 63 with recurrent unipolar depression (UP). The average number of individuals per pedigree is 11.8, with an average number of affected individuals per pedigree of 3.7.

Simulation analyses using SLINK and MSIM (Ott, *Proc. Natl. Acad. Sci. USA*, 86: 4175-4178, 1989; Weeks *et al. Am. J. Hum. Genet.* 47: A204, 1990) were performed on

these pedigrees to determine the power of the cohort to detect linkage and the expected maximum LOD scores to occur under heterogeneity and under the assumption of no linkage. Under the assumption of linkage and homogeneity, using a broad disease definition, a dominant model with maximum 90% age-specific penetrance and a six  
5 allele marker, the expected average and maximum LOD scores for the entire pedigree cohort are 8.3 and 22, respectively. Under the assumption of linkage and 50% heterogeneity, using a broad disease definition, a dominant model with maximum 90% age-specific penetrance and a six allele marker, the expected average and maximum LOD scores for the entire pedigree cohort are 2.5 and 19.3, respectively. Using the  
10 same model, but under the assumption of no linkage, the expected average and maximum LOD scores for the entire pedigree cohort are 0.3 and 4.9, respectively.

### *1.2 Genotyping*

DNA was extracted from whole blood using a standard salting-out method. Several  
15 microsatellite markers spanning ~50 cM on 4q35 were used in our analysis. The markers in the region were identified using the chromosome 4 summary map from The Genetic Location DataBase (LDB). Primer sequences, expected-size information, and known allele frequencies for most markers were obtained from The Genome Database. Several of the markers used in the present analysis and their relative location on  
20 Chromosome 4q are shown in Figure 1.

PCR was performed in a 15 µl volume containing 60 ng DNA, 250 µM dNTPs, 0.33 µM of each primer (the forward primer labeled with 6-FAM fluorescent dye), 2.5 mM MgCl<sub>2</sub>, 1 x PCR buffer, and 0.6 U AmpliTaq Gold polymerase (Applied Biosystems).  
25 PCR reactions were carried out on a hybaid OmniGene thermal cycler (Middlesex, UK) using the following protocol; 95°C for 12 min, 30 cycles of 95°C for 30 s, either 58 or 60°C for 30 s, 72°C for 30 s, 72°C for 5 min. PCR product (1.5 µl) was mixed with loading dye (2.5 µl formamide, 0.5 µl of 50 mg/ml blue dextran:50 mM EDTA, 0.5 µl GeneScan500 Tamra size standard). Samples were loaded onto a 4% polyacrylamide  
30 gel and electrophoresis was performed on an ABI PRISM 377 DNA Sequencer. Products were detected using the GeneScan Analysis program, version 3.1 and alleles were assigned using the Genotyper program, version 2.5 (Applied Biosystems).

There was an average of 383 genotypes determined per marker. The average number of  
35 informative meioses per marker was 290 and the average number of phase known meioses was 32.

### 1.3 Marker Ordering

CRIMAP (version 2.4) was used to construct multi-locus linkage maps of the 4q35 markers in our pedigree cohort. Markers were arranged according to informativeness (i.e., number of phase known meioses). The two most informative markers, D4S1554 and D4S171, were used as anchor markers. Each marker, in order of informativeness, was then added to the map using the 'all' function of CRIMAP and  $\log_{10}$  likelihoods were calculated. Alternative orders were tested using the 'flips' function, which calculates all permutations of adjacent markers, until only a single marker order was given. The 'fixed' function was then used to calculate the maximum likelihood recombination fractions and Kosambi cM distances for the genetic map.

### 1.4 Linkage Analysis

Two-point LOD score analysis was carried out using the ANALYZE package (Terwilliger, 1996). Three diseases and two penetrance models were used in analysis. In disease model I, individuals diagnosed with BPI or SZ/MA were classified as affected and all other family members were classified as unaffected. In model II, individuals diagnosed with BPI, SZ/MA, or BPII were classified as affected and all other family members were considered unaffected. In model III, individuals diagnosed with BPI, SZ/MA, and BPII or UP were classified as affected and all other family members were considered unaffected. Four liability classes (class 1, <20 years; class 2, 20-29 years; class 3, 30-39 years, and class 4, >40 years) were used in the analysis with maximum age-specific penetrance levels of either 60 or 90%. In the 90% model, liability classes were defined with penetrances of 0.18, 0.45, 0.68, and 0.9; those in the 60% model were defined with penetrances of 0.12, 0.30, 0.45, and 0.6. The data was analysed under both dominant and recessive inheritance models. The disease-allele frequencies was set at 0.035 for the dominant model and 0.2 for the recessive model, and the phenocopy rate of 5% was used in all analyses. Allele frequencies were calculated from the data using the DOWNFREQ program from the ANALYZE package (Terwilliger, 1996) using all individuals. Affected Sibpair and TDT analyses were performed using the ANALYZE package (Terwilliger, 1996).

### 1.5 Results

The expanded 55 pedigree cohort, comprising 674 individuals, of whom 214 are affected was genotyped with several markers spanning the 4q35 region, including

D4S1540, D4S426, D4S3051, D4S2921, and D4S1652, to test for evidence of linkage to the 4q35 region.

Evidence for linkage to the 4q35 region was strengthened in the 55 pedigree cohort, with a maximum two-point LOD score of 3.19 ( $\theta = 0.18$ ) at marker D4S1652, using diagnostic model III with a dominant mode of inheritance and 90% maximum age-specific penetrance. LOD scores greater than 1.5 were also observed for other markers genotyped in the 55 pedigrees including: D4S426, 2.49 ( $\theta = 0.2$ ) under a dominant model and D4S3051, 2.38 ( $\theta = 0.16$ ) and D4S1540, 1.57 ( $\theta = 0.18$ ) under a recessive model (as shown in Figure 1). No LOD scores greater than 1.5 were observed for any marker using the narrower disease models I (BPI and SZ/MA as affected) or II (BPI, SZ/MA, and BPII as affected).

15

#### EXAMPLE 2:

##### SNP analysis of genes in the susceptibility locus on chromosome 4q35

Following identification of the region of 4q35 of the human genome that is linked with bipolar affective disorder, SNPs located within this region and, in particular, SNPs located within the human FAT gene were analysed for an association with a bipolar affective disorder based upon a case-control study design.. These were screened in an affected individual (case) and their spouse (control) from the seven bipolar kindreds previously reported by Badenhop *et al. Am. J. Med. Genet. 117B*: 23-32 2003 as showing evidence for linkage to the chromosome 4q35 locus using the methods described below.

##### 2.1 SNP detection by direct sequencing following PCR amplification

Oligonucleotide primers were designed from genomic DNA sequence to amplify and sequence coding regions of the FAT gene, as well as flanking intronic sequences.

30

The sequence of the oligonucleotides are listed in Table 1:

Table 1  
Nucleotide sequences of oligonucleotides used to amplify and sequence regions of the  
FAT gene comprising SNPs

Gene	SNP	oligonucleotide sequence
FAT	rs172903	TGAACGATGAAAGAGGCACGACAC (SEQ ID NO: 32) GCTGAGTCACAGAAAGGCTGGTTA (SEQ ID NO: 33)
	rs2249916 & rs2249917	CTGAATCTGGGGTGTGTTTTG (SEQ ID NO: 34) CAAGTGAGTCCATTTGTTTTG (SEQ ID NO: 35)
	rs2637777	TGTGCTGGAAACAGAGAACAGGTT (SEQ ID NO: 36) ACAGTGCCATAGACAAAGGTGATT (SEQ ID NO: 37)
	rs767168	GCACCCCTTGAGACTGATTTAG (SEQ ID NO: 38) ATCTGTGGAGATTGATGACATTTG (SEQ ID NO: 39)
	rs2289550	CAACGCTGTGGAGAAACATACC (SEQ ID NO: 40) TAAAACCCCTAAATCAGTCTCAAGG (SEQ ID NO: 41)
	rs1280097	CCTCTACACTGGCAAACAAAGC (SEQ ID NO: 42) TTACAGACCTCGGAGAATAAAGAT (SEQ ID NO: 43)
	rs1280096	ATGACGCTATGAAAAGGTATGAAC (SEQ ID NO: 44) TTGTTTGCCAGTGTAGAGGATTAT (SEQ ID NO: 45)
	rs2306990	ATGACGCTATGAAAAGGTATGAAC (SEQ ID NO: 46) TTGTTTGCCAGTGTAGAGGATTAT (SEQ ID NO: 47)
	rs1298865, rs2306988, & rs2306987	TTCTTCGTTTGAGTTTGTAAGGTG (SEQ ID NO: 48) GTTAAGAAAGTTGCGAGGAAGATT (SEQ ID NO: 49)

5

PCR was performed in 25 µl volumes containing 10 mM Tris-Cl, pH 8.3; 50 mM KCl; 2.0 mM MgCl<sub>2</sub>; 200 µM each dNTP; 20 ng genomic DNA; 20 pmole each primer, and 1 U AmpliTaq Gold DNA polymerase (Applied Biosystems).

Reactions were cycled with initial denaturation at 94°C for 12 min, followed by 30 cycles of 94°C for 30 s, 60°C for 45 s, 72°C for 1 min, and a final extension of 10 min at 72°C.

5

Amplified products were purified (QIAquick PCR purification, Qiagen) and subjected to automated sequence analysis using the ABI377 automated sequencer with Big-Dye terminator sequencing (Applied Biosystems Inc.). Sequencing primers were the same as used in PCR amplification.

10

### *2.2 SNP analysis using mass spectrometry*

Oligonucleotide primers were designed from genomic DNA sequence to flank the SNPs of interest.

15 Nucleotide sequences of the oligonucleotides used in the analysis of SNPs from the FAT gene are shown in Table 2.

Table 2  
Oligonucleotides used in the analysis of SNPs in the human FAT gene using mass spectrometry

Gene	SNP	PCR oligonucleotide sequence	PCR product length	Extension oligonucleotide sequence
FAT	rs3775309	GTTGGATGTTCCCTGTACATACGAAGAAG (SEQ ID NO: 50)	118	AAAATTACTTCTGAACCTTTTCTT (SEQ ID NO: 52)
		ACGTTGGATGGAGAGCTTATCTGTAGGTGG (SEQ ID NO: 51)		
	rs1973352	ACGTTGGATGTGTTTCTGACAATCACAGCC (SEQ ID NO: 53)	90	AATCACAGCCTGAAAACACA (SEQ ID NO: 55)
		ACGTTGGATGGAGCCTGTTGTTTGTTC (SEQ ID NO: 54)		
	rs2306987	ACGTTGGATGTACTGACAAGTTCAAACACC (SEQ ID NO: 56)	89	CAAGTTCAAAACACCTATTCA (SEQ ID NO: 58)
		ACGTTGGATGTTGCATGAATGTCTGCTGGG (SEQ ID NO: 57)		



The PCR oligonucleotides were used to amplify the region of the FAT gene that comprises the SNP of interest (as indicated in Table 2). Genomic DNA (approximately 2.5ng) was used in a 5µl PCR reaction. Following amplification unincorporated nucleotides are dephosphorylated using arctic shrimp alkaline phosphatase, which is then heat inactivated.

Primer extension reactions were performed by using triple terminator mixes. Assays were grouped according to the SNP-specific requirements on the termination mixes (ddACG, ddACT, ddAGT, and ddCGT, respectively), ie. should one of the nucleotides present at the site of the SNP be a thymine (T), ddATP is used in the reaction. Accordingly, when the thymine residue is present at the sit of the SNP the extension oligonucleotide is extended by one nucleotide. When the thymine is not present at the site of the SNP, the extension oligonucleotide is extended by more than one nucleotide.

The resulting primer extension reactions are desalted and the molecular weight of the primer determined using MALDI-TOF.

### *2.3 Analysis of genotyping*

Analysis of the FAT SNPs was extended to our unrelated bipolar case-control cohort consisting of 71 bipolar cases and 66 control individuals. All individuals in the case-control cohort were genotyped for each identified SNP. While common alleles or genotypes are expected to be found in both cases and controls, a disease-associated allele or genotype will be found at greater frequency in cases. Association analysis was performed with all informative SNPs.  $\chi^2$  analysis was used to test for association between bipolar and individual SNP alleles and genotypes.

Results of analysis of SNPs located within the FAT gene are shown in Table 3 and Figure 5.

Table 3: Results of analysis of association of SNPs within *FAT* with bipolar affective disorder.

<i>FAT</i>	SNP position (including refSNP ID)	SNP	Genotype	Allele
			p-value	p-value
	Intron 2, rs172903, acceptor -4	G/C	0.23	0.43
	Exon 13, rs2249916, codon 3117	Synonymous, <u>GAT</u> ↔ <u>GAC</u>	0.56	0.31
	Exon 13, rs2249917, codon 3121	Synonymous, <u>AAC</u> ↔ <u>AAT</u>	0.38	0.31
	Exon 19, rs2637777, codon 3554	Non-synonymous, <u>ICT</u> ↔ <u>GCT</u>	0.09	0.12
	Intron 20, rs767168, acceptor -204	A/G	0.97	0.998
	Exon 21, rs2289550, codon 3847	Synonymous, <u>ACG</u> ↔ <u>ACA</u>	0.46	0.18
	Exon 23, rs1280097, codon 4061	Non-synonymous, <u>AAC</u> ↔ <u>AAG</u>	0.5	0.61
	Intron 23, rs1280096, donor +143	A/G	0.86	0.61
	Intron 23, rs2306990, donor +147	A/G	0.09	0.09
	Exon 26, rs1298865, codon 4367	Synonymous, <u>TCC</u> ↔ <u>TCT</u>	0.04	0.15
	Intron 26, rs2306988, donor +54	T/A		
	Intron 26, rs2306987, donor +188	T/A	0.016	0.04
	Intron 26, rs3775309, acceptor -3211	A/C		
	Intron 26, rs1973352, acceptor -1487	C/T		

As shown in Table 3 and Figures 4 to 6, SNPs that show a significant association with bipolar affective disorder are located between exon 19 and the 3' end of the *FAT* gene. The most significant associations are observed for the SNPs located in exon 26 and  
5 intron 26 of *FAT*. These data indicate that subjects that are homozygous for specific nucleotides at the SNPs located at the 3' end of the *FAT* gene have a higher incidence of developing a bipolar affective disorder, than those subjects that carry another nucleotide.

- 10 Genotype frequencies for each SNP were tested using  $\chi^2$  analysis and all were found to be in Hardy-Weinberg equilibrium.

Analysis of linkage disequilibrium (LD) among all tested SNPs, determined that the associated SNPs are in high LD and comprise a haplotype block that spans 8.7 kb,  
15 which is located wholly within the *FAT* gene (Figures 4 to 6). No LD was detected between *FAT* and any adjacent gene.

### EXAMPLE 3

- 20 Analysis SNPs in the *FAT* gene are associated with Bipolar Affective Disorder in a number of populations.

Using the methods described in Example 2 the association of several SNPs with bipolar affective disorder was assessed in independently ascertained bipolar disorder cohorts.  
25 These cohorts included (i) 333 New Zealand cases and controls (173 case, 160 controls), (ii) 1348 UK cases and controls (669 cases, 679 controls), (iii) 90 UK parent-proband trios, and (iv) 173 Bulgarian parent-proband trios. Given the high LD between putatively associated SNPs observed in the Australian case-control cohort, three representative tagSNPs were selected for analysis among subsequent cohorts (Table 4).  
30 In addition to total cohort analysis, association was also tested for the presence or absence of a known family history of psychiatric illness (in first or second degree relative), and for the presence or absence of psychosis.

Statistically significant evidence for association with bipolar affective disorder was  
35 observed in the UK case-control cohort for those cases with a family history of psychiatric illness (allelic  $P=0.007$ , genotypic  $P=0.025$ ). This result is consistent with

that observed for the familial biased Australian case-control cohort, with the same alleles over represented. Statistically significant evidence for association was also observed in the UK case-control cohort for those cases without a family history of mental illness (allelic  $P=0.050$ , genotypic  $P=0.020$ ), however, the observed bias was  
5 for the alternate allele to that over-represented among cases with a family history.

Both UK and Bulgarian trio cohorts showed statistically significant evidence for association among those bipolar cases who had exhibited psychosis (UK allelic  $P=0.003$ , Bulgarian allelic  $P=0.024$ ). This data provides compelling evidence for  
10 association between *FAT* genotype and bipolar disorder among unrelated individuals from four independent cohorts.

The significant but opposing shifts in genotype frequencies observed between cases with a family history of psychiatric illness, and those without a family history appear to  
15 be an example of molecular heterosis, a common phenomenon that may be seen in as many as 50% of association studies (Comings and MacMurray, *Mol. Genet. Metab.* 71: 19-31, 2000).

**Table 3** Association analysis of chromosome 4q35 tagSNPs

	rs2304865		rs1298865		rs2306987	
	Allele	geno	allele	geno	allele	geno
<b>Overall</b>						
Aust case-control	0.007	0.009	0.072	0.044	0.020	0.005
UK case-control	0.274	0.542	0.838	0.147	0.463	0.439
UK trios					0.084	
Bul trios					>0.5	
<b>FH</b>						
Aust case-control	0.007	0.006	0.010	0.007	0.010	0.004
UK case-control	0.007	0.025	0.038	0.078	0.365	0.592
UK trios					0.060	
Bul trios					0.128	
<b>No FH</b>						
Aust case-control	0.310	0.528	0.980	0.639	0.384	0.228
UK case-control	0.841	0.975	0.082	0.020	0.050	0.022
UK trios					n/a	
Bul trios					n/a	
<b>Psych</b>						
Aust case-control	0.092	0.176	0.197	0.382	0.178	0.261
UK case-control	0.466	0.487	0.512	0.194	0.329	0.484
UK trios					0.003	
Bul trios					0.024	
<b>No psych</b>						
Aust case-control	0.012	0.011	0.029	0.009	0.013	0.005
UK case-control	0.085	0.079	0.729	0.272	0.947	0.298
UK trios					>0.5	
Bul trios					0.058	

geno, genotype. Aust, Australian. UK, United Kingdom. Bul, Bulgarian. FH, family history of psychiatric illness. Psych, psychosis.

## EXAMPLE 4

Polymorphisms associated with bipolar affective disorder do not modulate FAT  
expression

*4.1 Real time PCR analysis of FAT mRNA expression*

Total RNA was prepared from human cerebellum with TRI Reagent (Sigma-Aldrich) and reverse transcribed using Superscript™ III M-MLV reverse transcriptase  
10 (Invitrogen) according to the manufacturer's instructions.

RT-PCR was carried out on reverse transcribed RNA derived from human cerebellum, as well as DNA from the following cDNA libraries (all from Clontech Laboratories Inc.); human brain-hypothalamus 5' Stretch cDNA library, human hippocampus cDNA  
15 library, human brain-amygdala 5' Stretch Plus cDNA library. RT-PCR was carried out as previously described (Blair *et al.*, *Mol. Psychiatry* 7: 867-873 2002).

*4.2 Results*

To determine whether the bipolar associated *FAT* genotype is correlated with *FAT*  
20 mRNA levels *in vivo*, we undertook quantitative real-time RT-PCR in neural tissue. No correlation was observed among an Australian population cohort of 115 normal individuals.

## EXAMPLE 5

25 Lithium and valproate modulate FAT expression

*5.1 Treatment of mice with lithium or valproate*

The animals used in the experiments to determine the effect of lithium and valproate on FAT expression were in-bred *Mus musculus*, C57Bl6 strain, between the ages of 8-  
30 16 weeks.

Control mice (matched littermates of the test mice) received intraperitoneal injections once daily of 500 µL of sterile 0.9% saline solution for a period of 7 days.

35 Mice treated with lithium were administered lithium chloride (Sigma-Aldrich) by intraperitoneal injection at a concentration of 340mg lithium/kg/day (8mmol/kg/day)

for 7 days (a single injection per day). Lithium chloride was prepared in water, and NaOH solution was added to adjust the pH to 7.5.

Mice treated with valproate were administered 2-propylpentanoic acid (Sigma-Aldrich) by intraperitoneal injection at a concentration of 350 mg/kg/day for 7 days (a single injection per day). Valproate was prepared in 0.9% saline solution.

Total volume of each injection did not exceed 500  $\mu$ L.

## 10 5.2 Tissue Collection

Four hours after the final injection on the seventh day of treatment, mice were euthanised using 4% halothane anaesthesia. The whole brain was immediately removed and snap-frozen in liquid nitrogen. In addition, a cardiac puncture was performed to collect 500  $\mu$ L of blood for drug serum quantitation. Whole mouse brains were stored at -80°C, until required.

## 5.3 Assessment of drug concentration in treated mice

To quantitate the circulating drug level in treated mice, cardiac puncture blood sample from each mouse were assayed for drug concentration by the St. Vincent's Hospital diagnostic testing facility.

Mouse brains were selected for further analysis if the serum concentration of individual mice were equivalent to that used to treat humans (i.e., 0.6-1.0 mmol/L of lithium or 45-125 mg/ml (315-885  $\mu$ mol/L) of valproate).

## 5.4 Total RNA isolation

Total RNA was prepared by extracting whole mouse brain tissue in TRI Reagent (Sigma-Aldrich, Sydney, NSW). Thawed whole brains were homogenised in TRI Reagent solution (1 mL of TRI Reagent used per 100 mg of brain tissue) for 10 min using a polypropylene hand homogeniser (Sigma-Aldrich). After homogenisation, 200  $\mu$ L of chloroform per 1 mL of TRI Reagent (Sigma-Aldrich) was added and mixed by vortexing for 30 sec. After a 10 min incubation, the upper inorganic phase was separated by centrifugation at 12,000x g (10,500 rpm) for 10 min at 4°C. Total RNA was precipitated (from the inorganic phase) by adding 500  $\mu$ L of isopropanol per mL of TRI Reagent. RNA pellets were washed with 2 mL of 75% ethanol, air dried in a fume hood and resuspended in 100  $\mu$ L of RNase-free water. The concentration of total RNA

samples were determined by measuring the absorbance at 260 nm using a GeneQuant UV spectrophotometer (Pharmacia Biotech, Sydney, NSW).

### 5.5 Reverse transcription

- 5 Reverse transcription was performed using 2 µg of total RNA. Prior to cDNA synthesis, total RNA was incubated for 15 min at room temperature with DNase I (2 units, Invitrogen, La Jolla, CA, USA) in DNase I reaction buffer (200 mM Tris-HCl (pH 8.4), 20 mM MgCl<sub>2</sub>, 500 mM KCl) to remove any DNA contamination. DNase I treatment was terminated by adding 2 µL of 25 mM EDTA (pH 8.0) and incubated at  
10 65°C for 10 min.

- Total RNA was then denatured for 10 min at 65°C in the presence of oligo dT<sub>12-18</sub> (500 ng; Invitrogen). After denaturing, cDNA was synthesised by adding first strand buffer (50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl<sub>2</sub>; Invitrogen), dNTP (400 µM  
15 each, Promega), DTT (10 mM), RNaseOUT™ ribonuclease inhibitor (80 units, Invitrogen), Superscript™ III M-MLV reverse transcriptase (400 units, Invitrogen) and incubated for 60 min at 50°C. The reaction was terminated by incubation at 70°C for 15 min and stored at -20°C.

### 20 5.6 Quantitative real-time PCR analysis

#### 5.6.1 PCR Primers

Forward and reverse primers were designed using MacVector v6.5.3 software (Oxford Molecular Group) and synthesised by Sigma Genosys Australia. Details of the oligonucleotides are shown in Table 4.



Table 4  
Details of the oligonucleotides used in the analysis of FAT mRNA expression levels

Gene	Forward primer	Reverse primer	PCR product size(bp)	An.(°C)
FAT	CCGCCGTTGTGTCTTTTG (SEQ ID NO: 59)	AACGACGCTAACACACCACAC (SEQ ID NO: 60)	426	65
GAPDH	AACCTTGGCATTGTGGAAGGG (SEQ ID NO: 61)	TCATCATACTTGGCAGGTTTCTCC (SEQ ID NO: 62)	272	58
$\beta$ -actin	TGGGAATGGGTCAGAAGACTC (SEQ ID NO: 63)	GGTCATCTTTTTCACGGTTGGC (SEQ ID NO: 64)	227	58
HPRT	GCTGGTGAAAAGGACCTCTCG (SEQ ID NO: 65)	CTGGCAACATCAACAGGACTCC (SEQ ID NO: 66)	221	52

An, annealing temperature for primer pair.

### 5.6.2 Real-Time PCR Amplification

Real-time PCR amplification was performed using 1  $\mu$ L of 2/5 diluted cDNA in a 10  $\mu$ L PCR reaction containing 1x Platinum<sup>®</sup> SYBR<sup>®</sup> Green qPCR SuperMix-UDG (SYBR<sup>®</sup> Green I, 30 U/mL Platinum<sup>®</sup> *Taq* DNA polymerase, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 3 mM MgCl<sub>2</sub>, 200  $\mu$ M dATP, 200  $\mu$ M dCTP, 200  $\mu$ M dGTP, 200  $\mu$ M dUTP, 20 U/mL UDG, and stabilisers, Invitrogen) and forward and reverse primers (200 nM each). Amplification conditions were as follows; uracil-DNA glycosylase treatment at 50°C for 2 min, denaturation at 95°C for 2 min, and 35 cycles of amplification (denaturation at 95°C for 5 sec, annealing for 15 sec, and extension for 15 sec at 72°C). SYBR Green I fluorescence was measured at the end of annealing and extension steps. Following amplification, samples were dissociated by incremental heating between 72°C and 99°C, at a rate of 1°C/5 sec. During this dissociation, SYBR Green I fluorescence was constantly measured. Amplification was performed in 100  $\mu$ L tubes (Corbett Research, Mortlake, NSW, Australia) using a Rotor-Gene 3000 PCR machine (Corbett Research).

### 5.6.3 PCR Quantitation and Statistical Analysis

PCR amplification was performed simultaneously on reverse transcribed RNA prepared from the whole brains of 7 control mice, 8 mice treated with lithium, and 6 mice treated with valproate. Quantitative PCR critical threshold values for each sample were determined using Rotor-Gene v5.0.37 computer program (Corbett Research). mRNA copy number was determined relative to DNA standards of known concentration. The relative expression for *mfat1* was expressed as a ratio of *mfat1* mRNA concentration, to that of the housekeeping gene *gapdh*. The mean ratio and standard deviation for control, lithium, and valproate cDNAs were calculated using the StatView software v5.47 (Abacus Concepts). Unpaired Student's t-tests were performed, with a two-tailed  $\alpha$  value of 0.05.

As shown in Figure 6 the relative mRNA expression levels for mouse FAT were reduced following administration of either lithium or valproate. In particular, administration of lithium alone significantly reduced *mfat1* expression by 2.7 fold ( $p=0.027$ ).

### Exon trapping to determine the effect of polymorphisms on the splicing of FAT

To study the effect of the SNPs on splicing, and in particular the polymorphisms that occurs at positions 148,129 and 148,333 of SEQ ID NO: 1, an exon-trapping system  
 5 (Life Technologies, Inc., Frederick, MA) was used. Genomic DNA from bipolar affective disorder subjects and from a normal individual containing exon 26, and flanking sequences from introns 25 and 26, was amplified using PCR. Clone 1 (which comprises a thymine at a position corresponding to nucleotide position 148,129 of SEQ ID NO: 1 and an adenine at a position corresponding to nucleotide position 148,333 of  
 10 SEQ ID NO: 1) and clone 2 (which comprises a cytosine at a position corresponding to nucleotide position 148,129 of SEQ ID NO: 1 and a thymine at a position corresponding to nucleotide position 148,333 of SEQ ID NO: 1) were amplified with oligonucleotides comprising the sequences set forth in SEQ ID NO: 67 (5'-TTCTTCGTTTGAGTTTGTAAGGTG-3') and SEQ ID NO: 68 (5'-  
 15 GTTAAGAAAGTTGCGAGGAAGATT-3'). Clone 3 (which comprises a thymine at a position corresponding to nucleotide position 148,129 of SEQ ID NO: 1) was amplified with oligonucleotides comprising the sequence set forth in SEQ ID NO: 69 (5'-TTCTTCGTTTGAGTTTGTAAGGTG-3') and SEQ ID NO: 70 (5'-CTATTTTCCCCAGCAGACATTC-3'). The PCR products were electrophoresed on  
 20 an agarose gel, stained with ethidium bromide, visualized under UV light, gel-purified (gel extraction kit, QIAGEN), and then subcloned into the pGEM-T-easy vector (Promega Corp., Madison WI). After the correct sequence is confirmed by DNA sequencing, the insert was cloned into the *EcoRI* site of the pSPL3 vector (Life Technologies, Inc.). Regions of the resulting vectors are shown in Figure 9. The  
 25 plasmid DNA was then amplified in *Escherichia coli*, extracted, purified, and used for transfection.

HEK-293 cells were grown in 10-cm dishes in DMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% bovine calf serum (Life Technologies,  
 30 Inc.) and 50 mg/liter gentamicin in a 10% CO<sub>2</sub> atmosphere at 37°C. When cells reached approximately 50% confluence, they were transfected with plasmid DNA (normal, mutant, or control pSPL3, containing an exon of known size)/10-cm dish. Twenty-four hours later cells were harvested, and total RNA extracted with TRIzol (Life Technologies, Inc.). First strand synthesis of cDNA was catalyzed by the Superscript II  
 35 ribonuclease H - reverse transcriptase (RT). RT-PCR was performed according to the manufacturer's instructions supplemented with the exon-trapping system (Life

Technologies, Inc.). The products of the RT-PCR were electrophoresed on an agarose gel, stained with ethidium bromide, and visualized under UV light (Figure 10). RT-PCR products were gel purified, cloned, and then sequenced (PE Applied Biosystems). Differences in the sequence of the mRNA produced by the nucleic acid isolated from a  
5 bipolar affective disorder subject compared to a normal subject indicates that a change in the nucleotide sequence of the FAT gene alters the splicing of this gene.

Analysis by RT-PCR of spliced mRNA derived from exon-trap clones following transfection in HEK293 cells indicates that cells comprising the clone 1 exon trap  
10 vector (ie. comprising the SNPs significantly associated with a bipolar affective disorder) preferentially spliced to a cryptic splice acceptor site that lies 93bp downstream of rs2306987. This resulted in an additional 55bp of FAT genomic DNA and flanking vector sequence being included in the PCR product (Figure 8) A similar splicing event was observed in cells comprising the clone 2 exon trap vector, however,  
15 to a dramatically reduced degree.

A search of the EST database (dbEST) did not identify any entries that contained the 55bp *FAT* genomic sequence present in the cryptically spliced product shown in Figure 8. Without being bound by theory this observation suggests that transcription of the  
20 endogenous *FAT* gene which utilises this cryptic splice site does not produce mature mRNA (ie. the mRNA is degraded).

#### EXAMPLE 7

##### Northern blotting analysis of FAT expression in the brain

25 Northern blotting to determine FAT expression is performed essentially as described in Dunne *et al.*, *Genomics*, 30: 207-223, 1995. Essentially RNA is isolated from brain tissue samples from bipolar affective disorder subjects or control subjects using the methods of Favaloro *et al.*, *Methods Enzymol.*, 65: 718, 1980. Poly(A)+ RNA is then  
30 selected using oligo(dT)-cellulose essentially as described in Aviv and Leder, *Proc. Natl. Acad. Sci. USA*, 69: 1408, 1972. mRNA is denatured and electrophoresed in a 1% formaldehyde gel and transferred to a Hybond-N+ filter (Amersham) using methods known in the art.

Probes that span the entire coding region of the FAT gene are prepared essentially as described in Dunne *et al.*, *Genomics*, 30: 207-223, 1995 and labelled with  $^{32}\text{P}$ . The use of a variety of probes determines the presence of multiple splice forms of FAT in the brain.

5

Probes are hybridised to the filters overnight at 42°C, before washing and finally hybridisation is detected using X-ray film.

#### EXAMPLE 8

10

#### Localisation of FAT gene expression in the brain

*In situ* hybridisation to detect FAT mRNA expression is performed to determine the localisation of FAT mRNA in the brain of bipolar affective disorder subjects and control subjects. Briefly, probes that correspond to the 5' end and 3' end of the FAT cDNA, in addition to probes that detect alternative splice forms of FAT observed in bipolar affective disorder subjects (Example 6) are amplified using PCR and cloned into the pGEM-T Easy vector (Promega). Vectors are then linearized with *ScaI* and single stranded RNA probes are synthesised using T7 or Sp6 polymerase as appropriate to produce both sense and antisense probes. The probes are synthesized with a DIG RNA labelling kit (Boehringer Mannheim GmbH, Mannheim, Germany).

Sections from various regions of the brain of bipolar affective disorder subjects and control subjects are fixed for 5 min in 2x SSC containing 4% formaldehyde, washed twice in 2x SSC for 1 min, and then rinsed in 0.1 M triethanolamine containing 0.25% acetic anhydride for 5 min at room temperature (RT). The sections are washed in 2x SSC for 5 min, dehydrated, air-dried and hybridised in 50 µl hybridisation solution (50% formamide, 4x SSPE, 1x Denhardt's reagent, 10% dextran sulfate, 100 mM DTT, 0.1% SDS, 100 µg/ml salmon sperm DNA, 100 µg/ml yeast tRNA; the pH of the solution is adjusted to 8.5) containing 200 fmol/ml DIG-labeled probe. Hybridisation is performed under parafilm coverslips in a humidified chamber at 55°C for 24 h. The sections are rinsed in 2x SSC at RT and 55°C for 5 and 10 min, respectively, then treated with RNase A (16 µg/ml) at 37°C for 30 min. The sections are then washed in 2x SSC/50% formamide at 55°C for 2 x 10min, and in 2x SSC at 55°C and RT for 10 min and 5 min, respectively. After post-hybridisation, the sections are washed in buffer

B1 (100 mM Tris-HCl pH 7.5 and 150 mM NaCl) for 5 min, blocked in 5% heat-inactivated sheep serum in B1 for 2 h and incubated in sheep anti-DIG-alkaline phosphatase conjugate (Boehringer Mannheim; 1:1,000 dilution) in 5% sheep serum in B1 at 4°C for 24 h. Sections are washed in B1 for 3 x 5 min, and then in buffer B2 (100 mM Tris-HCl pH 9.5, 100 mM NaCl and 50 mM MgCl<sub>2</sub>) for 10 min, and are developed in B2 containing 340 µg/ml nitroblue tetrazolium (NBT) and 180 µg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) for 24 h under darkroom conditions. The color reaction is stopped by rinsing the sections in a mixture of 10 mM Tris-HCl pH 8.0 and 1 mM EDTA for 5 min in RT, and the sections are then dehydrated and covered with Entellan (Merck, Darmstadt, Germany).

Stained sections are then viewed under a standard light microscope.

#### EXAMPLE 9

Preparation of a monoclonal antibody that recognizes human FAT

A monoclonal antibody that specifically binds human FAT1 is produced using methods known in the art. Briefly, a peptide antigen that corresponds to the N-terminus of human FAT (QQHTEV, SEQ ID NO: 31) is synthesised essentially using the methods described in Bodanszky, M. (1984) *Principles of Peptide Synthesis*, Springer-Verlag, Heidelberg and Bodanszky, M. & Bodanszky, A. (1984) *The Practice of Peptide Synthesis*, Springer-Verlag, Heidelberg.

A peptide comprising the sequence SKPKPSSEPISFEESVFSC (SEQ ID NO: 72) was also synthesized for production of a monoclonal antibody.

Peptides are purified using HPLC and purity assessed by amino acid analysis.

Female BalB/c mice are immunized with a purified form of the peptide. Initially mice are sensitised by intraperitoneal injection of Hunter's Titermax adjuvant (CytRx Corp., Norcross, GA,). Three boosts of the peptide are administered at 2, 5.5 and 6.5 months post initial sensitisation. The first of these boosts is a subcutaneous injection while the remaining are administered by intraperitoneal injection. The final boost is administered 3 days prior to fusion.

35

The splenocytes of one of the immunized BALB/c mice is fused to X63-Ag8.653 mouse myeloma cells using PEG 1500. Following exposure to the PEG 1500 cells are incubated at 37°C for 1 hour in heat inactivated foetal bovine serum. Fused cells are then transferred to RPMI 1640 medium and incubated overnight at 37°C with 10% CO<sub>2</sub>. The following day cells are plated using RPMI 1640 media that has been supplemented with macrophage culture supernatants.

Two weeks after fusion, hybridoma cells are screened for antibody production by solid phase ELISA assay. Standard microtitre plates are coated with the synthetic peptide in a carbonate based buffer. Plates are then blocked with BSA, washed and then the test samples (i.e. supernatant from the fused cells) is added, in addition to control samples, (i.e. supernatant from an unfused cell). Antigen-antibody binding is detected by incubating the plates with goat-anti-mouse HRP conjugate (Jackson ImmunoResearch Laboratories) and ABTS peroxidase substrate system (Vector Laboratories, Burlingame, Ca 94010, USA). Absorbance is read on an automatic plate reader at a wavelength of 405 nm.

Any colonies that are identified as positive by these screens continue to be grown and screened for several further weeks. Stable colonies are then isolated and stored at 80°C.

Positive stable hybridomas are then cloned by growing in culture for a short period of time and diluting the cells to a final concentration of 0.1 cells/well of a 96 well tissue culture plate. These clones are then screened using the previously described assay. This procedure is then repeated in order to ensure the purity of the clone.

Four different dilutions, 5 cells/well, 2 cells/well, 1 cell/well, 0.5 cells/well of the primary clone are prepared in 96-wells microtiter plates to start the secondary cloning. Cells are diluted in IMDM tissue culture media containing the following additives: 20% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml of penicillin, 100 µg/ml of streptomycin, 1% GMS-S, 0.075% NaHCO<sub>3</sub>. To determine clones that secrete anti-human FAT antibody, supernatants from individual wells of the 0.2 cells/well microtiter plate are withdrawn after two weeks of growth and tested for the presence of antibody by ELISA assay as described above.

All positive clones are then adapted and expanded in RPMI media containing the following additives: 10% FBS, 2 mM L-glutamine, 100 units/ml of penicillin, 100 .µg/ml of streptomycin, 1% GMS-S, 0.075% NaHCO<sub>3</sub>, and 0.013 mg/ml of oxalaacetic acid. A specific antibody is purified by Protein A affinity chromatography from the  
5 supernatant of cell culture.

The titer of the antibodies produced using this method are determined using the Easy Titer kit available from Pierce (Rockford, IL, USA). This kit utilises beads that specifically bind mouse antibodies, and following binding of such an antibody these  
10 beads aggregate and no longer absorb light to the same degree as unassociated beads. Accordingly, the amount of an antibody in the supernatant of a hybridoma is assessed by comparing the OD measurement obtained from this sample to the amount detected in a standard, such as for example mouse IgG.

15

#### EXAMPLE 10

##### FAT protein expression in the brain

Four-micron frozen sections isolated from human brain sections are postfixed in 4% paraformaldehyde and 20% glucose for 5 min at 4°C. Following washing sections are incubated for 30 min with CAS Block (Zymed, South San Francisco, CA, USA).  
20 Sections are then incubated overnight at 4°C with the mouse monoclonal antibody described in Example 9. Sections are incubated with 1:10 NGS instead of the primary antiserum as the negative control. After thorough washing with PBS (3 x 5 min changes), the sections are incubated with goat anti-mouse Alexa Fluor 568 (Molecular Probes), diluted 1:200 with PBS for 1 h at room temperature. Sections are rinsed with  
25 PBS (2 x 5 min), rinsed in tap water for 5 min, and mounted for microscope viewing.

#### EXAMPLE 11

##### Analysis of SNPs using fluorescent single nucleotide primer extension analysis

##### 30 11.1 PCR

In the first round of PCR, a fragment is amplified from genomic DNA using 0.5 µM each two primers comprising the sequences set forth in SEQ ID NOs: 8 and 9 or SEQ ID NOs: 11 and 12 and PCR supermix high fidelity (Life Technologies, Rockville, MD, USA) in a final volume of 50 µL containing 10 U/mL DNA polymerase in 60 mM  
35 Tris-SO<sub>4</sub> (pH 9.1), 18 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, and 200 µM each of the four



dNTPs. Thermocycling conditions: 3 min initial denaturation at 96°C and 25 cycles of 1 min 96°C, 30 s 58°C, 3 min 72°C.

### 11.2 Primer extension

- 5 PCR products are purified using Centri-sep columns (Princeton Separations, Adelphia, NJ, USA); 25-500 ng of this 422 bp fragment then serves as a template for subsequent primer extension using Cy5 labeled primer comprising the sequence set forth in SEQ ID NO: 7 (for the PCR product generated using the primers set forth in SEQ ID NO: 8 and 9) (300 nM) and 4 U of Thermo Sequenase, 0.2 mM of the three dNTPs (dATP, 10 dCTP and dGTP) and 0.2 mM of ddTTP in a buffer of 26 mM Tris-HCl (pH 9.5) and 6.5 mM MgCl<sub>2</sub> in a final volume of 20 µL. For the reaction using the PCR product generated using the primer set forth in SEQ ID NO: 11 and 12 a Cy5 labeled primer (300 nM) comprising the sequence set forth in SEQ ID NO: 10 is used in a reaction 15 comprising 4 U of Thermo Sequenase, 0.2 mM of the three dNTPs (dTTP, dCTP and dGTP) and 0.2 mM of ddATP in a buffer of 26 mM Tris-HCl (pH 9.5) and 6.5 mM MgCl<sub>2</sub> in a final volume of 20 µL. Thermocycling conditions: 3 min initial denaturation at 94°C and 40 cycles of 30 s 94°C, 30 s 58°C, 30 s 72°C, followed by a 2 min final extension at 72°C. dNTPs are from Life Technologies, ddTTP and ddATP are from Sigma (St. Louis, MO, USA), Thermo Sequenase and Sequenase reaction buffer 20 are from Amersham (Cleveland, OH, USA). 10 µL formamide is added to 2 µL primer extension product and incubated at 95°C for 2 min prior to CE analysis for denaturation.

### 11.3 Capillary electrophoresis

- 25 For all experiments the P/ACE-MDQ (Beckman Coulter Inc., Fullerton, CA, USA) instrument is used in normal polarity separations mode (cathode at the detection site). The separation is monitored on-column by laser-induced fluorescence detection (LIF) using a red diode laser (635 nm) and a narrow band pass emission filter (670 nm). The temperature of the cartridge holding the separation capillary column is thermostated at 30 30 ± 0.1°C by the active liquid cooling of the device. A 10 cm effective separation length capillary (30 cm total) with an ID of 75 µm is used for separation of the denatured primer extension products. 10% PVP (*M<sub>r</sub>* 1 300 000 from Aldrich) solution is used as sieving and wall coating matrix dissolved in 1 x TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA · Na<sub>2</sub>, pH 8.4). Bodipy FL Hydrazide is used as neutral 35 marker for electroosmotic flow (EOF) measurement (Molecular Probes, Eugene, OR, USA). The primer extension samples are electrokinetically injected at 10 kV for 30 s

and separated at 20 kV. The data is acquired and evaluated by the P/ACE System MDQ software.

## EXAMPLE 12

### 5 Analysis of SNPs using MALDI-TOF mass spectrometry

#### *12.1 Amplification of regions containing a single nucleotide polymorphism*

The bipolar affective disorder markers at position 148,108 or 148,333 of SEQ ID NO: 1 are amplified under universal conditions in a 25- $\mu$ L reaction containing 50-100 ng  
10 DNA, 0.2-0.4  $\mu$ M each primer (comprising the sequence set forth in SEQ ID NO: 8 and 9 for 148,108 and SEQ ID NO: 11 and 12 for 148,333 ), 2.5 mM  $MgCl_2$ , 200  $\mu$ M each dNTP and 1 U HotStarTaq DNA Polymerase (Qiagen) in reaction buffer supplied by the manufacturer. PCR The thermal cycling conditions are: 15 min at 95°C followed by 15 cycles of 94°C for 30 s, 58°C for 1 min and 72°C for 1 min, then 30 cycles of  
15 94°C for 30 s, 58°C for 1 min and 72°C for 1 min, with a final 10 min incubation at 72°C.

#### *12.2 Single nucleotide primer extension assay*

Following PCR, 1 U of shrimp alkaline phosphatase (SAP; Roche Molecular  
20 Biochemicals) is added to 20  $\mu$ L of PCR product to hydrolyze residual dNTPs. The mixture is incubated for 60 min at 37°C followed by enzyme inactivation for 20 min at 95°C. Primer extension reactions are performed in 10- $\mu$ L volumes and contained 5  $\mu$ L of 'SAP-treated' PCR product, 30  $\mu$ M each ddNTP, 1-3  $\mu$ M genotyping primer (SEQ ID NO: 7 for 148,108 and SEQ ID NO: 10 for 148,333) and 1-2 U ThermoSequenase  
25 DNA polymerase (Amersham Pharmacia Biotech). Thermal cycling conditions consisted of denaturation at 94°C for 2 min, followed by 50 cycles of 94°C for 30 s and 37°C for 90 s. Primer concentrations are balanced empirically to ensure that some unextended primer remained to act as an internal mass standard.

#### 30 *12.3 Sample preparation and MALDI-TOFMS analysis*

Prior to analysis, samples are desalted by dialysis through 96-well membrane filter plates with 0.05  $\mu$ m pore size (MAVM N05, Millipore) which are floated on deionized water for approximately 2 h. The MALDI plate is spotted with 1  $\mu$ L of 3-hydroxypicolinic acid (3-HPA) matrix (50 mg/mL in 50% acetonitrile and 25 mM  
35 diammonium citrate) and allowed to dry before deposition of 1  $\mu$ L of desalted primer extension sample. Mass spectra are collected using a Voyager-DE<sup>TM</sup> PRO MALDI-

TOF instrument (PerSeptive Biosystems, Framingham, MA, USA) equipped with a 337 nm nitrogen laser. Measurements are taken manually in linear, positive ion mode at a 20-24 kV acceleration voltage and 200 ns delayed ion extraction. To avoid saturation of the detector from matrix ions, masses <1000 Da are suppressed by an ion deflector.

- 5 Unextended primers are used as internal standards for mass calibration. The nucleotide incorporated at the variant site is determined manually by calculating the mass difference between the unextended primer and the extension product. In the case of a heterozygote, two mass-resolved extension products are produced.

10

## EXAMPLE 13

## Detection of SNPs using fluorescence-adapted SSCP

*13.1 PCR*

- The primers described in Examples 11 and 12 are then adapted for fluorescence-  
15 adapted SSCP analysis, four primers are prepared as follows: the sequence-specific forward primer (SEQ ID NO: 8 or SEQ ID NO: 11) is conjugated with 5'-TGA CCG GCA GCA AAA TTG-3' (SEQ ID NO: 13) tail at its 5' end (to form oligonucleotides that comprise the nucleotide sequence set forth in SEQ ID NOs: 15 and 17; the sequence-specific reverse primer (SEQ ID NOs: 9 or SEQ ID NO: 12) conjugated with  
20 5'-TGT AAA ACG ACG GCC AGT-3' (SEQ ID NO: 14) tail at its 5' end to form oligonucleotides comprising the nucleotide sequence set forth in SEQ ID NO: 16 and 18; the Cy-5 labeled 5'-TGA CCG GCA GCA AAA TTG-3' primer (SEQ ID NO: 19) (Amersham Bioscience, NJ, USA); and the Cy-5 labeled 5'-TGT AAA ACG ACG GCC AGT-3' (SEQ ID NO: 20) primer (Amersham Biosciences).

25

- PCR is performed using a PCR mix containing 50-100 ng of Genomic DNA (from normal or bipolar subjects, or a subject being tested) < 2 pmol of the conjugated sequence-specific forward primer (SEQ ID NO: 15 or 17), 2 pmol of the conjugated sequence-specific reverse primer (SEQ ID NO: 16 or 18), 10 pmol of Cy-5 labeled  
30 primer comprising the sequence set forth in SEQ ID NO: 19, 10 pmol of Cy-5 labeled primer comprising the sequence set forth in SEQ ID NO: 20, 200  $\mu$ M of dNTP, 2  $\mu$ L of 10 x reaction buffer, 1 U of rTaq polymerase (Takara Bio, Shiga, Japan) in a final 20  $\mu$ L reaction volume. The PCR amplification procedure entails an initial denaturation cycle (94°C, 4 min); 25 cycles of 1 min each at 94°C, 58°C and 72°C, and 10 cycles of 1  
35 min each at 94°C, 58°C and 72°C. This was followed by 7 min at 72°C for final extension in a GeneAmp PCR System 9600 (Applied Biosystems, CA, USA).

### 13.2 Gel electrophoresis

The fluorescence-labeled DNA fragments are diluted 2-5 times with a loading buffer consisting of formamide and EDTA (100% formamide:50 mM EDTA = 5:1). The DNA samples are heated at 94°C for 5 min and cooled immediately on ice. This solution (1 to 5 µL) is applied to a non-denaturing polyacrylamide gel using 0.5 x MDE gel solution (bioWhittaker Molecular Applications, ME, USA) with 1 x TBE buffer (100 mM Tris-borate, pH 8.3, 1 mM EDTA). The short gel plate is applied to the Amersham Biosciences Model ALF Express DNA sequencer. The gel temperature is maintained at 15°C. Electrophoresis is performed in 0.5 x TBE buffer at 30 W for 5 h, and the data is collected and analysed using Fragment Manager software (Amersham Biosciences).

## EXAMPLE 14

### Production of a transgenic mouse expressing human FAT

15

To produce a transgenic mouse expressing a human FAT gene a yeast artificial chromosome (YAC) that comprised the entire genomic FAT gene is isolated. *LYS2* gene is incorporated into the YAC by retrofitting with a 9-kb insert from pRV1, which also contains a neomycin-resistance gene (Srivastava *et al.*, *Gene*, 103: 53-59, 1991).

20

### 14.1 Mutagenesis of the FAT YAC

To mutate the FAT YAC, the "pop-in, pop-out" gene-targeting strategy is used (Duff *et al.*, *Gene Ther.*, 1: 70-75, 1994). The gene-targeting vector is constructed by cloning a fragment spanning from exon 26 to exon 27 of the human FAT gene (from a bipolar affective disorder subject, including either a cytosine at a position corresponding to position 148,108 of SEQ ID NO: 1 or an adenosine at a position corresponding to position 148333 of SEQ ID NO: 1) previously amplified by PCR into the yeast integrating vector pRS406, which contains the *URA3* gene (Stratagene). Following DNA sequencing, the gene-targeting vector is linearized and introduced into AB1380 spheroplasts containing the FAT YAC. Transformants are initially selected on plates lacking uracil and later grown on plates lacking uracil, and Lys. To identify targeted clones (the pop-in step), yeast colonies were analyzed by pulsed-field gel electrophoresis and Southern blot analysis. For the pop-out step, yeast harbouring a targeted YAC were grown in medium lacking Lys overnight and then plated onto 5-fluoroorotic acid plates (Rothstein, *Methods Enzymol.*, 194: 281-301, 1991). The

colonies were subsequently plated onto plates lacking Lys and examined by pulsed-field gel electrophoresis, Southern blot, and PCR analyses.

#### 14.2 Analysis of the Gene-Targeting Events in the YACs

- 5 High molecular weight yeast DNA is electrophoresed on a 1% pulsed-field agarose gel in 0.5 x TBE (1 x = 90 mM Tris/90 mM boric acid/2 mM EDTA, pH 8.3) at 6 V/cm at 14°C, with initial and final switching times of 0.22 and 21.79 sec, respectively. To identify gene-targeting events, fluorescent single nucleotide primer extension is performed essentially as described in Example 9.

10

#### 14.3 Generation of Transgenic Mice

- To generate transgenic mice expressing the mutant FAT genes, each of the YACs are purified from pulsed-field agarose gels as described (Peterson *et al.*, *Proc. Natl. Acad. Sci. USA.*, 90: 7593-7597, 1993), adjusted to a concentration of 3 ng/μl, and  
15 microinjected into C57BL/6 x SJL mouse zygotes. Transgenic founders are identified by analysis of tail DNA for the mutant sequence. Founders are then bred to generate lines expressing human FAT mutated at position 148,108 (tghFAT148,108) or at position 148333 (tghFAT148,333). Samples isolated from the brain of offspring of the founders mice are analysed for the presence of human FAT using specific Western  
20 blots using the monoclonal antibody described in Example 7 to determine those mice that express human FAT.

### EXAMPLE 15

#### Generation of a mouse deficient in mouse FAT that expresses human FAT

25

- The transgenic lines described in Example 14 are mated with the mFAT1<sup>+/-</sup> mice (Ciani *et al.*, *Molecular and Cellular Biology*, 23(10): 3575-3582) to produce mFAT<sup>+/-</sup> tghFAT148,108<sup>+/-</sup> mice and mFAT<sup>+/-</sup> tghFAT148,108<sup>+/-</sup> mice. Each of these lines are then interbred to produce mFAT<sup>-/-</sup> tghFAT148,108<sup>+/-</sup> mice and mFAT<sup>-/-</sup> tghFAT148,108<sup>-/-</sup> mice and mFAT<sup>-/-</sup> tghFAT148,108<sup>+/-</sup> mice and mFAT<sup>-/-</sup> tghFAT148,108<sup>+/-</sup> mice and mFAT<sup>-/-</sup> tghFAT148,108<sup>-/-</sup> mice. Accordingly, hemizygous and homozygous mice that express human FAT (either with a cytosine at a position corresponding to position 148,108 of SEQ ID NO: 1 or an adenosine at a position corresponding to position 148333 of SEQ ID NO: 1) in the absence of mouse FAT are produced.

35

### EXAMPLE 16

### Analysis of FAT transgenic mice for a bipolar affective disorder phenotype

The effect of the human FAT gene comprising either of the SNPs incorporated into the transgenes on anxiety in transgenic mice (Examples 14 and 15) is recorded in a dark/light exploratory model in a two-compartment light/dark box. The apparatus and conditions used are a clear acrylic chamber (40.5 x 40.5 x 30 cm) with an enclosed black acrylic box (10 x 20.5 x 20.5 cm) inserted into the right half of the chamber with an opening (13 x 5 cm) allowing for passage between the two compartments (movement between the compartments is monitored by an infrared beam). The apparatus is equipped with infrared sensors for the automatic recording of horizontal activity (Digiscan Model RXYZCM, Accuscan Instruments, Columbus, OH). The open compartment is directly illuminated by a 60-W bulb placed 40 cm above the floor of the compartment. Animals initially are placed in the centre of the dark compartment, and data collection commenced immediately for 10 min. Variables measured include latency to emerge from the dark compartment into the more aversive brightly lit compartment and the amount of time spent ambulating in each of the compartments.

PPI is assayed several weeks after the dark/light test. Each of two startle chambers (SR-Lab, San Diego Instruments) contains a transparent acrylic cylinder (4 cm in diameter) mounted on a frame to which a motion sensor is attached for the detection and transduction of movement, and a sound generation system is used for the delivery of background white noise and acoustic stimuli. A CompuAdd 386 microprocessor and San Diego Instruments interface board and software are used for the delivery of stimuli and response recording (100 1-ms readings beginning at startle stimulus onset). Response amplitude is calculated as the maximum response level occurring during the 100-ms recording. Both chambers are calibrated for equivalent stimulus intensities and response sensitivities, and experimental groups are balanced across chambers. Immediately after placement in the chamber, the animal is given a 4-min acclimation period during which background noise (65 dB) is continually present, and then received four no-stimulus trials, four startle stimulus alone trials, and then 10 sets of the following four trial types counter balanced to control for order: 40-ms, 115-dB noise burst alone (startle stimulus); startle stimulus preceded 100 ms by a 20-ms, 71-dB, or 77-dB noise burst; and no stimulus. Intertrial interval is variable (average 15 sec). At the end of this block of 40 trials, the animal again receive four startle stimulus alone trials followed by four no-stimulus trials. Mice that show attenuation of the startle

response have reduced sensorimotor gating, a phenotype also observed in subjects suffering from bipolar affective disorder.